<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain Behav Immun</journal-id><journal-id journal-id-type="iso-abbrev">Brain Behav. Immun</journal-id><journal-title-group><journal-title>Brain, Behavior, and Immunity</journal-title></journal-title-group><issn pub-type="ppub">0889-1591</issn><issn pub-type="epub">1090-2139</issn><publisher><publisher-name>Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7175848</article-id><article-id pub-id-type="publisher-id">S0889-1591(20)30589-4</article-id><article-id pub-id-type="doi">10.1016/j.bbi.2020.04.046</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Current status of potential therapeutic candidates for the COVID-19 crisis</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Zhang</surname><given-names>Jiancheng</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Xie</surname><given-names>Bing</given-names></name><xref rid="af010" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Hashimoto</surname><given-names>Kenji</given-names></name><email>hashimoto@faculty.chiba-u.jp</email><xref rid="af005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><aff id="af005"><label>a</label>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan</aff><aff id="af010"><label>b</label>Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author at: Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan. <email>hashimoto@faculty.chiba-u.jp</email></corresp><fn id="fn1"><label>1</label><p id="np005">Jiancheng Zhang and Bing Xie contributed equally to this work.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>22</day><month>4</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>7</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>22</day><month>4</month><year>2020</year></pub-date><volume>87</volume><fpage>59</fpage><lpage>73</lpage><history><date date-type="received"><day>16</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>18</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="ab005"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#x02022;</label><p id="p0005">The coronavirus disease 2019 (COVID-2019) pandemic has swept in the world.</p></list-item><list-item id="o0010"><label>&#x02022;</label><p id="p0010">There is currently no specific treatment available for patients with COVID-19 infection.</p></list-item><list-item id="o0015"><label>&#x02022;</label><p id="p0015">Clinical trials of numerous potential candidates are underway.</p></list-item><list-item id="o0020"><label>&#x02022;</label><p id="p0020">The current status of potential therapeutic approaches for COVID-19 is summarized.</p></list-item></list></p></abstract><abstract id="ab010"><p>As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy. There is currently no specific treatment available for patients with COVID-19 infection. The lessons learned from past management of respiratory viral infections have provided insights into treating COVID-19. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been tentatively applied in clinical settings. A number of these therapies have provided substantially curative benefits in treating patients with COVID-19 infection. Furthermore, intensive research and clinical trials are underway to assess the efficacy of existing drugs and identify potential therapeutic targets to develop new drugs for treating COVID-19. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and introduce their mechanisms of action, safety, and effectiveness.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>ACE2 blocker</kwd><kwd>Antimalaria</kwd><kwd>Antiviral: Chinese traditional medicine</kwd><kwd>COVID-19</kwd><kwd>Immunoenhancer</kwd><kwd>Monoclonal antibody</kwd><kwd>Vaccine</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0025">Coronavirus disease 2019 (COVID-2019), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China in December 2019 and has spread rapidly across the world due to its high transmissibility and pathogenicity (<xref rid="b0720" ref-type="bibr">Munster et al., 2020</xref>, <xref rid="b1195" ref-type="bibr">Zhu et al., 2020</xref>). SARS-CoV-2 is a distinct clade of beta coronaviruses encompassing severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) (<xref rid="b0640" ref-type="bibr">Lu et al., 2020</xref>). Although most cases of the disease caused by most pathogenic coronaviruses are mild (<xref rid="b0975" ref-type="bibr">Su et al., 2016</xref>), the SARS-CoV and MERS-CoV outbreaks in 2002 and 2012, respectively, demonstrated their high lethality (<xref rid="b0895" ref-type="bibr">Schoeman and Fielding, 2019</xref>). SARS-CoV-2 bears an 82% resemblance to the genomic sequence of SARS-CoV (<xref rid="b0125" ref-type="bibr">Chan et al., 2020</xref>); however, COVID-19 presents a lower case fatality rate and higher infectiousness than SARS, with mortality rates of approximately 3.7% for COVID-19 and 10% for SARS (<xref rid="b1070" ref-type="bibr">WHO, 2003</xref>, <xref rid="b1075" ref-type="bibr">WHO, 2020a</xref>). COVID-19 patients often exhibit mild symptoms, such as fever, cough, myalgia, and fatigue and generally have a good prognosis. However, a large proportion of COVID-19 cases have rapidly progressed to severe types, especially among older men with underlying diseases (<xref rid="b0155" ref-type="bibr">Chen et al., 2020c</xref>, <xref rid="b0440" ref-type="bibr">Huang et al., 2020</xref>, <xref rid="b0620" ref-type="bibr">Liu et al., 2020c</xref>, <xref rid="b1045" ref-type="bibr">Wang et al., 2020a</xref>). Severe cases can include dyspnea (<xref rid="b0605" ref-type="bibr">Lin et al., 2020</xref>), shock (<xref rid="b1045" ref-type="bibr">Wang et al., 2020a</xref>), organ dysfunction [acute respiratory distress syndrome (ARDS)] (<xref rid="b0350" ref-type="bibr">Guan et al., 2020</xref>, <xref rid="b1045" ref-type="bibr">Wang et al., 2020a</xref>, <xref rid="b1115" ref-type="bibr">Xu et al., 2020</xref>, <xref rid="b1130" ref-type="bibr">Yang et al., 2020</xref>, <xref rid="b1135" ref-type="bibr">Yao et al., 2020</xref>), acute cardiac injury (<xref rid="b0385" ref-type="bibr">Han et al., 2020a</xref>, <xref rid="b0965" ref-type="bibr">Strabelli and Uip, 2020</xref>, <xref rid="b1045" ref-type="bibr">Wang et al., 2020a</xref>, <xref rid="b1135" ref-type="bibr">Yao et al., 2020</xref>, <xref rid="b1185" ref-type="bibr">Zhou et al., 2020a</xref>), acute kidney injury (<xref rid="b0350" ref-type="bibr">Guan et al., 2020</xref>, <xref rid="b0590" ref-type="bibr">Li et al., 2020a</xref>, <xref rid="b0775" ref-type="bibr">Pan et al., 2020</xref>, <xref rid="b1045" ref-type="bibr">Wang et al., 2020a</xref>, <xref rid="b1135" ref-type="bibr">Yao et al., 2020</xref>), acute liver injury (<xref rid="b1100" ref-type="bibr">Xie et al., 2020</xref>, <xref rid="b1115" ref-type="bibr">Xu et al., 2020</xref>, <xref rid="b1135" ref-type="bibr">Yao et al., 2020</xref>; <xref rid="b1160" ref-type="bibr">Zhang et al., 2020a</xref>), neurological injury (<xref rid="b0670" ref-type="bibr">Mao et al., 2020</xref>, <xref rid="b1095" ref-type="bibr">Wu et al., 2020</xref>), gastrointestinal injury (<xref rid="b1135" ref-type="bibr">Yao et al., 2020</xref>), immune injury (<xref rid="b0145" ref-type="bibr">Chen et al., 2020b</xref>, <xref rid="b0350" ref-type="bibr">Guan et al., 2020</xref>, <xref rid="b0810" ref-type="bibr">Qin et al., 2020</xref>, <xref rid="b1050" ref-type="bibr">Wang et al., 2020b</xref>, <xref rid="b1115" ref-type="bibr">Xu et al., 2020</xref>, <xref rid="b1135" ref-type="bibr">Yao et al., 2020</xref>, <xref rid="b0615" ref-type="bibr">Liu et al., 2020b</xref>, <xref rid="b1180" ref-type="bibr">Zheng et al., 2020</xref>), coagulation impairment (<xref rid="b0390" ref-type="bibr">Han et al., 2020b</xref>, <xref rid="b0990" ref-type="bibr">Tang et al., 2020a</xref>), and even death (<xref rid="b0440" ref-type="bibr">Huang et al., 2020</xref>, <xref rid="b1045" ref-type="bibr">Wang et al., 2020a</xref>) (<xref rid="f0005" ref-type="fig">Fig. 1</xref>
). In addition, COVID-19 pandemic has great impact on psychological stress and mental health worldwide (<xref rid="b0075" ref-type="bibr">Bao et al., 2020</xref>, <xref rid="b0485" ref-type="bibr">Kang et al., 2020</xref>, <xref rid="b0595" ref-type="bibr">Li et al., 2020</xref>, <xref rid="b0795" ref-type="bibr">Pfefferbaum and North, 2020</xref>, <xref rid="b0920" ref-type="bibr">Shi et al., 2020a</xref>).<fig id="f0005"><label>Fig. 1</label><caption><p>SARS-CoV-2 infection-induced impairment of multiple organ function Impairment of multiple organ function by SARS-CoV-2 infection includes acute respiratory distress syndrome (ARDS), acute cardiac injury, acute kidney injury, acute liver injury, neurological injury, gastrointestinal injury, immune system injury, and coagulation impairment. Abbreviations: ALT, alanine transaminase; APTT, activated partial thromboplastin time; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; CK-MB, creatine kinase myocardial band; CNS, central nervous system; FDP, fibrinogen degradation products; HLA-DR, human leukocyte antigen DR; INR, international normalized ratio; LDH, lactate dehydrogenase; MYO, myoglobin; NK, natural killer cell; NT-proBNP, N terminal pro-B-type natriuretic peptide; PaO2/FiO2, oxygenation index; PNS, peripheral nervous system; PT, prothrombin time; RAAS, renin-angiotensin-aldosterone system; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TBIL, total bilirubin; Th, helper T cell; TNI, troponin I.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0030">At present, the pathogenesis and etiology of COVID-19 remain unclear, and there are no targeted therapies for COVID-19 patients, who are empirically administered symptomatic treatments, with organ support for those who are seriously ill (<xref rid="b1045" ref-type="bibr">Wang et al., 2020a</xref>). Given the pandemic spread of COVID-19 and the resulting global economic loss, developing alternative agents to contain SARS-CoV-2 is imperative. In this review, we summarize the potential therapeutic candidates under development for COVID-19 based on clinical trials and describe their potential mechanisms of action (<xref rid="f0010" ref-type="fig">Fig. 2</xref>
and <xref rid="f0015" ref-type="fig">Fig. 3</xref>
).<fig id="f0010"><label>Fig. 2</label><caption><p>The hypothetical replication cycle of SARS-CoV-2 and the possible targets of anti-COVID-19 drugs. SARS-CoV-2 binds to the ACE2 receptor on the surface of cells using the Spike protein, which subsequently triggers endocytosis. On releasing the viral nucleocapsid to the cytoplasm, encapsidated positive-strand genomic RNA [(+)gRNA] serves as a template to translate polypeptide chains, which are cleaved to non-structural proteins including RNA-dependent RNA polymerase. The single&#x000a0;negative&#x000a0;strand&#x000a0;RNA [(-)gRNA] synthesized from (+)gRNA template is employed to replicate more copies of viral RNAs. Subgenomic RNAs (sgRNAs) are synthesized by discontinuous transcription from the (+)gRNA template and then encode viral structural and accessary proteins, which are subsequently assembled with newly synthesized viral RNA to form new virions. The nascent virions are then transported in secretory vesicles to the plasma membrane and released by exocytosis. RhACE2, convalescent plasma and JAK inhibitor baricitinib could dampen the binding of the Spike protein on the surface of the SARS-CoV-2 to ACE2 expressed on the cell surface. Lopinavir/ritonavir and favipiravir inhibit the proteolysis of polypeptide chains. Remdesivir inhibits RNA-dependent RNA polymerase. EIDD-2801 could inhibit SARS-CoV-2 replication. NO and Zinc might inhibit SARS-CoV-2 replication. Vitamin D might induce antimicrobial peptides to reduce SARS-CoV-2 replication. Ivermectin could effectively block SARS-CoV-2 growth. Baricitinib could interrupt the passage of SARS-CoV-2 entering cells through inhibition of AAK1-mediated endocytosis. CQ and HCQ inhibit virus/cell fusion process. LHQW and IFNs could block the process of virus replication (RNAs transcription, protein translation, and post-translational modification). Abbreviations: AAK1, adaptor-associated kinase 1; CQ, chloroquine; ER, endoplasmic reticulum; HCQ, hydroxychloroquine sulfate; IFNs, interferons; iNO, inhaled nitric oxide; JAK, janus kinase; LHQW, Lianhua Qingwen; rhACE2, recombinant human angiotensin-converting enzyme 2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.</p></caption><graphic xlink:href="gr2_lrg"/></fig><fig id="f0015"><label>Fig. 3</label><caption><p>The hypothetical mechanisms of SARS-CoV-2 infection-induced cytokine storm and antiviral immunity and the possible therapeutic targets of patients with COVID-19 infection. &#x0201c;<italic>Cytokine storms</italic>&#x0201d; might start with inflammatory cytokine secretion into lung tissue and pulmonary blood vessels from virus-infected alveolar epithelial cells, pulmonary vascular endothelial cells, alveolar macrophages, multinucleated giant cells, and other infiltrated immune cells, which mainly serve to limit the replication and spreading of the virus and to induce downstream immune responses via the blood circulation. Following the recruitment and activation by primary cytokines, systemic immune cells (neutrophils, DCs, Mo-M&#x003c6;, NK cells, CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, Th1 cells, Th2 cells, and Th17 cells, etc.) further secrete inflammatory cytokines and promote the cascade of inflammatory processes to eliminate virus and virus-infected cells. Vitamin C might inhibit SARS-CoV-2 and alleviate the illness by decreasing inflammatory cytokines, stimulating IFN production, supporting lymphocyte proliferation, boosting the phagocytic capability of neutrophils, monocytes, and macrophages, protecting lung barrier function and reducing lung vascular injury, increasing IFN secretion from alveolar M&#x003c6;, Mo-M&#x003c6;, DCs, NK cells, and CD8<sup>+</sup> T cells. IFNs could enhance NK cell cytotoxicity, enhance expression of major histocompatibility complex &#x02160; proteins, and promote the production of IFNs and the proliferation of NK cells and M&#x003c6;. Bevacizumab could reduce vascular permeability. Vaccines (mRNA1273, Ad5-nCoV, PittCoVacc, and NVX-CoV2373) could induce protective antiviral immune memory, while MSCs could decrease pro-inflammatory cytokines, promote regeneration, secrete multiple paracrine factors and anti-inflammatory cytokines, and enlarge the proportion of Treg cells. iNO could alleviate pulmonary hypertension through its selective pulmonary vasodilation. Corticosteroids, LHQW, Xuebijing, IVIG, tocilizumab, sarilumab, baricitinib, vitamin D, CQ, and HCQ could also reduce inflammation. Heparin blocks the thrombus formation. Abbreviations: AT I, type I alveolar epithelial cell; AT &#x02161;, type &#x02161; alveolar epithelial cell; CQ, chloroquine; DC, dendritic cell; G-CSF, granulocyte-colony stimulating factor; HCQ, hydroxychloroquine sulfate; IFN-&#x003b3;, interferon gamma; IL, interleukin; iNO, inhaled nitric oxide; IP-10, interferon-inducible protein-10; IVIG, intravenous gamma globulin; LHQW, Lianhua Qingwen; MCP-1, monocyte chemotactic protein 1; MIP-1A, macrophage inflammatory protein-1a; Mo-M&#x003c6;, monocyte-macrophage; MSCs, mesenchymal stem cells; NK, natural killer cell; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Th, helper T cell; TNF-&#x003b1;, tumor necrosis factor alpha; Treg, regulatory T cell.</p></caption><graphic xlink:href="gr3_lrg"/></fig></p></sec><sec id="s0010"><label>2</label><title>Antiviral treatments</title><sec id="s0015"><label>2.1</label><title>Remdesivir</title><p id="p0035">Remdesivir, a nucleotide prodrug, originally developed to control the Ebola virus (<xref rid="b0935" ref-type="bibr">Siegel et al., 2017</xref>) and subsequently demonstrating its efficacy in inhibiting coronaviruses such as SARS-CoV and MERS-CoV <italic>in vitro</italic> (<xref rid="b0910" ref-type="bibr">Sheahan et al., 2017</xref>), presents antiviral activity by interfering with RNA-dependent RNA polymerase, thereby attacking the virus&#x02019;s ability to replicate in the body (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) (<xref rid="b0020" ref-type="bibr">Agostini et al., 2018</xref>). A recent study indicated that remdesivir efficiently protected a human cell line against SARS-CoV-2 infection (<xref rid="b1055" ref-type="bibr">Wang et al., 2020c</xref>). Treatment with intravenous remdesivir successfully improved the clinical state of the first U.S. COVID-19 patient (<xref rid="b0435" ref-type="bibr">Holshue et al., 2020</xref>). Remdesivir is now being tested in several clinical trials designed to evaluate its efficacy and safety for the treatment of COVID-19. Notably, Gilead Sciences announced the result of a very recent clinical study on the efficacy of remdesivir on COVID-19 (<xref rid="b0340" ref-type="bibr">Grein et al., 2020</xref>). In this report, 53 patients infected with severe COVID-19 were tracked, and 34 patients of whom were critically ill, with 30 patients requiring mechanical ventilation and 4 patients relying on extracorporeal membrane oxygenation (ECMO). Over a median follow-up of 18&#x000a0;days, 36 patients (68%) presented with improved oxygen-support class. 20 patients of 34 severely ill patients showed improvement in clinical conditions, with 17 of 30 patients stopped receiving invasive mechanical ventilation and 3 of 4 patients stopped receiving ECMO treatment respectively. The treatment of remdesivir limited the mortality rate of seriously ill patients needing invasive ventilation to 18%, and 5% for those who did not needed. Generally, the efficacy of remdesivir reflected in this study is hopeful. However, the sample size of this study was quite small, and definite effectiveness of remdesivir in the treatment of COVID-19 needs to be further verified (<xref rid="t0005" ref-type="table">Table 1</xref>
).<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Potential therapeutic drugs for COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Intervention</th><th>Type</th><th>Status and mechanisms</th><th>Recommendations</th></tr></thead><tbody><tr><td>Remdesivir</td><td>Antiviral</td><td>Remdesivir interferes with virus RNA polymerases to inhibit virus replication, and was used for Ebola virus outbreak</td><td>Being tested in clinical trials</td></tr><tr><td>Lopinavir/Ritonavir</td><td>Antiviral</td><td>Lopinavir/ritonavir are approved protease inhibitors for HIV</td><td>Inconsistent results in completed clinical trials</td></tr><tr><td>Favipiravir</td><td>Antiviral</td><td>Favipiravir inhibits viral RNA polymerase, thus interfering with viral replication</td><td>Proven efficacy in completed clinical trials</td></tr><tr><td>EIDD-2801</td><td>Antiviral</td><td>EIDD-2801 is incorporated during RNA synthesis and then drives mutagenesis, thus inhibiting viral replication</td><td>Prepared for clinical trials</td></tr><tr><td>Convalescent plasma</td><td>Antiviral</td><td>Convalescent plasma from cured patients provides protective antibody against SARS-CoV-2</td><td>Proven efficacy</td></tr><tr><td>rhACE2</td><td>ACE2 blocker</td><td>rhACE2 completely binds to virus S-protein, thus protects host lungs from virus attack</td><td>Being tested in clinical trials</td></tr><tr><td>Chloroquine Hydroxychloroquine</td><td>Antimalaria</td><td>Endosomal acidification fusion inhibitor anti-inflammatory activity</td><td>Proven efficacy in completed clinical trials (clinical data partly not shown)</td></tr><tr><td>Tocilizumab</td><td>mAb</td><td>Humanized mAb targeting IL-6</td><td>Being tested in clinical trials</td></tr><tr><td>Sarilumab</td><td>mAb</td><td>Humanized mAb targeting IL-6</td><td>Being tested in clinical trials</td></tr><tr><td>Bevacizumab</td><td>mAb</td><td>Humanized mAb targeting VEGF</td><td>Being tested in clinical trials</td></tr><tr><td>Baricitinib</td><td>JAK inhibitor</td><td>Baricitinib attenuates proinflammatory response by inhibiting JAK and blocks virus entering into host cells through inhibiting AAK1</td><td>Being tested in clinical trials</td></tr><tr><td>MSCs</td><td>Cell therapy</td><td>MSCs have regenerative and immunomodulatory properties and protect lungs against ARDS</td><td>Proven efficacy in completed clinical trials</td></tr><tr><td>iNO</td><td>Vasodilator</td><td>iNO possesses capability of potent and selective pulmonary vasodilation and antimicrobial activity</td><td>Being tested in clinical trials</td></tr><tr><td>LHQW</td><td>TCM</td><td>LHQW is used for prevention and treatment for infuenza, and has previously been used for SARS outbreak</td><td>Being tested in clinical trials</td></tr><tr><td>Xuebijing injection</td><td>TCM</td><td>Xuebijing serving as endotoxin antagonist, anti-inflammatory agent and anti-coagulant is used for sepsis</td><td>Being tested in clinical trials</td></tr><tr><td>IFNs</td><td>Immunoenhancer</td><td>IFNs inhibit viral RNA transcription, protein translation and post translational modifification, thus suppress virus replication</td><td>Being tested in clinical trials</td></tr><tr><td>IVIG</td><td>Immunoenhancer</td><td>IVIG provides passive immunity and anti-inflammatory effects</td><td>Being tested in clinical trials</td></tr><tr><td>NK cell therapy</td><td>Immunoenhancer</td><td>NK cells can elicit rapid and robust protective effects in defense against viral infections through direct cytotoxicity and immunomodulatory capability</td><td>Being tested in clinical trials</td></tr><tr><td>Corticosteroids</td><td>Corticosteroids</td><td>Corticosteroids dampen proinflammatory cytokines and possess antifibrotic property</td><td>Still in controversy</td></tr><tr><td>Heparin</td><td>Anticoagulants</td><td>Heparin can reverse the hypercoagulability in severe cases of COVID-19</td><td>Proven efficacy in severe types of COVID-19</td></tr><tr><td>Vitamin C</td><td>Nutritional supportive care</td><td>Vitamin C boosts immunity by stimulating IFN production, supplying lymphocyte&#x000a0;proliferation and enhancing neutrophil phagocytic capability</td><td>Being tested in clinical trials</td></tr><tr><td>Vitamin D</td><td>Nutritional supportive care</td><td>Vitamin D induces secretion of antimicrobial peptides and has immunomodulatory property</td><td>Being tested in clinical trials</td></tr><tr><td>Zinc</td><td>Nutritional supportive care</td><td>Zinc is necessary for the immune system and has anti-viral activities</td><td>Being tested in clinical trials</td></tr><tr><td>Ibuprofen</td><td>NSAIDs</td><td>Ibuprofen has been widely used to treat fever or pain</td><td>Still in controversy</td></tr><tr><td>mRNA-1273</td><td>Vaccine</td><td>mRNA-1273 contains mRNA that can encode S protein of SARS-CoV-2</td><td>Being tested in clinical trials</td></tr><tr><td>Ad5-nCoV</td><td>Vaccine</td><td>Ad5-nCoV uses replication-defective adenovirus type 5 as vector to load some gene fragments of SARS-CoV-2 on it to express SARS-CoV-2 S protein</td><td>Being tested in clinical trials</td></tr><tr><td>PittCoVacc</td><td>Vaccine</td><td>PittCoVacc utilizes microneedle array to deliver pieces of S-protein of SARS-CoV-2 into body</td><td>Prepared for phase &#x02160; clinical trials</td></tr><tr><td>NVX-CoV2373</td><td>Vaccine</td><td>NVX-CoV2373 is a stable, prefusion protein developed through the advanced nanoparticle technology</td><td>Prepared for phase &#x02160; clinical trials</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviation: ARDS, acute respiratory distress syndrome; COVID-2019, corona virus disease 2019; HIV, human immunodeficiency virus; IFNs, interferons; IL-6, interleukin 6; iNO, inhaled nitric oxide; IVIG, intravenous gammaglobulin; LHQW, Lianhua Qingwen; mAb, monoclonal antibody; MSCs, mesenchymal stem cells; NK, natural killer cell; NSAIDs, non-steroidal anti-inflammatory drugs; rhACE2, recombinant human angiotensin-converting enzyme 2; SARS, severe acute respiratory syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TCM, traditional Chinese medicine; VEGF, vascular endothelial growth factor.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s0020"><label>2.2</label><title>Lopinavir/ritonavir</title><p id="p0040">Lopinavir/ritonavir (LPV-r) is a co-formulated human immunodeficiency virus (HIV)-specific protease inhibitor that serves as first-line therapy for HIV (<xref rid="b0080" ref-type="bibr">Barragan and Podzamczer, 2008</xref>). Concomitant use of ritonavir could increase the plasma half-life of lopinavir through cytochrome P450 inhibition in the liver. During the 2003 SARS outbreak, LPV-r was reported to have <italic>in vitro</italic> inhibitory activity against SARS-CoV (<xref rid="b0175" ref-type="bibr">Chu et al., 2004a</xref>), and combination therapy of LPV-r and ribavirin provided favorable results in treating patients with SARS (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) (<xref rid="b0175" ref-type="bibr">Chu et al., 2004b</xref>). Triple combination therapy with LPV-r, ribavirin, and IFN-&#x003b1; has shown clinical effectiveness for MERS (<xref rid="b0525" ref-type="bibr">Kim et al., 2016</xref>). Notwithstanding, a recent open-label randomized study with 199 patients in Wuhan showed that LPV-r monotherapy did not produce any therapeutic benefits for COVID-19 patients compared with standard supportive care, which might be caused by the higher throat viral loads in the LPV-r group, concurrent pharmacologic interventions, and late treatment initiation (<xref rid="t0005" ref-type="table">Table 1</xref>) (<xref rid="b0100" ref-type="bibr">Cao et al., 2020</xref>). The enrolled COVID-19 patients were critically ill, and LPV-r treatment might have been started relatively late. However, in another retrospective cohort study, combination therapy of LPV-r and arbidol was associated with improved pulmonary computed tomography images (<xref rid="b0205" ref-type="bibr">Deng et al., 2020</xref>). Collectively, the combination therapy of LPV-r and other antiviral agents in early stages of COVID-19 infection might hold promise for treating COVID-19.</p></sec><sec id="s0025"><label>2.3</label><title>Favipiravir</title><p id="p0045">Favipiravir, also known as Avigan&#x000ae; and originally developed and approved for the influenza virus infection epidemic in Japan, has a broad spectrum of antiviral activity (<xref rid="b0305" ref-type="bibr">Furuta et al., 2013</xref>). Once it enters cells, favipiravir undergoes phosphorylation to convert into its active phosphorylated form (favipinavir-RTP), which potently inhibits viral RNA polymerase, thereby interfering with viral genome replication (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) (<xref rid="b0310" ref-type="bibr">Furuta et al., 2005</xref>). Favipiravir demonstrated efficacy in inhibiting a wide range of viruses, including resistant influenza viruses and other RNA viruses, such as arenaviruses, bunyaviruses, and filoviruses (<xref rid="b0200" ref-type="bibr">Delang et al., 2018</xref>). Previous studies have showed that favipiravir is efficacious against Ebola virus in rodent models (<xref rid="b0760" ref-type="bibr">Oestereich et al., 2014</xref>, <xref rid="b0950" ref-type="bibr">Smither et al., 2014</xref>), while its effectiveness in humans is unproven (<xref rid="b0945" ref-type="bibr">Sissoko et al., 2016</xref>). Favipiravir appears to be effective in COVID-19. Two clinical trials involving a total of 340 patients were conducted in Wuhan and Shenzhen. At a press conference in March 17, 2020, Xinmin Zhang, an official of China&#x02019;s Science and Technology Ministry, stated that favipiravir appeared to be effective in COVID-19 (<xref rid="b0375" ref-type="bibr">Hackett, 2020</xref>). Preliminary clinical data from 80 patients in the Third People&#x02019;s Hospital of Shenzhen suggested that favipiravir exerted antiviral effects more potently than LPV-r, with no overt adverse reactions (<xref rid="b1010" ref-type="bibr">Third People's, 2020</xref>). The other clinical trial in Wuhan showed that, based on conventional therapy, favipiravir demonstrated higher efficacy than arbidol in terms of the 7-day recovery rate and duration of symptom attenuation in patients with moderate COVID-19 infection (<xref rid="b0135" ref-type="bibr">Chen et al., 2020a</xref>). Taken together, the clinical results of favipiravir are favorable (<xref rid="t0005" ref-type="table">Table 1</xref>); however, further study of favipiravir monotherapy using a large sample size is needed.</p></sec><sec id="s0030"><label>2.4</label><title>EIDD-2801</title><p id="p0050">Researchers from Emory University, the University of North Carolina, and Vanderbilt University Medical Center tested a new drug, EIDD-2801, for its <italic>in vitro</italic> efficacy against SARS-CoV-2, and its laboratory results are encouraging (<xref rid="b0915" ref-type="bibr">Sheahan et al., 2020</xref>). Based on EIDD-1931, an orally bioavailable ribonucleotide analog, EIDD-2801 is designed to optimize oral bioavailability and improve drug uptake in humans and non-human primates (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). EIDD-1931 has a variety of antiviral activities against numerous causal agents of deleterious viral infectious diseases, including influenza, chikungunya, Ebola, Venezuelan equine encephalitis, and coronavirus-associated diseases (<xref rid="b0025" ref-type="bibr">Agostini et al., 2019</xref>, <xref rid="b0770" ref-type="bibr">Painter et al., 2019</xref>, <xref rid="b0830" ref-type="bibr">Reynard et al., 2015</xref>, <xref rid="b1020" ref-type="bibr">Toots et al., 2019</xref>). As a ribonucleotide analog, EIDD-1931 shares similar mechanisms of action with remdesivir and exerts antiviral effects by mimicking a ribonucleotide, thereby mistakenly being incorporated into viral RNA, leading to lethal mutagenesis during virion RNA synthesis and inhibiting the RNA-dependent RNA polymerase encoded by the virus during viral replication (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) (<xref rid="b0770" ref-type="bibr">Painter et al., 2019</xref>, <xref rid="b0915" ref-type="bibr">Sheahan et al., 2020</xref>). The study suggested that EIDD-1931 robustly blocked the replication of SARS-CoV, MERS-CoV, and the newly emerging SARS-CoV-2 in cell assays. EIDD-2801 demonstrated its prophylactic and therapeutic effects in murine models of SARS and MERS, showing diminished viral lung titers, attenuated weight loss, ameliorated lung damage, and improved pulmonary function, which are dependent on the administered dosage and the treatment initiation time. Compared with remdesivir, EIDD-2801 appears to be favorable. EIDD-2801 has a more convenient oral administration, while remdesivir must rely on intravenous administration by a trained specialist. More importantly, EIDD-2801 showed active antiviral activity against remdesivir-resistant viruses, according to the data presented by the study. Of significant importance, EIDD-1931 appeared to be effective not just for SARS-CoV, MERS-CoV, and SARS-CoV-2, but also other coronavirus species, indicating its potential efficacy for emerging coronaviruses in the future. The U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug application for EIDD-2801, and clinical studies in humans are expected to start as soon as possible (<xref rid="t0005" ref-type="table">Table 1</xref>) (<xref rid="b0090" ref-type="bibr">BioSpace, 2020</xref>).</p></sec></sec><sec id="s0035"><label>3</label><title>Convalescent plasma</title><p id="p0055">Convalescent plasma collected from donors who have survived an infectious disease by producing protective antibodies is considered to provide a great degree of protection for recipients affected by the emerging virus (<xref rid="b0225" ref-type="bibr">Dodd, 2012</xref>). Convalescent plasma has been successfully employed to treat numerous infectious diseases, including the 2003 SARS-CoV-1 epidemic, 2009&#x02013;2010 H1N1 influenza virus pandemic, and 2012 MERS-CoV epidemic (<xref rid="b0225" ref-type="bibr">Dodd, 2012</xref>, <xref rid="b0445" ref-type="bibr">Hung et al., 2011</xref>, <xref rid="b0660" ref-type="bibr">Mair-Jenkins et al., 2015</xref>), for which modern medicine has no specifically effective treatment. In the absence of specific antiviral agents and vaccines for COVID-19, clinical trials have been conducted aimed at investigating the efficacy of convalescent plasma in treating COVID-19. A very recently published study by Chinese researchers confirmed the efficacy of convalescent plasma in controlling SARS-CoV-2 (<xref rid="t0005" ref-type="table">Table 1</xref>) (<xref rid="b0845" ref-type="bibr">Roback and Guarner, 2020</xref>). The report suggested that COVID-19 patients showed signs of improvement approximately 1&#x000a0;week after convalescent plasma transfusion. Another clinical study involved 10 critically ill patients infected with COVID-19 from 3 different hospitals in Wuhan suggested high-titer convalescent plasma transfusion can effectively neutralize SARS-CoV-2, leading to impeded inflammatory responses and improved symptom conditions without severe adverse events. All 10 patients receiving convalescent plasma transfusion showed improvement of clinical outcomes or were cured and discharged from hospital (<xref rid="b0240" ref-type="bibr">Duan et al., 2020</xref>). Given the clinical effectiveness of convalescent plasma, the FDA has granted clinical permission for applying convalescent plasma to the treatment of critically ill COVID-19 patients (<xref rid="b0265" ref-type="bibr">FDA, 2020</xref>).</p></sec><sec id="s0040"><label>4</label><title>Spike Protein-Angiotensin-Converting enzyme 2 blockers</title><sec id="s0045"><title>4.1. Angiotensin-converting enzyme 2 (ACE2)</title><p id="p0060">ACE2 serves as a negative regulator of the renin angiotensin system (RAS) and is widely distributed among lung tissue and many extrapulmonary tissues, including brain, heart, liver, kidney, endothelium, and intestine (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) (<xref rid="b0190" ref-type="bibr">Crackower et al., 2002</xref>, <xref rid="b0215" ref-type="bibr">Ding et al., 2004</xref>, <xref rid="b0380" ref-type="bibr">Hamming et al., 2004</xref>). Of them, alveolar epithelial type &#x02161; cells possess an abundance of ACE2 receptors (<xref rid="b1170" ref-type="bibr">Zhao et al., 2020</xref>). Unfortunately, ACE2 is also a functional receptor of SARS-CoV (<xref rid="b0585" ref-type="bibr">Li et al., 2003</xref>) and SARS-CoV-2 (<xref rid="b1190" ref-type="bibr">Zhou et al., 2020b</xref>). The spike (S) protein of SARS-CoV and SARS-CoV-2 binds to the host ACE2 receptor and then enters target cells (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). Critically, SARS-CoV-2 shows higher affinity for ACE2 than SARS-CoV (<xref rid="b1090" ref-type="bibr">Wrapp et al., 2020</xref>). Moreover, the S protein of SARS-CoV-2 contains a site that can be recognized and activated by a host enzyme called furin, which is highly expressed in the lungs (<xref rid="b0185" ref-type="bibr">Coutard et al., 2020</xref>). These findings might provide strong evidence for the high pathogenicity of SARS-CoV-2. Due to the pivotal role of widely distributed ACE2 in the entry and replication of viruses, blocking S protein binding to ACE2 might offer some protection against SARS-CoV-2 infection (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). A study using a murine model of SARS showed that SARS-CoV S protein binding to ACE2 led to RAS downregulation and consequently contributed to severe lung injury (<xref rid="b0455" ref-type="bibr">Imai et al., 2005</xref>). Therefore, recombinant human ACE2 (rhACE2) might protect host lungs against infection through an enhanced ACE2 level to neutralize the S protein on the SARS-CoV-2 surface. Clinical evidence has demonstrated the safety of rhACE2 application (<xref rid="b0400" ref-type="bibr">Haschke et al., 2013</xref>, <xref rid="b0515" ref-type="bibr">Khan et al., 2017</xref>). A recent <italic>in vitro</italic> study demonstrated that the fusion protein of rhACE2 with an Fc fragment shows high affinity binding to the receptor-binding domain of SARS-CoV-2 and potently neutralizes SARS-CoV-2 (<xref rid="b0560" ref-type="bibr">Lei et al., 2020</xref>). Additionally, the findings from a newly online published report in <italic>Cell</italic> were strongly supportive of potential efficacy of rhACE2 for SARS-CoV-2 infection (<xref rid="b1030" ref-type="bibr">Monteil et al., 2020</xref>). The study showed that clinical-grade human recombinant soluble ACE2 (hrsACE2) displayed potently inhibitory activity against SARS-CoV-2 in cell cultures and in engineered replicas of human blood vessels and kidneys in a dose-dependent manner. The researchers found that before infecting cells, SARS-CoV-2 co-incubated with hrsACE2, rather than mouse recombinant soluble ACE2, demonstrated dropped activity to infect cells. In the organoid level, administration of hrsACE2 significantly blocked SARS-CoV-2 infection in both engineered human blood vessels and kidneys without observed toxicity. However, note that this study focused on the early stages of SARS-CoV-2 infection, it is still unclear whether hrsACE2 can play a role in the later infection process. Taken together, it is likely that rhACE2 has potentially curative effectiveness in COVID-19. A clinical trial is underway to investigate the efficacy of rhACE2 in the treatment of COVID-19 (NCT04287686) (<xref rid="t0005" ref-type="table">Table 1</xref>).</p><p id="p0065">ACE inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are widely used for treating cardiovascular diseases. Studies have shown that ACEIs/ARBs can upregulate ACE2 expression (<xref rid="b0280" ref-type="bibr">Ferrario et al., 2005</xref>, <xref rid="b0470" ref-type="bibr">Ishiyama et al., 2004</xref>, <xref rid="b0490" ref-type="bibr">Karram et al., 2005</xref>), which might correlate with the susceptibility to SARS-CoV-2. However, evidence has shown that RAS activation and decreased ACE2 expression contribute to the pathological process of lung injury after SARS-CoV infection (<xref rid="b0535" ref-type="bibr">Kuba et al., 2005</xref>). Serum angiotensin II levels are markedly elevated and exhibit a linear positive correlation to viral load and lung injury in COVID-19 (<xref rid="b0625" ref-type="bibr">Liu et al., 2020d</xref>). Consequently, the effects of ACEIs/ARBs on lung-specific ACE2 expression in COVID-19 remain unknown. ACEIs/ARBs might have a dual role in COVID-19. On the one hand, the elevated ACE2 level might increase susceptibility to SARS-CoV-2, while on the other, ACE2 activation and RAS deregulation might ameliorate the acute lung injury, heart injury, and renal damage induced by SARS-CoV-2 (<xref rid="b0355" ref-type="bibr">Guo et al., 2020</xref>). However, there has been no definite evidence on whether taking ACEIs/ARBs is beneficial or harmful for COVID-19 infected patients.</p></sec></sec><sec id="s0050"><label>5</label><title>Chloroquine and hydroxychloroquine</title><p id="p0070">Chloroquine (CQ), a drug widely used in treating malarial and autoimmune diseases, also confers considerable broad-spectrum antiviral effects even against SARS-CoV (<xref rid="t0005" ref-type="table">Table 1</xref>) (<xref rid="b0505" ref-type="bibr">Keyaerts et al., 2004b</xref>, <xref rid="b0885" ref-type="bibr">Savarino et al., 2006</xref>, <xref rid="b1125" ref-type="bibr">Yan et al., 2013</xref>). A recent study demonstrated that CQ has anti-SARS-CoV-2 activity <italic>in vitro</italic> (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b1055" ref-type="bibr">Wang et al., 2020c</xref>). A subsequent letter in <italic>Bioscience</italic> confirmed that CQ is efficacious in treating COVID-19 pneumonia in numerous related clinical trials (<xref rid="b0320" ref-type="bibr">Gao et al., 2020</xref>). CQ therapy resulted in improved pulmonary lesions, shortened disease course, and good outcomes (<xref rid="t0005" ref-type="table">Table 1</xref>) (<xref rid="b0320" ref-type="bibr">Gao et al., 2020</xref>). Given the efficiency displayed by CQ in clinical practice, CQ has been included in the Guidelines for the Diagnosis and Treatment of COVID-19 (7th edition) issued by the National Commission of the People&#x02019;s Republic of China (<xref rid="b0730" ref-type="bibr">NHPFC, 2020</xref>).</p><p id="p0075">Hydroxychloroquine sulfate (HCQ) shares a similar chemical structure and mechanisms of action with CQ but with lower ocular toxicity (<xref rid="b0600" ref-type="bibr">Lim et al., 2009</xref>) and has proven efficacious in containing SARS-CoV-2 <italic>in vitro</italic> (<xref rid="b0610" ref-type="bibr">Liu et al., 2020a</xref>). CQ and HCQ exert antiviral function through various mechanisms. CQ has been shown to interfere with the glycosylation process of ACE2 in host cells, thereby inhibiting the efficiency of the binding of S protein with ACE2, in turn disrupting the virus/cell fusion process (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0885" ref-type="bibr">Savarino et al., 2006</xref>). CQ can increase the pH of acidic cellular organelles required for virus entry into host cells (<xref rid="b0880" ref-type="bibr">Savarino et al., 2003</xref>). In addition to its direct antiviral activity, CQ and HCQ can attenuate major &#x0201c;<italic>cytokine storms</italic>&#x0201d; (an overreaction of the immune system causing inflammatory &#x0201c;<italic>storms</italic>&#x0201d;) by decreasing cytokine production (interleukin [IL]-1, IL-6, and tumor necrosis factor [TNF], etc.) (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b1025" ref-type="bibr">van den Borne et al., 1997</xref>). Notably, high cytokine concentrations have been observed in seriously ill COVID-19 patients (<xref rid="b0440" ref-type="bibr">Huang et al., 2020</xref>), indicating that over-reactive immune responses exacerbate COVID-19. Therefore, the immune-modulating activity of HCQ might partially account for its efficient control of SARS-CoV-2 infection. CQ and HCQ are therefore promising drugs of choice for large-scale use due to their low cost, wide availability and potential efficacy for treating COVID-19. CQ and HCQ need to be administered with caution when treating COVID-19 infection to prevent toxicity.</p><p id="p0080">A recent open-label study in France showed that HCQ treatment was significantly associated with viral load reduction/disappearance in COVID-19 patients and that its effect was reinforced by azithromycin (<xref rid="b0325" ref-type="bibr">Gautret et al., 2020</xref>). Although this study is an open-label study using small sample size, the combination of HCQ and azithromycin could be promising candidate for COVID-19 patients. In contrast, a multinational, network cohort and self-controlled case series study demonstrated that short-term HCQ treatment is safe (<xref rid="b0540" ref-type="bibr">Lane et al., 2020</xref>). However, combination of HCQ and azithromycin may induce an increased risk of 30&#x000a0;day cardiovascular mortality, chest pain/angina, and heart failure (<xref rid="b0540" ref-type="bibr">Lane et al., 2020</xref>). Therefore, we must pay the attention for the combination therapy in the management of COVID-19 patients.</p></sec><sec id="s0055"><label>6</label><title>Human monoclonal antibody</title><sec id="s0060"><label>6.1</label><title>Tocilizumab and sarilumab</title><p id="p0085">Tocilizumab (TCZ) and sarilumab are monoclonal antibodies against IL-6 receptors and have been employed to treat rheumatoid arthritis (<xref rid="b0745" ref-type="bibr">Nishimoto et al., 2000</xref>, <xref rid="b0815" ref-type="bibr">Raimondo et al., 2017</xref>). TCZ and sarilumab efficiently inhibit IL-6 through both membrane-bound and soluble IL-6R (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0815" ref-type="bibr">Raimondo et al., 2017</xref>, <xref rid="b0870" ref-type="bibr">Sakkas, 2016</xref>). TCZ has been approved by the FDA for treating cytokine release syndrome marked by excessive cytokine production and consequently rapid multiorgan damage (lungs, kidney, and heart) (<xref rid="b0930" ref-type="bibr">Shimabukuro-Vornhagen et al., 2018</xref>). COVID-19 disease severity depends on the increase in pro-inflammatory factors [IL-6, IL-1, IL-2, IL-7, IL-10, granulocyte-colony stimulating factor, interferon-&#x003b3;-inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein-1 alpha, and TNF-&#x003b1;] (<xref rid="b0440" ref-type="bibr">Huang et al., 2020</xref>, <xref rid="b0855" ref-type="bibr">Ruan et al., 2020</xref>, <xref rid="b1185" ref-type="bibr">Zhou et al., 2020a</xref>), suggesting that cytokine storms are involved in the development of COVID-19. One of the key cytokines involved in the immune system perturbation is IL-6 (<xref rid="b0685" ref-type="bibr">Mehta et al., 2020</xref>). As IL-6 receptor antagonists, TCZ and sarilumab have therefore been hypothesized to exert suppressive effects on exuberant and dysfunctional systematic inflammation in patients infected with SARS-CoV-2 and further improve patients&#x02019; condition. Three clinical trials (ChiCTR2000030196, ChiCTR2000030442, and ChiCTR2000029765) for TCZ have been approved for COVID-19, and the National Health and Family Planning Commission of China has approved the treatment with TCZ in patients with elevated IL-6 level. (<xref rid="t0005" ref-type="table">Table 1</xref>) (<xref rid="b0730" ref-type="bibr">NHPFC, 2020</xref>). Encouraging results have been seen in Italy where three seriously ill patients administered TCZ showed the signs of improvement (<xref rid="b0465" ref-type="bibr">Italian ANSA News Agency, 2020</xref>). According to the announcement from Regeneron Pharmaceuticals and Sanofi on March 16, 2020, a phase &#x02161;/III clinical trial in the U.S. for sarilumab has been conducted to assess its therapeutic effects in patients with severe COVID-19 infection (<xref rid="t0005" ref-type="table">Table 1</xref>) (<xref rid="b0820" ref-type="bibr">Regeneron, 2020</xref>).</p></sec><sec id="s0065"><label>6.2</label><title>Bevacizumab</title><p id="p0090">Bevacizumab is a monoclonal anti-vascular endothelial growth factor (VEGF) antibody that competes with VEGF receptors on the surface of endothelial cells for VEGF binding, thereby inhibiting the effects caused by binding VEGF to its receptors, such as endothelial cell proliferation and neovascularization (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0275" ref-type="bibr">Ferrara et al., 2004</xref>). VEGF produced by various inflammatory and epithelial cells is a potent vascular permeability inducer (<xref rid="b0245" ref-type="bibr">Dvorak et al., 1995</xref>). Previous reports have shown that plasma VEGF levels markedly increase in patients with ARDS (<xref rid="b1005" ref-type="bibr">Thickett et al., 2001</xref>). Given the causal link between ARDS and increased vascular permeability and pulmonary edema (<xref rid="b0255" ref-type="bibr">Fanelli and Ranieri, 2015</xref>). Bevacizumab might be a potential anti-ARDS therapeutic approach. ARDS is a common complication in severe cases of COVID-19 (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). Bevacizumab is therefore likely to be a promising therapy against COVID-19 (<xref rid="t0005" ref-type="table">Table 1</xref>).</p></sec></sec><sec id="s0070"><label>7</label><title>Janus Kinase inhibitor</title><sec id="s0075"><label>7.1</label><title>Baricitinib</title><p id="p0095">Baricitinib, a highly selective janus kinase (JAK) inhibitor, has been approved for treating rheumatoid arthritis (<xref rid="b0040" ref-type="bibr">Al-Salama and Scott, 2018</xref>). JAK-dependent pathways are responsible for producing a variety of cytokines involved in the pathogenesis of the progression process of COVID-19 characterized by elevated levels of inflammatory factors (e.g., IL-6, IL-7, and IL-2) (<xref rid="b0755" ref-type="bibr">O'Shea and Plenge, 2012</xref>). Baricitinib also serves as an inhibitor of adaptor-associated kinase 1 (AAK1, a member of the numb-associated kinase family), which plays a central role in regulating endocytosis through which the virus invades host cells (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0840" ref-type="bibr">Richardson et al., 2020</xref>). Therefore, baricitinib might exert beneficial effects on COVID-19 pneumonia, not only by impeding overexuberant immune responses by hijacking cytokine signaling pathways but also preventing SARS-CoV-2 from entering host cells. However, blockage of JAK-dependent pathways by baricitinib can also inhibit production of interferons (IFNs) (<xref rid="b0755" ref-type="bibr">O'Shea and Plenge, 2012</xref>), which might have antiviral activity against SARS-CoV-2 (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0970" ref-type="bibr">Str&#x000f6;her et al., 2004</xref>). Baricitinib treatment is therefore a double-edged sword (<xref rid="t0005" ref-type="table">Table 1</xref>), and choosing the appropriate time to administer baricitinib is vitally important. For severely ill patients with abnormal biomarkers, cautious baricitinib treatment might yield clinically beneficial effects.</p></sec></sec><sec id="s0080"><label>8</label><title>Mesenchymal stem cells</title><p id="p0100">Mesenchymal stem cells (MSCs) are multipotent cells isolated from diverse mesenchymal tissues (e.g., bone marrow, umbilical cord, adipose tissue) (<xref rid="b0655" ref-type="bibr">Lv et al., 2014</xref>). By virtue of their low immunogenicity (<xref rid="b0120" ref-type="bibr">Chamberlain et al., 2007</xref>), proven safety (<xref rid="b1175" ref-type="bibr">Zheng et al., 2014</xref>), and reparative and immunomodulatory properties (<xref rid="b0315" ref-type="bibr">Galipeau and Sens&#x000e9;b&#x000e9;, 2018</xref>, <xref rid="b0690" ref-type="bibr">Mei et al., 2010</xref>), MSCs are attractive therapeutic candidates for treating a wide range of diseases [e.g., graft-versus-host disease (<xref rid="b0545" ref-type="bibr">Le Blanc et al., 2008</xref>), sepsis, and ARDS] (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0070" ref-type="bibr">Asmussen et al., 2014</xref>, <xref rid="b0530" ref-type="bibr">Krasnodembskaya et al., 2012</xref>). A large body of preclinical data has demonstrated the efficacy of MSCs in treating ARDS, manifested in reduced pulmonary edema, decreased plasma concentrations of pro-inflammatory cytokines, and reduced mortality rates (<xref rid="b0165" ref-type="bibr">Chimenti et al., 2012</xref>, <xref rid="b0210" ref-type="bibr">Devaney et al., 2015</xref>, <xref rid="b1110" ref-type="bibr">Xu et al., 2007</xref>). Although not fully understood, the mechanisms by which MSCs exert protective effects include their direct regenerative ability and secretion of multiple paracrine factors including antibacterial peptides and anti-inflammatory cytokines such as IL-10 (<xref rid="b0360" ref-type="bibr">Gupta et al., 2012</xref>, <xref rid="b0365" ref-type="bibr">Gupta et al., 2007</xref>). Another attractive property of MSCs is immune response modulation (<xref rid="b0015" ref-type="bibr">Aggarwal and Pittenger, 2005</xref>). MSCs have been shown to enlarge the proportion of regulatory T cells and decrease pro-inflammatory factors such as IL-6 and TNF-&#x003b1; (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0360" ref-type="bibr">Gupta et al., 2012</xref>, <xref rid="b0580" ref-type="bibr">Li et al., 2012</xref>, <xref rid="b0805" ref-type="bibr">Prevosto et al., 2007</xref>). MSCs showed positive efficacy in a recent study of COVID-19 patients. Treatment with allogenic MSC transplantation at Beijing YouAn Hospital showed significantly improved functional outcomes without obvious adverse effects in 7 COVID-19 patients (<xref rid="t0005" ref-type="table">Table 1</xref>) (<xref rid="b0565" ref-type="bibr">Zikuan Leng et al., 2020</xref>). Adoptive MSC transfer might therefore be a valuable treatment option for COVID-19.</p></sec><sec id="s0085"><label>9</label><title>Inhaled nitric oxide (iNO)</title><p id="p0105">Nitric oxide (NO) is a key endogenous molecule implicated in a variety of physiological and pathological processes including smooth muscle relaxation, immune responses and antimicrobial activities (<xref rid="b0875" ref-type="bibr">Saura et al., 1999</xref>, <xref rid="b0890" ref-type="bibr">Schmidt and Walter, 1994</xref>). Due to its potent and selective pulmonary vasodilation, iNO has been extensively applied to treat pulmonary hypertension, ARDS and other respiratory diseases with a relative good safety profile (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0345" ref-type="bibr">Griffiths and Evans, 2005</xref>, <xref rid="b0790" ref-type="bibr">Pepke-Zaba et al., 1991</xref>). Of note, previously published <italic>in-vitro</italic> studies indicated NO possessed inhibitory effects on SARS-CoV replication (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) (<xref rid="b0035" ref-type="bibr">Akerstr&#x000f6;m et al., 2005</xref>, <xref rid="b0500" ref-type="bibr">Keyaerts et al., 2004a</xref>). Moreover, a small-sample clinical study testing the efficacy of iNO in the treatment of SARS showed, 6 severely infected patients receiving iNO therapy presented with improved arterial oxygenation and reduction in a need for ventilator support (<xref rid="b0150" ref-type="bibr">Chen et al., 2004</xref>). In view of the high incidence of pulmonary complications in COVID-19 infected patients, iNO therapy may serve as a promising candidate for treating severe cases of COVID-19 via alleviating lung damage. Currently, a related phase &#x02161; clinical trial testing iNO is underway in COVID-19 infected patients complicated with ARDS (NCT04306393 and NCT04305457).</p></sec><sec id="s0090"><label>10</label><title>Traditional Chinese medicine treatment</title><p id="p0110">Traditional Chinese medicine (TCM) is a unique and well-established system of medicine widely employed for thousands of years to prevent and treat numerous diseases in China. In the battle to stop the epidemic situation of COVID-19, the integration of traditional Chinese and western medicine is a unique scheme in China. Approximately 85% of Chinese COVID-19 patients underwent TCM treatment as reported by XuNanping, the vice minister of Science and Technology of China (<xref rid="b0170" ref-type="bibr">China's State Council, 2020</xref>). In clinical practice, several kinds of TCM have demonstrated their beneficial effects in treating patients with COVID-19 pneumonia (<xref rid="b0825" ref-type="bibr">Ren et al., 2020</xref>). Lianhua Qingwen (LHQW) has a broad-spectrum antiviral effect on a host of influenza viruses, such as influenza A (H1N1), and HPAI A (H7N9) viruses, by inhibiting viral propagation and regulating immune function (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0220" ref-type="bibr">Ding et al., 2017</xref>, <xref rid="b0230" ref-type="bibr">Dong et al., 2014</xref>). LHQW has been commonly used for treating viral influenza clinically and played a key role in controlling SARS-CoV during the 2003 outbreak. Recently, LHQW was reported to have inhibitory activity against SARS-CoV-2 and anti-inflammatory effects <italic>in vitro</italic> (<xref rid="t0005" ref-type="table">Table 1</xref>) (<xref rid="b0860" ref-type="bibr">Runfeng et al., 2020</xref>).</p><p id="p0115">Xuebijing (whose chemical composition includes safflower yellow A, paginin, ferulic acid, and salvianolic acid B) functions as an endotoxin antagonist, anti-inflammatory agent, and anticoagulant (<xref rid="b0405" ref-type="bibr">He et al., 2013</xref>, <xref rid="b0980" ref-type="bibr">Sun et al., 2010</xref>, <xref rid="b1105" ref-type="bibr">Xu et al., 2009</xref>, <xref rid="b1150" ref-type="bibr">Zhang et al., 2006</xref>) and has been widely used in China as a therapy for sepsis (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0140" ref-type="bibr">Chen et al., 2018</xref>). A clinical trial showed that injecting Xuebijing improved the symptoms of severe pneumonia (<xref rid="b1060" ref-type="bibr">Wang et al., 2016</xref>). Given the cytokine storms in severe COVID-19 infection, administering Xuebijing could turn critically ill cases into mild ones by attenuating the overactivated immune responses and preventing progressive pathological deterioration. Two clinical trials aimed at testing the efficacy and safety of Xuebijing injection for COVID-19 have been registered in the Chinese Clinical Trial Registry (ChiCTR2000030388 and ChiCTR2000029381) (<xref rid="t0005" ref-type="table">Table 1</xref>).</p><p id="p0120">In addition to LHQW and Xuebijing, the Chinese clinical guidelines for COVID-19 pneumonia treatment have included Jinhua Qinggan granules, Shufeng Jiedu capsules, and Lung Cleansing and Detoxifying Decoction, given their potential efficacy and few adverse effects in clinically treating COVID-19 infection (<xref rid="b0730" ref-type="bibr">NHPFC, 2020</xref>).</p></sec><sec id="s0095"><label>11</label><title>Immunoenhancers</title><sec id="s0100"><label>11.1</label><title>Interferons</title><p id="p0125">IFNs are large families of numerous type &#x02160; species (IFN-&#x003b1;, IFN-&#x003b2;, IFN-&#x003b5;, IFN-&#x003ba;, and IFN-&#x003c9;) and one type &#x02161; species (IFN-&#x003b3;) (<xref rid="b0630" ref-type="bibr">Liu, 2005</xref>, <xref rid="b0785" ref-type="bibr">Parkin and Cohen, 2001</xref>). Type &#x02160; IFNs have demonstrated inhibitory effects on a wide range of viruses including SARS-CoV (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0700" ref-type="bibr">Minagawa et al., 1987</xref>, <xref rid="b0955" ref-type="bibr">Sperber and Hayden, 1989</xref>, <xref rid="b0970" ref-type="bibr">Str&#x000f6;her et al., 2004</xref>, <xref rid="b0985" ref-type="bibr">Tan et al., 2004</xref>). When they encounter viruses, host cells form and release IFNs, which protect the original and adjacent cells against attack. The antiviral state produces its effects by several means, such as inhibiting viral RNA transcription, protein translation, and post-translational modification (<xref rid="f0010" ref-type="fig">Fig. 2</xref> and <xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0195" ref-type="bibr">De Andrea et al., 2002</xref>). To date, the clinical effect of IFN intervention in COVID-19 infection is ambiguous. Previous evidence confirmed IFN efficacy in inhibiting SARS-CoV (<xref rid="b0180" ref-type="bibr">Cinatl et al., 2003</xref>, <xref rid="b0865" ref-type="bibr">Sainz et al., 2004</xref>). IFN-&#x003b1; showed <italic>in vitro</italic> inhibitory effects on SARS-CoV at concentrations of 1000&#x000a0;IU/ml (<xref rid="b0970" ref-type="bibr">Str&#x000f6;her et al., 2004</xref>). Interestingly, recombinant human IFN-&#x003b2;1a within a safe dose range exhibited more potent activity on SARS-CoV (<xref rid="b0420" ref-type="bibr">Hensley et al., 2004</xref>). As a registered agent for chronic hepatitis C, IFN-&#x003b1;2b was reported to protect type 1 pneumocytes against SARS coronavirus infection in macaques (<xref rid="b0370" ref-type="bibr">Haagmans et al., 2004</xref>). Combined treatment of IFN-&#x003b1;-2a and ribavirin was shown to have antiviral effects on MERS-CoV (<xref rid="b0250" ref-type="bibr">Falzarano et al., 2013</xref>). In addition to their antiviral activity, IFNs show an immunomodulatory capability; type &#x02160; interferons can enhance natural killer (NK)-cell cytotoxicity, enhance the expression of major histocompatibility complex &#x02160; proteins, as well as promote IFN production and the proliferation of NK cells and macrophages (<xref rid="b0195" ref-type="bibr">De Andrea et al., 2002</xref>, <xref rid="b0330" ref-type="bibr">Goodbourn et al., 2000</xref>, <xref rid="b0905" ref-type="bibr">Sen, 2001</xref>). IFN-&#x003b1; in conjunction with corticosteroids were shown to improve oxygen saturation and facilitate more rapid resolution of radiographic lung abnormalities in SARS infection (<xref rid="b0635" ref-type="bibr">Loutfy et al., 2003</xref>). A study using a MERS-CoV infection mouse model indicated that early application of exogenous IFN-&#x003b2; facilitated virus clearance and protected against fatal lung infection, while delayed IFN-&#x003b2; administration tended to elevate damaging proinflammatory cytokine responses and led to deleterious outcomes (<xref rid="b0130" ref-type="bibr">Channappanavar et al., 2019</xref>). Given the inconclusive effects of IFNs in treating viral infectious diseases, IFNs and combined therapy should be prudently employed with COVID-19 infection (<xref rid="t0005" ref-type="table">Table 1</xref>).</p></sec><sec id="s0105"><label>11.2</label><title>Intravenous gamma globulin</title><p id="p0130">Intravenous gamma globulin (IVIG) as purified IgG products prepared from pooled human plasma has been widely used for treating numerous inflammation-related diseases including heart failure, adult respiratory distress syndrome, and vasculitis (<xref rid="b0475" ref-type="bibr">Jolles et al., 2005</xref>). IVIG demonstrates its passive immunity and anti-inflammatory effects by supplying idiotypic antibodies (<xref rid="b0495" ref-type="bibr">Kaveri et al., 1991</xref>), binding to Fc receptors (<xref rid="b0270" ref-type="bibr">Fehr et al., 1982</xref>), suppressing pathogenic cytokines (<xref rid="b0050" ref-type="bibr">Andersson and Andersson, 1990</xref>, <xref rid="b0055" ref-type="bibr">Andersson et al., 1993</xref>), preventing formation of membranolytic attack complexes (<xref rid="b0650" ref-type="bibr">Lutz et al., 1996</xref>), and modulating T-cell function (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0675" ref-type="bibr">Marchalonis et al., 1992</xref>). Transchromosomic bovine-produced human polyclonal immunoglobulin G antibodies inhibited MERS-CoV in murine models and <italic>in vitro</italic> assays (<xref rid="b0645" ref-type="bibr">Luke et al., 2016</xref>). Due to the scarcity of human-derived IgG products (or convalescent plasma), therapeutic immunoglobulin might provide insights for COVID-19 treatment (<xref rid="t0005" ref-type="table">Table 1</xref>). However, IVIG should be carefully administered given its numerous adverse effects (e.g., myalgia, fever, renal failure (<xref rid="b0005" ref-type="bibr">Achiron, 1997</xref>, <xref rid="b0085" ref-type="bibr">Bertorini et al., 1996</xref>, <xref rid="b1040" ref-type="bibr">Wajanaponsan and Cheng, 2004</xref>), and venous thromboembolism (<xref rid="b0430" ref-type="bibr">Hoffmann and Enk, 2019</xref>). Thromboembolism was found in a third of patients with SARS who underwent IVIG treatment during the SARS outbreak in Singapore (<xref rid="b0570" ref-type="bibr">Lew et al., 2003</xref>).</p></sec><sec id="s0110"><label>11.3</label><title>Natural killer (NK) cell therapy</title><p id="p0135">NK cells, a small subset of peripheral white blood cells, serve as an essential part of innate immune response. NK cells can elicit rapid and robust protective effects in defense against viral infections through direct cytotoxicity and immunomodulatory capability (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b1035" ref-type="bibr">Vivier et al., 2008</xref>). Once recognizing infected host cells, NK cells trigger targeted cell apoptosis by perforin- and granzyme B-mediated pathways and secrete multiple cytokines involved in regulation of innate and adaptive immune responses, which facilitate viral clearance (<xref rid="b0450" ref-type="bibr">Iannello et al., 2008</xref>). NK cell-based immunotherapies have long been investigated for treating malignancies, albeit with limited clinical practice due to the difficulty to obtain sufficient cell numbers for adoptive transfer (<xref rid="b0555" ref-type="bibr">Lee, 2019</xref>). Recently, CYNK-001, an investigational allogeneic NK cell therapy derived from placental hematopoietic stem cells, has passed through an investigational new drug application approved by FDA (<xref rid="b0115" ref-type="bibr">Celularity, 2020</xref>). As a NK cell product, CYNK-001 harbors the potential for inhibiting viral infection through direct killing SARS-CoV-2 infected host cells and indirect inducing immune responses. However, there exists controversy about whether the elicited strong inflammatory responses are favorable or detrimental for patients infected with severe COVID-19. The efficacy and safety of NK cell therapy for COVID-19 require to be tested by ongoing related clinical trials.</p></sec></sec><sec id="s0115"><label>12</label><title>Corticosteroids</title><p id="p0140">Due to their excellent anti-inflammatory, antifibrotic properties and ability to suppress collagen deposition, corticosteroids are frequently used to treat ARDS and sepsis (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0415" ref-type="bibr">Heming et al., 2018</xref>, <xref rid="b0835" ref-type="bibr">Rhen and Cidlowski, 2005</xref>, <xref rid="b1015" ref-type="bibr">Thompson, 2003</xref>). Despite the long history of administering corticosteroids, their therapeutic effectiveness and safety remain controversial. Several clinical trials and <italic>meta</italic>-analyses have indicated that corticosteroids are associated with increased mortality, a tendency for requiring mechanical ventilation therapy, and relatively longer hospitalizations for SARS, MERS, and H1N1 infections (<xref rid="b0060" ref-type="bibr">Arabi et al., 2018</xref>, <xref rid="b0395" ref-type="bibr">Han et al., 2011</xref>, <xref rid="b0960" ref-type="bibr">Stockman et al., 2006</xref>). These adverse events are partly due to the suppression of normal host immune responses and impeded viral clearance. Numerous studies have, however, demonstrated corticosteroids&#x02019; beneficial effects on physiologic outcomes in virus-associated respiratory diseases, supporting the proper application of corticosteroids in these cases, especially critical cases (<xref rid="b0575" ref-type="bibr">Li et al., 2017</xref>, <xref rid="b0940" ref-type="bibr">Siemieniuk et al., 2015</xref>). A retrospective study of 401 patients with SARS showed that corticosteroids reduced case fatality rates and shorten hospital stays (<xref rid="b0160" ref-type="bibr">Chen et al., 2006</xref>). An accurate conclusion regarding the therapeutic effect of corticosteroids in treating COVID-19 cannot therefore be drawn (<xref rid="t0005" ref-type="table">Table 1</xref>). High corticosteroid doses are closely associated with adverse events such as secondary infections, delayed viral clearance, and emergence of viral resistance. According to the Guidelines for the Diagnosis and Treatment of COVID19 (7th edition) in China (<xref rid="b0730" ref-type="bibr">NHPFC, 2020</xref>), however, prudent low-to-moderate doses of corticosteroids could yield potential therapeutic benefits for a subset of seriously ill patients with COVID-19 pneumonia, recommendations in line with the interim clinical management guidance for COVID-19 released by the World Health Organization, which advised against routinely administering corticosteroids except for clinical indications such as exacerbated chronic obstructive pulmonary disease and septic shock (<xref rid="b1080" ref-type="bibr">WHO, 2020b</xref>).</p></sec><sec id="s0120"><label>13</label><title>Anticoagulants</title><p id="p0145">
<xref rid="b0995" ref-type="bibr">Tang et al. (2020b)</xref> investigated the effects of anticoagulant heparin in patients with severe COVID-19. The D-dimer, prothrombin time and age were positively, and platelet count was negatively correlated with 28-day mortality. There was no difference on 28-day mortality between heparin users and nonusers. However, the 28-day mortality of heparin users was lower than nonusers. This study suggests that anticoagulant therapy with heparin appears to be associated with better prognosis in severe COVID-19 patients (<xref rid="b0995" ref-type="bibr">Tang et al., 2020b</xref>). Interestingly, patients with severe pneumonia by COVID-19 had higher platelet count than those induced non-COVID-19, and only the former with markedly elevated D-dimer may benefit from anticoagulant therapy (<xref rid="b1140" ref-type="bibr">Yin et al., 2020</xref>). Future study using a large sample size is needed to confirm the effects of heparin in the management of COVID-19 patients.</p><p id="p0150">A recent study demonstrated the interaction between the SARS-CoV-2 spike S1 protein receptor binding domain (SARS-CoV-2 S1 RBD) and heparin, suggesting the development of heparin-based therapeutics (<xref rid="b0695" ref-type="bibr">Microft-West et al., 2020</xref>). It is of great interest to develop the novel heparin-based compounds for COVID-19.</p></sec><sec id="s0125"><label>14</label><title>Vitamins</title><sec id="s0130"><label>14.1</label><title>Vitamin C</title><p id="p0155">Vitamin C has pleiotropic roles in modulating the immune system (<xref rid="b0105" ref-type="bibr">Carr and Maggini, 2017</xref>) and is known for its antioxidant properties, and antioxidants are generally accepted as an adjuvant therapy for critically ill patients, whose vitamin C levels are markedly decreased (<xref rid="b0110" ref-type="bibr">Carr et al., 2017</xref>, <xref rid="b0725" ref-type="bibr">Nakano and Suzuki, 1984</xref>). Vitamin C exerts positive effects on the immune system by stimulating IFN production, supporting lymphocyte proliferation, and boosting neutrophil phagocytic capability (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0680" ref-type="bibr">May and Harrison, 2013</xref>, <xref rid="b0765" ref-type="bibr">Oudemans-van Straaten et al., 2014</xref>, <xref rid="b1085" ref-type="bibr">Wilson, 2013</xref>). In acute lung injury and ARDS, excessive neutrophil accumulation in inflammatory loci results in lung tissue damage through the release of necrotic cell contents (known as neutrophil extracellular traps) (<xref rid="b0780" ref-type="bibr">Papayannopoulos, 2018</xref>, <xref rid="b1065" ref-type="bibr">Weiss, 1989</xref>), and vitamin C is reported to prevent this process (<xref rid="b0715" ref-type="bibr">Mohammed et al., 2013</xref>). In animal models of sepsis, vitamin C was shown to protect lung barrier function and reduce lung vascular injury through diminishing inflammatory responses and coagulant changes (<xref rid="b0285" ref-type="bibr">Fisher et al., 2012</xref>, <xref rid="b0290" ref-type="bibr">Fisher et al., 2011</xref>). A phase &#x02160; trial in patients with critically severe sepsis reported that high doses of vitamin C reduced the extent of multiple organ failure and mitigated circulating injury biomarker levels (<xref rid="b0300" ref-type="bibr">Fowler et al., 2014</xref>). Placebo-controlled trials have shown that vitamin C could reduce the duration of colds (<xref rid="b0410" ref-type="bibr">Hemil&#x000e4; and Chalker, 2013</xref>). Given that COVID-19 patients frequently present lung damage, vitamin C could be a promising candidate (<xref rid="t0005" ref-type="table">Table 1</xref>).</p></sec><sec id="s0135"><label>14.2</label><title>Vitamin D</title><p id="p0160">Vitamin D is known to modulate the innate and adaptive immune system, and its deficiency is associated with increased autoimmunity as well as in an increased susceptibility to infection (<xref rid="b0065" ref-type="bibr">Aranow, 2011</xref>). <xref rid="b0335" ref-type="bibr">Grant et al. (2020)</xref> pointed the role of vitamin D in reducing the risk of respiratory tract infections by COVID-19. Actions of mechanism of vitamin D include the induction of antimicrobial peptides (i.e., cathelicidins and defensins) that can reduce viral replication rate and impeding pro-inflammatory cytokines. Several clinical trials of vitamin D in patients with COVID-19 (i.e., NCT04334005, NCT04344041) are underway.</p></sec></sec><sec id="s0140"><label>15</label><title>Non-steroidal anti-inflammatory drugs (NSAIDs)</title><p id="p0165">The non-steroidal anti-inflammatory drugs (NSAIDs) including ibuprofen have been widely used to treat fever or pain. In March 11, 2020, <xref rid="b0260" ref-type="bibr">Fang et al. (2020)</xref> reported the hypothesis that ibuprofen can increase the risk of developing severe and fatal COVID-19 since ibuprofen is known to upregulate ACE2 receptors. However, there is no evidence indicating that ibuprofen worsens the clinical symptoms of COVID-19 infected patients (<xref rid="b0295" ref-type="bibr">FitzGerald, 2002</xref>, <xref rid="b0480" ref-type="bibr">Kakodkar et al., 2020</xref>). In March 23, 2020, US FDA announced that it is not aware of any evidence that NSAIDs such as ibuprofen could worsen COVID-19.</p></sec><sec id="s0145"><label>16</label><title>Vaccine</title><p id="p0170">There is no specific vaccine currently available for containing COVID-19 infection. To meet the urgent need for an effective vaccine in the context of active SARS-CoV-2 transmission, companies and institutions worldwide have been working on a SARS-CoV-2 vaccine through various approaches, resulting in a series of vaccine candidates (<xref rid="b0850" ref-type="bibr">Routley, 2020</xref>). One of the most promising one of them is mRNA-1273, which is developed by National Institute of Allergy and Infectious Disease scientists together with biotechnology company Moderna (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0705" ref-type="bibr">Moderna, 2020a</xref>; <xref rid="b0735" ref-type="bibr">NIH, 2020</xref>). As an mRNA vaccine, mRNA-1273 embedded in lipid nanoparticles encodes viral S proteins of SARS-CoV-2 and then delivers the antigen into human cells to elicit SARS-CoV-2-specific neutralizing antibodies and potent immune responses, thereby protecting healthy individuals against COVID-19 infection (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). mRNA vaccine is superior to other conventional vaccines, given its high potency, short production cycles and safety as lack of actual viral genome (<xref rid="b0030" ref-type="bibr">Ahn et al., 2020</xref>). A phase &#x02160;, open-label, dose-ranging trial of mRNA-1273 was conducted in 45 healthy adult volunteers aged 18 to 55&#x000a0;years with three different doses of mRNA-1273 to assess its efficacy and appropriate effective dose (<xref rid="t0005" ref-type="table">Table 1</xref>) (NCT04283461). On April 16, 2020, Moderna received the award from US Government Agency BRADA for up to $483 million to accelerate development of mRNA-1273 against COVID-19 (<xref rid="b0710" ref-type="bibr">Moderna, 2020b</xref>).</p><p id="p0175">mRNA-1273 was the first vaccine to be tested in a clinical trial, followed closely by another promising candidate called Ad5-nCoV, which was jointly developed by Tianjin-based biotechnology company Cansino and the Institute of Biotechnology of the Academy of Military Medical Sciences. Developed with Cansino&#x02019;s adenovirus-based viral vector vaccine technology platform, Ad5-nCoV uses replication-defective adenovirus type 5 as a vector to load SARS-CoV-2 gene fragments onto it to express the SARS-CoV-2 S protein (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) (<xref rid="b0925" ref-type="bibr">Shi et al., 2020b</xref>). According to Cansino, preclinical data in animal models demonstrated that Ad5-nCoV can elicit robust immune responses and a favorable safety profile (<xref rid="b0665" ref-type="bibr">Mak, 2020</xref>). Currently, the phase &#x02160; clinical trial evaluating the safety and efficacy of Ad5-nCoV has been initiated in Wuhan (<xref rid="t0005" ref-type="table">Table 1</xref>) (<xref rid="b0925" ref-type="bibr">Shi et al., 2020b</xref>).</p><p id="p0180">A recently published study in <italic>the Lancet</italic> introduced a newly developed potentially effective SARS-CoV-2 vaccine named PittCoVacc, short for Pittsburgh Coronavirus Vaccine, developed by University of Pittsburgh School of Medicine scientists (<xref rid="b0520" ref-type="bibr">Kim et al., 2020</xref>). PittCoVacc uses S-protein fragments of SARS-CoV-2 to stimulate the generation of specific antibodies (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). PittCoVacc is delivered with a novel technique known as microneedle array, a fingertip-sized patch of 400 tiny needles. This strategy can elicit more potent immune responses than conventional subcutaneous needle injection and has been demonstrated to be sufficiently safe. PittCoVacc has been tested immunogenicity in mice with the emergence of substantial SARS-CoV-2 antibodies within 2&#x000a0;weeks after prime immunization. The research team hoped to test PittCoVacc in humans in clinical trials in the next few months (<xref rid="t0005" ref-type="table">Table 1</xref>) (<xref rid="b0900" ref-type="bibr">ScienceDaily, 2020</xref>).</p><p id="p0185">The US-based company Novavax has identified a vaccine candidate NVX-CoV2373, a stable, prefusion protein developed through the advanced nanoparticle technology (<xref rid="t0005" ref-type="table">Table 1</xref> and <xref rid="f0015" ref-type="fig">Fig. 3</xref>). The Matrix-M adjuvant will be incorporated with NVX-CoV2373 to enhance immune responses and stimulate increased levels of neutralizing antibodies (<xref rid="b0750" ref-type="bibr">Novavax, 2020</xref>). A first-in-human trial will be started in May 2020.</p><p id="p0190">Other types of vaccines (e.g., DNA, RNA, vector, whole-cell killed and live-attenuated vaccines) are in the rapid development process (<xref rid="b0850" ref-type="bibr">Routley, 2020</xref>). A phase 1 study of the novel DNA vaccine INO-4800 (NCT04336410) is underway (<xref rid="b0460" ref-type="bibr">Inovio, 2020</xref>). Despite the seriousness of the pandemic ravaging the world, researchers should take the time to assess the safety and efficacy of vaccines in animal models and then conduct related human clinical trials to prevent more harm than good from occurring with hastily produced vaccines.</p></sec><sec id="s0150"><label>17</label><title>Zinc</title><p id="p0195">Zinc, a trace mineral, is necessary for the immune system since zinc-deficient patients had severe immune dysfunctions (<xref rid="b0800" ref-type="bibr">Prasad, 2008</xref>). Interestingly, there are numerous reports showing the loss of sense of smell and taste in the early stages of COVID-19 infected people (<xref rid="b0510" ref-type="bibr">Keyhan et al., 2020</xref>, <xref rid="b0550" ref-type="bibr">Lechien et al., 2020</xref>). It is well known that zinc deficiency is associated with loss of taste, and that zinc supplementation has beneficial effects in subjects with loss of taste (<xref rid="b0235" ref-type="bibr">Doty, 2019</xref>, <xref rid="b0425" ref-type="bibr">Heyneman, 1996</xref>, <xref rid="b1120" ref-type="bibr">Yagi et al., 2013</xref>). Collectively, it is likely that zinc deficiency in patients with COVID-19 infection may be associated with the loss of smell and taste in these patients.</p><p id="p0200">Importantly, zinc is a potent inhibitor of various RNA viruses such as SARS-CoV (<xref rid="b1000" ref-type="bibr">te Velthuis et al., 2010</xref>). Given the inhibiting action of zinc in the replication of coronavirus, it is possible that zinc may have beneficial effects for COVID-19 infection since zinc supplement is available in the world. First clinical trial of intravenous zinc in COVID-19 patients is underway in Australia (ACTRN12620000454976). Furthermore, several clinical trials of the combination of zinc and other candidates (i.e., HCQ, vitamin D, vitamin C) in patients with COVID-19 are underway (NCT04326725, NCT04351490, NCT04342728).</p></sec><sec id="s0155"><label>18</label><title>Others</title><p id="p0205">The findings of a recent <italic>in vitro</italic> study by Australian researchers are notable. They found that ivermectin (an anti-parasitic drug) could effectively block SARS-CoV-2 growth in cell cultures within 48&#x000a0;h, even at a single dose (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). However, the mechanism though which ivernectin exerts its antiviral action is unknown. This study only demonstrated the effectiveness of ivernectin for the control of SARS-CoV-2 <italic>in vitro</italic> (<xref rid="b0095" ref-type="bibr">Caly et al., 2020</xref>). Further study of its efficacy and safety for inhibiting SARS-CoV-2 in humans or animals needs to be investigated.</p></sec><sec id="s0160"><label>19</label><title>Conclusion</title><p id="p0210">The COVID-19 pandemic is an unprecedented crisis for public health and world economy and has had a huge impact not only on China but other countries. In the fight against COVID-19, we should unite and understand that benefiting one benefits all, whereas harming one harms all. Scientists worldwide struggle to seek efficacious COVID-19 treatments. Learning from previous experience in coping with SARS and MERS, a series of existing drugs have been used in clinical practice to treat COVID-19 infection and clinical trials evaluating their efficacy and safety for COVID-19 are ongoing. Given the unique viral structure and distinct pathogenesis, there is an urgent need for novel COVID-19-specific therapies, including vaccines and antivirals. As discussed above, there are many different candidates for COVID-19 infected patients. Part of patients with COVID-19 infection have been medicated with other drugs for their illness. Therefore, potential drug- drug interactions should be considered for the combination (<xref rid="b1165" ref-type="bibr">Zhang et al., 2020b</xref>).</p><p id="p0215">Research teams from China, Singapore and the United States published a new study on the preprint website BioRxiv (<xref rid="b0045" ref-type="bibr">Anderson et al., 2020</xref>). Through systematic and comprehensive screening of more than 20,000 genes in bat cells, the teams identified MTHFV1, a gene indispensable for viral replication in bat and human cells and found that carolacton, a host protein MTHFV1 inhibitor, could effectively inhibit replication of several RNA viruses including SARS-CoV-2, suggesting that carolacton (a natural bacteria-derived product) could be a novel therapeutic drug for COVID-19.</p><p id="p0220">Finally, further understanding of SARS-CoV-2 mechanisms in humans could help in developing novel therapeutic drugs for COVID-19. We must protect ourselves against COVID-19 infection until the aforementioned candidates for COVID-19 are approved.</p></sec><sec id="s0165"><label>20</label><title>Authors&#x02019; contributions</title><p id="p0225">JZ and BX performed the study design, data collection, data analysis, data interpretation, and writing. KH performed the study design, data interpretation, and writing. All authors approved the final manuscript.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0235">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Achiron</surname><given-names>A.</given-names></name></person-group><article-title>Complications of intravenous gammaglobulin in neuromuscular diseases</article-title><source>Neurology</source><volume>49</volume><year>1997</year><fpage>899</fpage><lpage>900</lpage></element-citation></ref><ref id="b0015"><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>S.</given-names></name><name><surname>Pittenger</surname><given-names>M.F.</given-names></name></person-group><article-title>Human mesenchymal stem cells modulate allogeneic immune cell responses</article-title><source>Blood</source><volume>105</volume><year>2005</year><fpage>1815</fpage><lpage>1822</lpage><pub-id pub-id-type="pmid">15494428</pub-id></element-citation></ref><ref id="b0020"><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>M.L.</given-names></name><name><surname>Andres</surname><given-names>E.L.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Smith</surname><given-names>E.C.</given-names></name><name><surname>Case</surname><given-names>J.B.</given-names></name><name><surname>Feng</surname><given-names>J.Y.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Ray</surname><given-names>A.S.</given-names></name><name><surname>Cihlar</surname><given-names>T.</given-names></name><name><surname>Siegel</surname><given-names>D.</given-names></name><name><surname>Mackman</surname><given-names>R.L.</given-names></name><name><surname>Clarke</surname><given-names>M.O.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Denison</surname><given-names>M.R.</given-names></name></person-group><article-title>Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease</article-title><source>mBio</source><volume>9</volume><year>2018</year><fpage>e00221</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">29511076</pub-id></element-citation></ref><ref id="b0025"><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>M.L.</given-names></name><name><surname>Pruijssers</surname><given-names>A.J.</given-names></name><name><surname>Chappell</surname><given-names>J.D.</given-names></name><name><surname>Gribble</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Andres</surname><given-names>E.L.</given-names></name><name><surname>Bluemling</surname><given-names>G.R.</given-names></name><name><surname>Lockwood</surname><given-names>M.A.</given-names></name><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Natchus</surname><given-names>M.G.</given-names></name><name><surname>Saindane</surname><given-names>M.</given-names></name><name><surname>Kolykhalov</surname><given-names>A.A.</given-names></name><name><surname>Painter</surname><given-names>G.R.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Denison</surname><given-names>M.R.</given-names></name></person-group><article-title>Small-molecule antiviral &#x003b2;-d&#x02013;hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance</article-title><source>J. Virol.</source><volume>93</volume><year>2019</year><fpage>e01348</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">31578288</pub-id></element-citation></ref><ref id="b0030"><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>D.G.</given-names></name><name><surname>Shin</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>M.H.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Myoung</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>B.T.</given-names></name><name><surname>Kim</surname><given-names>S.J.</given-names></name></person-group><article-title>Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)</article-title><source>J. Microbiol. Biotechnol.</source><volume>30</volume><year>2020</year><fpage>313</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">32238757</pub-id></element-citation></ref><ref id="b0035"><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Akerstr&#x000f6;m</surname><given-names>S.</given-names></name><name><surname>Mousavi-Jazi</surname><given-names>M.</given-names></name><name><surname>Klingstr&#x000f6;m</surname><given-names>J.</given-names></name><name><surname>Leijon</surname><given-names>M.</given-names></name><name><surname>Lundkvist</surname><given-names>A.</given-names></name><name><surname>Mirazimi</surname><given-names>A.</given-names></name></person-group><article-title>Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>1966</fpage><lpage>1969</lpage><pub-id pub-id-type="pmid">15650225</pub-id></element-citation></ref><ref id="b0040"><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Al-Salama</surname><given-names>Z.T.</given-names></name><name><surname>Scott</surname><given-names>L.J.</given-names></name></person-group><article-title>Baricitinib: A review in rheumatoid arthritis</article-title><source>Drugs</source><volume>78</volume><year>2018</year><fpage>761</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">29687421</pub-id></element-citation></ref><ref id="b0045"><mixed-citation publication-type="other" id="h0040">Anderson, D.E., Cui, J., Ye, Q., Huang, B.Y., Zu, W.H., Gong, J., Liu, W.Q., Kim, S.Y., Yan, B.G., Sigmundsson, K., Lim, X.F., Ye, F., Niu, P.H., Zhou, X.M., Tan, W.J., Wang, L.F., Tan, X., 2020. Orthogonal genome-wide screenings in bat cells identify MTHFD1 as a target of broad antiviral therapy. bioRxiv, 2020.2003.2029.014209.</mixed-citation></ref><ref id="b0050"><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>J.P.</given-names></name><name><surname>Andersson</surname><given-names>U.G.</given-names></name></person-group><article-title>Human intravenous immunoglobulin modulates monokine production <italic>in vitro</italic></article-title><source>Immunology</source><volume>71</volume><year>1990</year><fpage>372</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">2269476</pub-id></element-citation></ref><ref id="b0055"><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>U.G.</given-names></name><name><surname>Bj&#x000f6;rk</surname><given-names>L.</given-names></name><name><surname>Skans&#x000e9;n-Saphir</surname><given-names>U.</given-names></name><name><surname>Andersson</surname><given-names>J.P.</given-names></name></person-group><article-title>Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG</article-title><source>Immunology</source><volume>79</volume><year>1993</year><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">8344700</pub-id></element-citation></ref><ref id="b0060"><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>Y.M.</given-names></name><name><surname>Mandourah</surname><given-names>Y.</given-names></name><name><surname>Al-Hameed</surname><given-names>F.</given-names></name><name><surname>Sindi</surname><given-names>A.A.</given-names></name><name><surname>Almekhlafi</surname><given-names>G.A.</given-names></name><name><surname>Hussein</surname><given-names>M.A.</given-names></name><name><surname>Jose</surname><given-names>J.</given-names></name><name><surname>Pinto</surname><given-names>R.</given-names></name><name><surname>Al-Omari</surname><given-names>A.</given-names></name><name><surname>Kharaba</surname><given-names>A.</given-names></name><name><surname>Almotairi</surname><given-names>A.</given-names></name><name><surname>Al Khatib</surname><given-names>K.</given-names></name><name><surname>Alraddadi</surname><given-names>B.</given-names></name><name><surname>Shalhoub</surname><given-names>S.</given-names></name><name><surname>Abdulmomen</surname><given-names>A.</given-names></name><name><surname>Qushmaq</surname><given-names>I.</given-names></name><name><surname>Mady</surname><given-names>A.</given-names></name><name><surname>Solaiman</surname><given-names>O.</given-names></name><name><surname>Al-Aithan</surname><given-names>A.M.</given-names></name><name><surname>Al-Raddadi</surname><given-names>R.</given-names></name><name><surname>Ragab</surname><given-names>A.</given-names></name><name><surname>Balkhy</surname><given-names>H.H.</given-names></name><name><surname>Al Harthy</surname><given-names>A.</given-names></name><name><surname>Deeb</surname><given-names>A.M.</given-names></name><name><surname>Al Mutairi</surname><given-names>H.</given-names></name><name><surname>Al-Dawood</surname><given-names>A.</given-names></name><name><surname>Merson</surname><given-names>L.</given-names></name><name><surname>Hayden</surname><given-names>F.G.</given-names></name><name><surname>Fowler</surname><given-names>R.A.</given-names></name></person-group><article-title>Corticosteroid therapy for critically ill patients with middle east respiratory syndrome</article-title><source>Am. J. Respir. Crit. Care Med.</source><volume>197</volume><year>2018</year><fpage>757</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">29161116</pub-id></element-citation></ref><ref id="b0065"><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Aranow</surname><given-names>C.</given-names></name></person-group><article-title>Vitamin D and the immune system</article-title><source>J. Investig. Med.</source><volume>59</volume><year>2011</year><fpage>881</fpage><lpage>886</lpage></element-citation></ref><ref id="b0070"><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Asmussen</surname><given-names>S.</given-names></name><name><surname>Ito</surname><given-names>H.</given-names></name><name><surname>Traber</surname><given-names>D.L.</given-names></name><name><surname>Lee</surname><given-names>J.W.</given-names></name><name><surname>Cox</surname><given-names>R.A.</given-names></name><name><surname>Hawkins</surname><given-names>H.K.</given-names></name><name><surname>McAuley</surname><given-names>D.F.</given-names></name><name><surname>McKenna</surname><given-names>D.H.</given-names></name><name><surname>Traber</surname><given-names>L.D.</given-names></name><name><surname>Zhuo</surname><given-names>H.</given-names></name><name><surname>Wilson</surname><given-names>J.</given-names></name><name><surname>Herndon</surname><given-names>D.N.</given-names></name><name><surname>Prough</surname><given-names>D.S.</given-names></name><name><surname>Liu</surname><given-names>K.D.</given-names></name><name><surname>Matthay</surname><given-names>M.A.</given-names></name><name><surname>Enkhbaatar</surname><given-names>P.</given-names></name></person-group><article-title>Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia</article-title><source>Thorax</source><volume>69</volume><year>2014</year><fpage>819</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">24891325</pub-id></element-citation></ref><ref id="b0075"><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Meng</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name></person-group><article-title>2019-nCoV epidemic: address mental health care to empower society</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>e37</fpage><lpage>e38</lpage><pub-id pub-id-type="pmid">32043982</pub-id></element-citation></ref><ref id="b0080"><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Barragan</surname><given-names>P.</given-names></name><name><surname>Podzamczer</surname><given-names>D.</given-names></name></person-group><article-title>Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment</article-title><source>Expert Opin. Pharmacother.</source><volume>9</volume><year>2008</year><fpage>2363</fpage><lpage>2375</lpage><pub-id pub-id-type="pmid">18710360</pub-id></element-citation></ref><ref id="b0085"><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>Bertorini</surname><given-names>T.E.</given-names></name><name><surname>Nance</surname><given-names>A.M.</given-names></name><name><surname>Horner</surname><given-names>L.H.</given-names></name><name><surname>Greene</surname><given-names>W.</given-names></name><name><surname>Gelfand</surname><given-names>M.S.</given-names></name><name><surname>Jaster</surname><given-names>J.H.</given-names></name></person-group><article-title>Complications of intravenous gammaglobulin in neuromuscular and other diseases</article-title><source>Muscle Nerve</source><volume>19</volume><year>1996</year><fpage>388</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">8606709</pub-id></element-citation></ref><ref id="b0090"><mixed-citation publication-type="other" id="h0085">BioSpace. April 07, 2020. FDA clears the way for ridgeback biotherapeutics to begin human testing of a promising potential treatment for COVID-19.</mixed-citation></ref><ref id="b0095"><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L.</given-names></name><name><surname>Druce</surname><given-names>J.D.</given-names></name><name><surname>Catton</surname><given-names>M.G.</given-names></name><name><surname>Jans</surname><given-names>D.A.</given-names></name><name><surname>Wagstaff</surname><given-names>K.M.</given-names></name></person-group><article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 <italic>in vitro</italic></article-title><source>Antiviral Res.</source><volume>104787</volume><year>2020</year></element-citation></ref><ref id="b0100"><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Ruan</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>B.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Xiang</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Bai</surname><given-names>T.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Tu</surname><given-names>S.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Shang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Ruan</surname><given-names>S.</given-names></name><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>L.</given-names></name><name><surname>Cheng</surname><given-names>F.</given-names></name><name><surname>Pan</surname><given-names>L.</given-names></name><name><surname>Zou</surname><given-names>J.</given-names></name><name><surname>Jia</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Ge</surname><given-names>Q.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Zhan</surname><given-names>H.</given-names></name><name><surname>Qiu</surname><given-names>F.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Jaki</surname><given-names>T.</given-names></name><name><surname>Hayden</surname><given-names>F.G.</given-names></name><name><surname>Horby</surname><given-names>P.W.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id></element-citation></ref><ref id="b0105"><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>A.C.</given-names></name><name><surname>Maggini</surname><given-names>S.</given-names></name></person-group><article-title>Vitamin C and Immune Function</article-title><source>Nutrients</source><volume>9</volume><year>2017</year><fpage>1211</fpage></element-citation></ref><ref id="b0110"><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>A.C.</given-names></name><name><surname>Rosengrave</surname><given-names>P.C.</given-names></name><name><surname>Bayer</surname><given-names>S.</given-names></name><name><surname>Chambers</surname><given-names>S.</given-names></name><name><surname>Mehrtens</surname><given-names>J.</given-names></name><name><surname>Shaw</surname><given-names>G.M.</given-names></name></person-group><article-title>Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes</article-title><source>Crit. Care</source><volume>21</volume><year>2017</year><fpage>300</fpage><pub-id pub-id-type="pmid">29228951</pub-id></element-citation></ref><ref id="b0115"><mixed-citation publication-type="other" id="h0110">Celularity. April 02, 2020. Celularity announces FDA clearance of IND application for CYNK-001 in coronavirus, first in cellular therapy. https://www.prnewswire.com/news-releases/celularity-announces-fda-clearance-of-ind-application-for-cynk-001-in-coronavirus-first-in-cellular-therapy-301034141.html.</mixed-citation></ref><ref id="b0120"><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>G.</given-names></name><name><surname>Fox</surname><given-names>J.</given-names></name><name><surname>Ashton</surname><given-names>B.</given-names></name><name><surname>Middleton</surname><given-names>J.</given-names></name></person-group><article-title>Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing</article-title><source>Stem Cells</source><volume>25</volume><year>2007</year><fpage>2739</fpage><lpage>2749</lpage><pub-id pub-id-type="pmid">17656645</pub-id></element-citation></ref><ref id="b0125"><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Kok</surname><given-names>K.H.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title><source>Emerg. Microbes Infect.</source><volume>9</volume><year>2020</year><fpage>221</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">31987001</pub-id></element-citation></ref><ref id="b0130"><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Fehr</surname><given-names>A.R.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name><surname>Abrahante</surname><given-names>J.E.</given-names></name><name><surname>Mack</surname><given-names>M.</given-names></name><name><surname>Sompallae</surname><given-names>R.</given-names></name><name><surname>McCray</surname><given-names>P.B.</given-names></name><name><surname>Meyerholz</surname><given-names>D.K.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes</article-title><source>J. Clin. Invest.</source><volume>130</volume><year>2019</year><fpage>3625</fpage><lpage>3639</lpage></element-citation></ref><ref id="b0135"><mixed-citation publication-type="other" id="h0130">Chen, C., Huang, J., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Zhang, J., Yin, P., Wang, X., 2020a. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv, 2020.2003.2017.20037432.</mixed-citation></ref><ref id="b0140"><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Tan</surname><given-names>D.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name></person-group><article-title>Efficacy and safety of Xuebijing injection combined with Ulinastatin as adjunctive therapy on sepsis: a systematic review and meta-analysis</article-title><source>Front. Pharmacol.</source><volume>9</volume><year>2018</year><fpage>743</fpage><pub-id pub-id-type="pmid">30087610</pub-id></element-citation></ref><ref id="b0145"><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Ning</surname><given-names>Q.</given-names></name></person-group><article-title>Clinical and immunologic features in severe and moderate Coronavirus Disease 2019</article-title><source>J. Clin Invest.</source><year>2020</year><object-id pub-id-type="publisher-id">137244</object-id></element-citation></ref><ref id="b0150"><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>B.</given-names></name><name><surname>Chao</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Hedenstierna</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>C.G.</given-names></name></person-group><article-title>Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing</article-title><source>Clin. Infect. Dis.</source><volume>39</volume><year>2004</year><fpage>1531</fpage><lpage>1535</lpage><pub-id pub-id-type="pmid">15546092</pub-id></element-citation></ref><ref id="b0155"><mixed-citation publication-type="other" id="h0150">Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J.a., Yu, T., Zhang, X., Zhang, L., 2020c. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507-513.</mixed-citation></ref><ref id="b0160"><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R.C.</given-names></name><name><surname>Tang</surname><given-names>X.P.</given-names></name><name><surname>Tan</surname><given-names>S.Y.</given-names></name><name><surname>Liang</surname><given-names>B.L.</given-names></name><name><surname>Wan</surname><given-names>Z.Y.</given-names></name><name><surname>Fang</surname><given-names>J.Q.</given-names></name><name><surname>Zhong</surname><given-names>N.</given-names></name></person-group><article-title>Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience</article-title><source>Chest</source><volume>129</volume><year>2006</year><fpage>1441</fpage><lpage>1452</lpage><pub-id pub-id-type="pmid">16778260</pub-id></element-citation></ref><ref id="b0165"><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Chimenti</surname><given-names>L.</given-names></name><name><surname>Luque</surname><given-names>T.</given-names></name><name><surname>Bonsignore</surname><given-names>M.R.</given-names></name><name><surname>Ram&#x000ed;rez</surname><given-names>J.</given-names></name><name><surname>Navajas</surname><given-names>D.</given-names></name><name><surname>Farr&#x000e9;</surname><given-names>R.</given-names></name></person-group><article-title>Pre-treatment with mesenchymal stem cells reduces ventilator-induced lung injury</article-title><source>Eur. Respir. J.</source><volume>40</volume><year>2012</year><fpage>939</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">22441745</pub-id></element-citation></ref><ref id="b0170"><mixed-citation publication-type="other" id="h0165">China's State Council. February 21, 2020. Press conference on scientific and technological innovation to support epidemic prevention and control. http://www.scio.gov.cn/xwfbh/xwbfbh/wqfbh/42311/42568/index.htm.</mixed-citation></ref><ref id="b0175"><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Wong</surname><given-names>M.M.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Chan</surname><given-names>K.S.</given-names></name><name><surname>Kao</surname><given-names>R.Y.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name><name><surname>Wong</surname><given-names>C.L.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title><source>Thorax</source><volume>59</volume><year>2004</year><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">14985565</pub-id></element-citation></ref><ref id="b0180"><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>Morgenstern</surname><given-names>B.</given-names></name><name><surname>Bauer</surname><given-names>G.</given-names></name><name><surname>Chandra</surname><given-names>P.</given-names></name><name><surname>Rabenau</surname><given-names>H.</given-names></name><name><surname>Doerr</surname><given-names>H.W.</given-names></name></person-group><article-title>Treatment of SARS with human interferons</article-title><source>Lancet</source><volume>362</volume><year>2003</year><fpage>293</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">12892961</pub-id></element-citation></ref><ref id="b0185"><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name><surname>Coutard</surname><given-names>B.</given-names></name><name><surname>Valle</surname><given-names>C.</given-names></name><name><surname>de Lamballerie</surname><given-names>X.</given-names></name><name><surname>Canard</surname><given-names>B.</given-names></name><name><surname>Seidah</surname><given-names>N.G.</given-names></name><name><surname>Decroly</surname><given-names>E.</given-names></name></person-group><article-title>The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade</article-title><source>Antiviral Res.</source><volume>176</volume><year>2020</year><object-id pub-id-type="publisher-id">104742</object-id></element-citation></ref><ref id="b0190"><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name><surname>Crackower</surname><given-names>M.A.</given-names></name><name><surname>Sarao</surname><given-names>R.</given-names></name><name><surname>Oudit</surname><given-names>G.Y.</given-names></name><name><surname>Yagil</surname><given-names>C.</given-names></name><name><surname>Kozieradzki</surname><given-names>I.</given-names></name><name><surname>Scanga</surname><given-names>S.E.</given-names></name><name><surname>Oliveira-dos-Santos</surname><given-names>A.J.</given-names></name><name><surname>da Costa</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Pei</surname><given-names>Y.</given-names></name><name><surname>Scholey</surname><given-names>J.</given-names></name><name><surname>Ferrario</surname><given-names>C.M.</given-names></name><name><surname>Manoukian</surname><given-names>A.S.</given-names></name><name><surname>Chappell</surname><given-names>M.C.</given-names></name><name><surname>Backx</surname><given-names>P.H.</given-names></name><name><surname>Yagil</surname><given-names>Y.</given-names></name><name><surname>Penninger</surname><given-names>J.M.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 is an essential regulator of heart function</article-title><source>Nature</source><volume>417</volume><year>2002</year><fpage>822</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">12075344</pub-id></element-citation></ref><ref id="b0195"><mixed-citation publication-type="other" id="h0190">De Andrea, M., Ravera, R., Gioia, D., Gariglio, M., Landolfo, S., 2002. The interferon system: an overview. Eur. J. Paediatr. Neurol. 6 Suppl A, A41-A46 and A55-A58.</mixed-citation></ref><ref id="b0200"><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name><surname>Delang</surname><given-names>L.</given-names></name><name><surname>Abdelnabi</surname><given-names>R.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name></person-group><article-title>Favipiravir as a potential countermeasure against neglected and emerging RNA viruses</article-title><source>Antiviral Res.</source><volume>153</volume><year>2018</year><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">29524445</pub-id></element-citation></ref><ref id="b0205"><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zeng</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Hong</surname><given-names>Z.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name></person-group><article-title>Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study</article-title><source>J. Infect.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.002</pub-id></element-citation></ref><ref id="b0210"><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name><surname>Devaney</surname><given-names>J.</given-names></name><name><surname>Horie</surname><given-names>S.</given-names></name><name><surname>Masterson</surname><given-names>C.</given-names></name><name><surname>Elliman</surname><given-names>S.</given-names></name><name><surname>Barry</surname><given-names>F.</given-names></name><name><surname>O'Brien</surname><given-names>T.</given-names></name><name><surname>Curley</surname><given-names>G.F.</given-names></name><name><surname>O'Toole</surname><given-names>D.</given-names></name><name><surname>Laffey</surname><given-names>J.G.</given-names></name></person-group><article-title>Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat</article-title><source>Thorax</source><volume>70</volume><year>2015</year><fpage>625</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">25986435</pub-id></element-citation></ref><ref id="b0215"><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Che</surname><given-names>X.</given-names></name><name><surname>Hou</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Qiu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Geng</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Kang</surname><given-names>W.</given-names></name><name><surname>Weng</surname><given-names>D.</given-names></name><name><surname>Liang</surname><given-names>P.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways</article-title><source>J. Pathol.</source><volume>203</volume><year>2004</year><fpage>622</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">15141376</pub-id></element-citation></ref><ref id="b0220"><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Cheng</surname><given-names>P.L.</given-names></name><name><surname>Yutao</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function</article-title><source>BMC Complement. Altern. Med.</source><volume>17</volume><year>2017</year><fpage>130</fpage><pub-id pub-id-type="pmid">28235408</pub-id></element-citation></ref><ref id="b0225"><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>R.Y.</given-names></name></person-group><article-title>Emerging pathogens and their implications for the blood supply and transfusion transmitted infections</article-title><source>Br. J. Haematol.</source><volume>159</volume><year>2012</year><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">22924410</pub-id></element-citation></ref><ref id="b0230"><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L.</given-names></name><name><surname>Xia</surname><given-names>J.W.</given-names></name><name><surname>Gong</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>H.H.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>X.D.</given-names></name></person-group><article-title>Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease</article-title><source>Evid. Based Complement Alternat. Med.</source><volume>2014</volume><year>2014</year><object-id pub-id-type="publisher-id">637969</object-id></element-citation></ref><ref id="b0235"><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name><surname>Doty</surname><given-names>R.L.</given-names></name></person-group><article-title>Treatment for smell and taste disorders: a critical review</article-title><source>Handb. Clin. Neurol.</source><volume>164</volume><year>2019</year><fpage>455</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">31604562</pub-id></element-citation></ref><ref id="b0240"><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Meng</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>C.</given-names></name><name><surname>Yuan</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Deng</surname><given-names>K.</given-names></name><name><surname>Xia</surname><given-names>Z.</given-names></name><name><surname>Gong</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Hou</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title><source>Proc. Natl. Acad. Sci. U S A.</source><year>2020</year><pub-id pub-id-type="doi">10.1073/pnas.2004168117</pub-id></element-citation></ref><ref id="b0245"><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name><surname>Dvorak</surname><given-names>H.F.</given-names></name><name><surname>Brown</surname><given-names>L.F.</given-names></name><name><surname>Detmar</surname><given-names>M.</given-names></name><name><surname>Dvorak</surname><given-names>A.M.</given-names></name></person-group><article-title>Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis</article-title><source>Am. J. Pathol.</source><volume>146</volume><year>1995</year><fpage>1029</fpage><lpage>1039</lpage><pub-id pub-id-type="pmid">7538264</pub-id></element-citation></ref><ref id="b0250"><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>Martellaro</surname><given-names>C.</given-names></name><name><surname>Callison</surname><given-names>J.</given-names></name><name><surname>Munster</surname><given-names>V.J.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name></person-group><article-title>Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin</article-title><source>Sci. Rep.</source><volume>3</volume><year>2013</year><fpage>1686</fpage><pub-id pub-id-type="pmid">23594967</pub-id></element-citation></ref><ref id="b0255"><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name><surname>Fanelli</surname><given-names>V.</given-names></name><name><surname>Ranieri</surname><given-names>V.M.</given-names></name></person-group><article-title>Mechanisms and clinical consequences of acute lung injury</article-title><source>Ann. Am. Thorac. Soc.</source><volume>12</volume><issue>Suppl 1</issue><year>2015</year><fpage>S3</fpage><lpage>S8</lpage><pub-id pub-id-type="pmid">25830831</pub-id></element-citation></ref><ref id="b0260"><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Karakiulakis</surname><given-names>G.</given-names></name><name><surname>Roth</surname><given-names>M.</given-names></name></person-group><article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?</article-title><source>Lancet Respir. Med.</source><volume>8</volume><year>2020</year><object-id pub-id-type="publisher-id">e21</object-id></element-citation></ref><ref id="b0265"><mixed-citation publication-type="other" id="h0260">FDA, March 24, 2020. Investigational covid-19 convalescent plasma-emergency INDs. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds.</mixed-citation></ref><ref id="b0270"><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>J.</given-names></name><name><surname>Hofmann</surname><given-names>V.</given-names></name><name><surname>Kappeler</surname><given-names>U.</given-names></name></person-group><article-title>Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin</article-title><source>N. Engl. J. Med.</source><volume>306</volume><year>1982</year><fpage>1254</fpage><lpage>1258</lpage><pub-id pub-id-type="pmid">6803159</pub-id></element-citation></ref><ref id="b0275"><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N.</given-names></name><name><surname>Hillan</surname><given-names>K.J.</given-names></name><name><surname>Gerber</surname><given-names>H.-P.</given-names></name><name><surname>Novotny</surname><given-names>W.</given-names></name></person-group><article-title>Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</article-title><source>Nat. Rev. Drug Discov.</source><volume>3</volume><year>2004</year><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">15136787</pub-id></element-citation></ref><ref id="b0280"><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name><surname>Ferrario</surname><given-names>C.M.</given-names></name><name><surname>Jessup</surname><given-names>J.</given-names></name><name><surname>Chappell</surname><given-names>M.C.</given-names></name><name><surname>Averill</surname><given-names>D.B.</given-names></name><name><surname>Brosnihan</surname><given-names>K.B.</given-names></name><name><surname>Tallant</surname><given-names>E.A.</given-names></name><name><surname>Diz</surname><given-names>D.I.</given-names></name><name><surname>Gallagher</surname><given-names>P.E.</given-names></name></person-group><article-title>Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2</article-title><source>Circulation</source><volume>111</volume><year>2005</year><fpage>2605</fpage><lpage>2610</lpage><pub-id pub-id-type="pmid">15897343</pub-id></element-citation></ref><ref id="b0285"><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>B.J.</given-names></name><name><surname>Kraskauskas</surname><given-names>D.</given-names></name><name><surname>Martin</surname><given-names>E.J.</given-names></name><name><surname>Farkas</surname><given-names>D.</given-names></name><name><surname>Wegelin</surname><given-names>J.A.</given-names></name><name><surname>Brophy</surname><given-names>D.</given-names></name><name><surname>Ward</surname><given-names>K.R.</given-names></name><name><surname>Voelkel</surname><given-names>N.F.</given-names></name><name><surname>Fowler</surname><given-names>A.A.</given-names><suffix>3rd</suffix></name><name><surname>Natarajan</surname><given-names>R.</given-names></name></person-group><article-title>Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid</article-title><source>Am. J. Physiol. Lung Cell Mol. Physiol.</source><volume>303</volume><year>2012</year><fpage>L20</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">22523283</pub-id></element-citation></ref><ref id="b0290"><element-citation publication-type="journal" id="h0285"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>B.J.</given-names></name><name><surname>Seropian</surname><given-names>I.M.</given-names></name><name><surname>Kraskauskas</surname><given-names>D.</given-names></name><name><surname>Thakkar</surname><given-names>J.N.</given-names></name><name><surname>Voelkel</surname><given-names>N.F.</given-names></name><name><surname>Fowler</surname><given-names>A.A.</given-names><suffix>3rd</suffix></name><name><surname>Natarajan</surname><given-names>R.</given-names></name></person-group><article-title>Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury</article-title><source>Crit. Care Med.</source><volume>39</volume><year>2011</year><fpage>1454</fpage><lpage>1460</lpage><pub-id pub-id-type="pmid">21358394</pub-id></element-citation></ref><ref id="b0295"><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name><surname>FitzGerald</surname><given-names>G.A.</given-names></name></person-group><article-title>Misguided drug advice for COVID-19</article-title><source>Science</source><volume>367</volume><year>2002</year><fpage>1434</fpage></element-citation></ref><ref id="b0300"><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>A.A.</given-names><suffix>3rd</suffix></name><name><surname>Syed</surname><given-names>A.A.</given-names></name><name><surname>Knowlson</surname><given-names>S.</given-names></name><name><surname>Sculthorpe</surname><given-names>R.</given-names></name><name><surname>Farthing</surname><given-names>D.</given-names></name><name><surname>DeWilde</surname><given-names>C.</given-names></name><name><surname>Farthing</surname><given-names>C.A.</given-names></name><name><surname>Larus</surname><given-names>T.L.</given-names></name><name><surname>Martin</surname><given-names>E.</given-names></name><name><surname>Brophy</surname><given-names>D.F.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Fisher</surname><given-names>B.J.</given-names></name><name><surname>Natarajan</surname><given-names>R.</given-names></name></person-group><article-title>Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis</article-title><source>J. Transl. Med.</source><volume>12</volume><year>2014</year><fpage>32</fpage><pub-id pub-id-type="pmid">24484547</pub-id></element-citation></ref><ref id="b0305"><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y.</given-names></name><name><surname>Gowen</surname><given-names>B.B.</given-names></name><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Shiraki</surname><given-names>K.</given-names></name><name><surname>Smee</surname><given-names>D.F.</given-names></name><name><surname>Barnard</surname><given-names>D.L.</given-names></name></person-group><article-title>Favipiravir (T-705), a novel viral RNA polymerase inhibitor</article-title><source>Antiviral. Res.</source><volume>100</volume><year>2013</year><fpage>446</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">24084488</pub-id></element-citation></ref><ref id="b0310"><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y.</given-names></name><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Kuno-Maekawa</surname><given-names>M.</given-names></name><name><surname>Sangawa</surname><given-names>H.</given-names></name><name><surname>Uehara</surname><given-names>S.</given-names></name><name><surname>Kozaki</surname><given-names>K.</given-names></name><name><surname>Nomura</surname><given-names>N.</given-names></name><name><surname>Egawa</surname><given-names>H.</given-names></name><name><surname>Shiraki</surname><given-names>K.</given-names></name></person-group><article-title>Mechanism of action of T-705 against influenza virus</article-title><source>Antimicrob. Agents Chemother.</source><volume>49</volume><year>2005</year><fpage>981</fpage><lpage>986</lpage><pub-id pub-id-type="pmid">15728892</pub-id></element-citation></ref><ref id="b0315"><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name><surname>Galipeau</surname><given-names>J.</given-names></name><name><surname>Sens&#x000e9;b&#x000e9;</surname><given-names>L.</given-names></name></person-group><article-title>Mesenchymal stromal cells: clinical challenges and therapeutic opportunities</article-title><source>Cell Stem Cell</source><volume>22</volume><year>2018</year><fpage>824</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">29859173</pub-id></element-citation></ref><ref id="b0320"><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</article-title><source>Biosci. Trends</source><volume>14</volume><year>2020</year><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">32074550</pub-id></element-citation></ref><ref id="b0325"><mixed-citation publication-type="other" id="h0320">Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., Doudier, B., Coujon, J., Giordanengo, V., Vieira, V.E., Dupont, H.T., Honore, S., Colson, P., Chabriere, E., La Scola, B., Rolain, J.M., Brouqui, P., Raoult D., 2020. Hydrochloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 10.1016/j.ijantimicag.2020.105949.</mixed-citation></ref><ref id="b0330"><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name><surname>Goodbourn</surname><given-names>S.</given-names></name><name><surname>Didcock</surname><given-names>L.</given-names></name><name><surname>Randall</surname><given-names>R.E.</given-names></name></person-group><article-title>Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures</article-title><source>J. Gen. Virol.</source><volume>81</volume><year>2000</year><fpage>2341</fpage><lpage>2364</lpage><pub-id pub-id-type="pmid">10993923</pub-id></element-citation></ref><ref id="b0335"><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>W.B.</given-names></name><name><surname>Lahore</surname><given-names>H.</given-names></name><name><surname>McDonnell</surname><given-names>S.L.</given-names></name><name><surname>Baggerly</surname><given-names>C.A.</given-names></name><name><surname>French</surname><given-names>C.B.</given-names></name><name><surname>Aliano</surname><given-names>J.L.</given-names></name><name><surname>Bhattoa</surname><given-names>H.P.</given-names></name></person-group><article-title>Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths</article-title><source>Nutrients</source><volume>12</volume><year>2020</year><fpage>E988</fpage><pub-id pub-id-type="pmid">32252338</pub-id></element-citation></ref><ref id="b0340"><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name><surname>Grein</surname><given-names>J.</given-names></name><name><surname>Ohmagari</surname><given-names>N.</given-names></name><name><surname>Shin</surname><given-names>D.</given-names></name><name><surname>Diaz</surname><given-names>G.</given-names></name><name><surname>Asperges</surname><given-names>E.</given-names></name><name><surname>Castagna</surname><given-names>A.</given-names></name><name><surname>Feldt</surname><given-names>T.</given-names></name><name><surname>Green</surname><given-names>G.</given-names></name><name><surname>Green</surname><given-names>M.L.</given-names></name><name><surname>Lescure</surname><given-names>F.-X.</given-names></name><name><surname>Nicastri</surname><given-names>E.</given-names></name><name><surname>Oda</surname><given-names>R.</given-names></name><name><surname>Yo</surname><given-names>K.</given-names></name><name><surname>Quiros-Roldan</surname><given-names>E.</given-names></name><name><surname>Studemeister</surname><given-names>A.</given-names></name><name><surname>Redinski</surname><given-names>J.</given-names></name><name><surname>Ahmed</surname><given-names>S.</given-names></name><name><surname>Bernett</surname><given-names>J.</given-names></name><name><surname>Chelliah</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Chihara</surname><given-names>S.</given-names></name><name><surname>Cohen</surname><given-names>S.H.</given-names></name><name><surname>Cunningham</surname><given-names>J.</given-names></name><name><surname>D'Arminio Monforte</surname><given-names>A.</given-names></name><name><surname>Ismail</surname><given-names>S.</given-names></name><name><surname>Kato</surname><given-names>H.</given-names></name><name><surname>Lapadula</surname><given-names>G.</given-names></name><name><surname>L'Her</surname><given-names>E.</given-names></name><name><surname>Maeno</surname><given-names>T.</given-names></name><name><surname>Majumder</surname><given-names>S.</given-names></name><name><surname>Massari</surname><given-names>M.</given-names></name><name><surname>Mora-Rillo</surname><given-names>M.</given-names></name><name><surname>Mutoh</surname><given-names>Y.</given-names></name><name><surname>Nguyen</surname><given-names>D.</given-names></name><name><surname>Verweij</surname><given-names>E.</given-names></name><name><surname>Zoufaly</surname><given-names>A.</given-names></name><name><surname>Osinusi</surname><given-names>A.O.</given-names></name><name><surname>DeZure</surname><given-names>A.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhong</surname><given-names>L.</given-names></name><name><surname>Chokkalingam</surname><given-names>A.</given-names></name><name><surname>Elboudwarej</surname><given-names>E.</given-names></name><name><surname>Telep</surname><given-names>L.</given-names></name><name><surname>Timbs</surname><given-names>L.</given-names></name><name><surname>Henne</surname><given-names>I.</given-names></name><name><surname>Sellers</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>H.</given-names></name><name><surname>Tan</surname><given-names>S.K.</given-names></name><name><surname>Winterbourne</surname><given-names>L.</given-names></name><name><surname>Desai</surname><given-names>P.</given-names></name><name><surname>Mera</surname><given-names>R.</given-names></name><name><surname>Gaggar</surname><given-names>A.</given-names></name><name><surname>Myers</surname><given-names>R.P.</given-names></name><name><surname>Brainard</surname><given-names>D.M.</given-names></name><name><surname>Childs</surname><given-names>R.</given-names></name><name><surname>Flanigan</surname><given-names>T.</given-names></name></person-group><article-title>Compassionate use of remdesivir for patients with severe COVID-19</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEHMoa2007016</pub-id></element-citation></ref><ref id="b0345"><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>M.J.D.</given-names></name><name><surname>Evans</surname><given-names>T.W.</given-names></name></person-group><article-title>Inhaled nitric oxide therapy in adults</article-title><source>N. Eng. J. Med.</source><volume>353</volume><year>2005</year><fpage>2683</fpage><lpage>2695</lpage></element-citation></ref><ref id="b0350"><element-citation publication-type="journal" id="h0345"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.J.</given-names></name><name><surname>Ni</surname><given-names>Z.Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W.H.</given-names></name><name><surname>Ou</surname><given-names>C.Q.</given-names></name><name><surname>He</surname><given-names>J.X.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Shan</surname><given-names>H.</given-names></name><name><surname>Lei</surname><given-names>C.L.</given-names></name><name><surname>Hui</surname><given-names>D.</given-names></name><name><surname>Du</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>L.J.</given-names></name><name><surname>Zeng</surname><given-names>G.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Chen</surname><given-names>R.C.</given-names></name><name><surname>Tang</surname><given-names>C.L.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>P.Y.</given-names></name><name><surname>Xiang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>S.Y.</given-names></name><name><surname>Wang</surname><given-names>J.L.</given-names></name><name><surname>Liang</surname><given-names>Z.J.</given-names></name><name><surname>Peng</surname><given-names>Y.X.</given-names></name><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>Y.H.</given-names></name><name><surname>Peng</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>J.M.</given-names></name><name><surname>Liu</surname><given-names>J.Y.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Zheng</surname><given-names>Z.J.</given-names></name><name><surname>Qiu</surname><given-names>S.Q.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>C.J.</given-names></name><name><surname>Zhu</surname><given-names>S.Y.</given-names></name><name><surname>Zhong</surname><given-names>N.S.</given-names></name></person-group><article-title>Clinical Characteristics of Coronavirus Disease 2019 in China</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id></element-citation></ref><ref id="b0355"><element-citation publication-type="journal" id="h0350"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Lv</surname><given-names>J.</given-names></name></person-group><article-title>Coronavirus Disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection</article-title><source>J. Am. Heart. Assoc.</source><volume>9</volume><year>2020</year><object-id pub-id-type="publisher-id">e016219</object-id></element-citation></ref><ref id="b0360"><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>N.</given-names></name><name><surname>Krasnodembskaya</surname><given-names>A.</given-names></name><name><surname>Kapetanaki</surname><given-names>M.</given-names></name><name><surname>Mouded</surname><given-names>M.</given-names></name><name><surname>Tan</surname><given-names>X.</given-names></name><name><surname>Serikov</surname><given-names>V.</given-names></name><name><surname>Matthay</surname><given-names>M.A.</given-names></name></person-group><article-title>Mesenchymal stem cells enhance survival and bacterial clearance in murine <italic>Escherichia coli</italic> pneumonia</article-title><source>Thorax</source><volume>67</volume><year>2012</year><fpage>533</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">22250097</pub-id></element-citation></ref><ref id="b0365"><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>N.</given-names></name><name><surname>Su</surname><given-names>X.</given-names></name><name><surname>Popov</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>J.W.</given-names></name><name><surname>Serikov</surname><given-names>V.</given-names></name><name><surname>Matthay</surname><given-names>M.A.</given-names></name></person-group><article-title>Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice</article-title><source>J. Immunol.</source><volume>179</volume><year>2007</year><fpage>1855</fpage><lpage>1863</lpage><pub-id pub-id-type="pmid">17641052</pub-id></element-citation></ref><ref id="b0370"><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>Kuiken</surname><given-names>T.</given-names></name><name><surname>Martina</surname><given-names>B.E.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name><name><surname>Rimmelzwaan</surname><given-names>G.F.</given-names></name><name><surname>van Amerongen</surname><given-names>G.</given-names></name><name><surname>van Riel</surname><given-names>D.</given-names></name><name><surname>de Jong</surname><given-names>T.</given-names></name><name><surname>Itamura</surname><given-names>S.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Tashiro</surname><given-names>M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name></person-group><article-title>Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques</article-title><source>Nat. Med.</source><volume>10</volume><year>2004</year><fpage>290</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">14981511</pub-id></element-citation></ref><ref id="b0375"><mixed-citation publication-type="other" id="h0370">Hackett, D.W., Mach 17, 2020. China endorses avigan/favipiravir for COVID-19 disease treatment. https://www.precisionvaccinations.com/avigan-favipiravir-t-705-broad-spectrum-inhibitor-viral-rna-polymerase.</mixed-citation></ref><ref id="b0380"><element-citation publication-type="journal" id="h0375"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I.</given-names></name><name><surname>Timens</surname><given-names>W.</given-names></name><name><surname>Bulthuis</surname><given-names>M.L.C.</given-names></name><name><surname>Lely</surname><given-names>A.T.</given-names></name><name><surname>Navis</surname><given-names>G.J.</given-names></name><name><surname>van Goor</surname><given-names>H.</given-names></name></person-group><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title><source>J. Pathol.</source><volume>203</volume><year>2004</year><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="b0385"><mixed-citation publication-type="other" id="h0380">Han, H., Xie, L., Liu, R., Yang, J., Liu, F., Wu, K., Chen, L., Hou, W., Feng, Y., Zhu, C., 2020a. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J. Med. Virol. doi: 10.1002/jmv.25809.</mixed-citation></ref><ref id="b0390"><mixed-citation publication-type="other" id="h0385">Han, H., Yang, L., Liu, R., Liu, F., Wu, K.L., Li, J., Liu, X.H., Zhu, C.L., 2020b. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin. Chem. Lab. Med. doi: 10.1515/cclm-2020-0188.</mixed-citation></ref><ref id="b0395"><element-citation publication-type="journal" id="h0390"><person-group person-group-type="author"><name><surname>Han</surname><given-names>K.</given-names></name><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>An</surname><given-names>X.</given-names></name><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Lian</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>B.P.</given-names></name><name><surname>Fontaine</surname><given-names>R.E.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Zeng</surname><given-names>G.</given-names></name></person-group><article-title>Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection</article-title><source>Clin. Infect. Dis.</source><volume>53</volume><year>2011</year><fpage>326</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">21810744</pub-id></element-citation></ref><ref id="b0400"><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name><surname>Haschke</surname><given-names>M.</given-names></name><name><surname>Schuster</surname><given-names>M.</given-names></name><name><surname>Poglitsch</surname><given-names>M.</given-names></name><name><surname>Loibner</surname><given-names>H.</given-names></name><name><surname>Salzberg</surname><given-names>M.</given-names></name><name><surname>Bruggisser</surname><given-names>M.</given-names></name><name><surname>Penninger</surname><given-names>J.</given-names></name><name><surname>Kr&#x000e4;henb&#x000fc;hl</surname><given-names>S.</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects</article-title><source>Clin. Pharmacokinet.</source><volume>52</volume><year>2013</year><fpage>783</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">23681967</pub-id></element-citation></ref><ref id="b0405"><element-citation publication-type="journal" id="h0400"><person-group person-group-type="author"><name><surname>He</surname><given-names>X.D.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>H.X.</given-names></name><name><surname>Chen</surname><given-names>Z.D.</given-names></name><name><surname>Zheng</surname><given-names>R.S.</given-names></name><name><surname>Wang</surname><given-names>Z.S.</given-names></name><name><surname>Wang</surname><given-names>J.B.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>Xuebijing protects rats from sepsis challenged with acinetobacter baumannii by promoting annexin A1 expression and inhibiting proinflammatory cytokines secretion</article-title><source>Evid. Based Complement Alternat. Med.</source><volume>2013</volume><year>2013</year><object-id pub-id-type="publisher-id">804940</object-id></element-citation></ref><ref id="b0410"><mixed-citation publication-type="other" id="h0405">Hemil&#x000e4;, H., Chalker, E., 2013. Vitamin C for preventing and treating the common cold. Cochrane Database Syst. Rev. CD000980. doi: 10.1002/14651858.CD000980.pib4.</mixed-citation></ref><ref id="b0415"><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name><surname>Heming</surname><given-names>N.</given-names></name><name><surname>Sivanandamoorthy</surname><given-names>S.</given-names></name><name><surname>Meng</surname><given-names>P.</given-names></name><name><surname>Bounab</surname><given-names>R.</given-names></name><name><surname>Annane</surname><given-names>D.</given-names></name></person-group><article-title>Immune effects of corticosteroids in sepsis</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>1736</fpage><pub-id pub-id-type="pmid">30105022</pub-id></element-citation></ref><ref id="b0420"><element-citation publication-type="journal" id="h0415"><person-group person-group-type="author"><name><surname>Hensley</surname><given-names>L.E.</given-names></name><name><surname>Fritz</surname><given-names>L.E.</given-names></name><name><surname>Jahrling</surname><given-names>P.B.</given-names></name><name><surname>Karp</surname><given-names>C.L.</given-names></name><name><surname>Huggins</surname><given-names>J.W.</given-names></name><name><surname>Geisbert</surname><given-names>T.W.</given-names></name></person-group><article-title>Interferon-beta 1a and SARS coronavirus replication</article-title><source>Emerg. Infect. Dis.</source><volume>10</volume><year>2004</year><fpage>317</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">15030704</pub-id></element-citation></ref><ref id="b0425"><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name><surname>Heyneman</surname><given-names>C.A.</given-names></name></person-group><article-title>Zinc deficiency and taste disorders</article-title><source>Ann. Pharmacother.</source><volume>30</volume><year>1996</year><fpage>186</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">8835055</pub-id></element-citation></ref><ref id="b0430"><element-citation publication-type="journal" id="h0425"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>J.H.O.</given-names></name><name><surname>Enk</surname><given-names>A.H.</given-names></name></person-group><article-title>High-dose intravenous immunoglobulin in skin autoimmune disease</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><fpage>1090</fpage><pub-id pub-id-type="pmid">31244821</pub-id></element-citation></ref><ref id="b0435"><element-citation publication-type="journal" id="h0430"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>M.L.</given-names></name><name><surname>DeBolt</surname><given-names>C.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name><name><surname>Lofy</surname><given-names>K.H.</given-names></name><name><surname>Wiesman</surname><given-names>J.</given-names></name><name><surname>Bruce</surname><given-names>H.</given-names></name><name><surname>Spitters</surname><given-names>C.</given-names></name><name><surname>Ericson</surname><given-names>K.</given-names></name><name><surname>Wilkerson</surname><given-names>S.</given-names></name><name><surname>Tural</surname><given-names>A.</given-names></name><name><surname>Diaz</surname><given-names>G.</given-names></name><name><surname>Cohn</surname><given-names>A.</given-names></name><name><surname>Fox</surname><given-names>L.</given-names></name><name><surname>Patel</surname><given-names>A.</given-names></name><name><surname>Gerber</surname><given-names>S.I.</given-names></name><name><surname>Kim</surname><given-names>L.</given-names></name><name><surname>Tong</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Lindstrom</surname><given-names>S.</given-names></name><name><surname>Pallansch</surname><given-names>M.A.</given-names></name><name><surname>Weldon</surname><given-names>W.C.</given-names></name><name><surname>Biggs</surname><given-names>H.M.</given-names></name><name><surname>Uyeki</surname><given-names>T.M.</given-names></name><name><surname>Pillai</surname><given-names>S.K.</given-names></name></person-group><article-title>First case of 2019 novel coronavirus in the United States</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>929</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">32004427</pub-id></element-citation></ref><ref id="b0440"><element-citation publication-type="journal" id="h0435"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Yin</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>R.</given-names></name><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Jin</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="b0445"><element-citation publication-type="journal" id="h0440"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Lee</surname><given-names>C.K.</given-names></name><name><surname>Lee</surname><given-names>K.L.</given-names></name><name><surname>Chan</surname><given-names>K.</given-names></name><name><surname>Yan</surname><given-names>W.W.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Watt</surname><given-names>C.L.</given-names></name><name><surname>Chan</surname><given-names>W.M.</given-names></name><name><surname>Lai</surname><given-names>K.Y.</given-names></name><name><surname>Koo</surname><given-names>C.K.</given-names></name><name><surname>Buckley</surname><given-names>T.</given-names></name><name><surname>Chow</surname><given-names>F.L.</given-names></name><name><surname>Wong</surname><given-names>K.K.</given-names></name><name><surname>Chan</surname><given-names>H.S.</given-names></name><name><surname>Ching</surname><given-names>C.K.</given-names></name><name><surname>Tang</surname><given-names>B.S.</given-names></name><name><surname>Lau</surname><given-names>C.C.</given-names></name><name><surname>Li</surname><given-names>I.W.</given-names></name><name><surname>Liu</surname><given-names>S.H.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Lin</surname><given-names>C.K.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection</article-title><source>Clin. Infect. Dis.</source><volume>52</volume><year>2011</year><fpage>447</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">21248066</pub-id></element-citation></ref><ref id="b0450"><element-citation publication-type="journal" id="h0445"><person-group person-group-type="author"><name><surname>Iannello</surname><given-names>A.</given-names></name><name><surname>Debbeche</surname><given-names>O.</given-names></name><name><surname>Samarani</surname><given-names>S.</given-names></name><name><surname>Ahmad</surname><given-names>A.</given-names></name></person-group><article-title>Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS</article-title><source>J. Leukoc. Biol.</source><volume>84</volume><year>2008</year><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">18388298</pub-id></element-citation></ref><ref id="b0455"><element-citation publication-type="journal" id="h0450"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>Y.</given-names></name><name><surname>Kuba</surname><given-names>K.</given-names></name><name><surname>Rao</surname><given-names>S.</given-names></name><name><surname>Huan</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Guan</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Sarao</surname><given-names>R.</given-names></name><name><surname>Wada</surname><given-names>T.</given-names></name><name><surname>Leong-Poi</surname><given-names>H.</given-names></name><name><surname>Crackower</surname><given-names>M.A.</given-names></name><name><surname>Fukamizu</surname><given-names>A.</given-names></name><name><surname>Hui</surname><given-names>C.-C.</given-names></name><name><surname>Hein</surname><given-names>L.</given-names></name><name><surname>Uhlig</surname><given-names>S.</given-names></name><name><surname>Slutsky</surname><given-names>A.S.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Penninger</surname><given-names>J.M.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 protects from severe acute lung failure</article-title><source>Nature</source><volume>436</volume><year>2005</year><fpage>112</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">16001071</pub-id></element-citation></ref><ref id="b0460"><mixed-citation publication-type="other" id="h0455">Inovio. press release at March 03, 2020. Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800. http://ir.inovio.com/news-and-media/news/press-release-details/2020/Inovio-Accelerates-Timeline-for-COVID-19-DNA-Vaccine-INO-4800/default.aspx.</mixed-citation></ref><ref id="b0465"><mixed-citation publication-type="other" id="h0460">Italian ANSA news agency. March 13, 2020. 3 patients get better on arthritis drug. http://www.ansa.it/english/news/general_news/2020/03/13/3-patients-get-better-on-arthritis-drug_90d4764d-d93f-463e-ab07-168b34b084d0.html.</mixed-citation></ref><ref id="b0470"><element-citation publication-type="journal" id="h0465"><person-group person-group-type="author"><name><surname>Ishiyama</surname><given-names>Y.</given-names></name><name><surname>Gallagher</surname><given-names>P.E.</given-names></name><name><surname>Averill</surname><given-names>D.B.</given-names></name><name><surname>Tallant</surname><given-names>E.A.</given-names></name><name><surname>Brosnihan</surname><given-names>K.B.</given-names></name><name><surname>Ferrario</surname><given-names>C.M.</given-names></name></person-group><article-title>Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors</article-title><source>Hypertension</source><volume>43</volume><year>2004</year><fpage>970</fpage><lpage>976</lpage><pub-id pub-id-type="pmid">15007027</pub-id></element-citation></ref><ref id="b0475"><element-citation publication-type="journal" id="h0470"><person-group person-group-type="author"><name><surname>Jolles</surname><given-names>S.</given-names></name><name><surname>Sewell</surname><given-names>W.A.</given-names></name><name><surname>Misbah</surname><given-names>S.A.</given-names></name></person-group><article-title>Clinical uses of intravenous immunoglobulin</article-title><source>Clin. Exp. Immunol.</source><volume>142</volume><year>2005</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">16178850</pub-id></element-citation></ref><ref id="b0480"><element-citation publication-type="journal" id="h0475"><person-group person-group-type="author"><name><surname>Kakodkar</surname><given-names>P.</given-names></name><name><surname>Kaka</surname><given-names>N.</given-names></name><name><surname>Baig</surname><given-names>M.N.</given-names></name></person-group><article-title>A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 19 (COVID-19)</article-title><source>Cureus</source><volume>12</volume><year>2020</year><object-id pub-id-type="publisher-id">e7560</object-id></element-citation></ref><ref id="b0485"><element-citation publication-type="journal" id="h0480"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>B.X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Guan</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus</article-title><source>Lancet Psychiatry</source><volume>7</volume><year>2020</year><object-id pub-id-type="publisher-id">e14</object-id></element-citation></ref><ref id="b0490"><element-citation publication-type="journal" id="h0485"><person-group person-group-type="author"><name><surname>Karram</surname><given-names>T.</given-names></name><name><surname>Abbasi</surname><given-names>A.</given-names></name><name><surname>Keidar</surname><given-names>S.</given-names></name><name><surname>Golomb</surname><given-names>E.</given-names></name><name><surname>Hochberg</surname><given-names>I.</given-names></name><name><surname>Winaver</surname><given-names>J.</given-names></name><name><surname>Hoffman</surname><given-names>A.</given-names></name><name><surname>Abassi</surname><given-names>Z.</given-names></name></person-group><article-title>Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><volume>289</volume><year>2005</year><fpage>H1351</fpage><lpage>H1358</lpage><pub-id pub-id-type="pmid">15894569</pub-id></element-citation></ref><ref id="b0495"><element-citation publication-type="journal" id="h0490"><person-group person-group-type="author"><name><surname>Kaveri</surname><given-names>S.V.</given-names></name><name><surname>Dietrich</surname><given-names>G.</given-names></name><name><surname>Hurez</surname><given-names>V.</given-names></name><name><surname>Kazatchkine</surname><given-names>M.D.</given-names></name></person-group><article-title>Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases</article-title><source>Clin. Exp. Immunol.</source><volume>86</volume><year>1991</year><fpage>192</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">1934588</pub-id></element-citation></ref><ref id="b0500"><element-citation publication-type="journal" id="h0495"><person-group person-group-type="author"><name><surname>Keyaerts</surname><given-names>E.</given-names></name><name><surname>Vijgen</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Maes</surname><given-names>P.</given-names></name><name><surname>Hedenstierna</surname><given-names>G.</given-names></name><name><surname>Van Ranst</surname><given-names>M.</given-names></name></person-group><article-title>Inhibition of SARS-coronavirus infection <italic>in vitro</italic> by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound</article-title><source>Int. J. Infect. Dis.</source><volume>8</volume><year>2004</year><fpage>223</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">15234326</pub-id></element-citation></ref><ref id="b0505"><element-citation publication-type="journal" id="h0500"><person-group person-group-type="author"><name><surname>Keyaerts</surname><given-names>E.</given-names></name><name><surname>Vijgen</surname><given-names>L.</given-names></name><name><surname>Maes</surname><given-names>P.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name><name><surname>Van Ranst</surname><given-names>M.</given-names></name></person-group><article-title><italic>In vitro</italic> inhibition of severe acute respiratory syndrome coronavirus by chloroquine</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>323</volume><year>2004</year><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">15351731</pub-id></element-citation></ref><ref id="b0510"><element-citation publication-type="journal" id="h0505"><person-group person-group-type="author"><name><surname>Keyhan</surname><given-names>S.O.</given-names></name><name><surname>Fallahi</surname><given-names>H.R.</given-names></name><name><surname>Cheshmi</surname><given-names>B.</given-names></name></person-group><article-title>Dysosmia and dysgeusia due to the 2019 novel coronavirus; a hypothesis that needs further investigation</article-title><source>Maxillofac Plast. Reconstr. Surg.</source><volume>42</volume><year>2020</year><fpage>9</fpage><pub-id pub-id-type="pmid">32289035</pub-id></element-citation></ref><ref id="b0515"><element-citation publication-type="journal" id="h0510"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>A.</given-names></name><name><surname>Benthin</surname><given-names>C.</given-names></name><name><surname>Zeno</surname><given-names>B.</given-names></name><name><surname>Albertson</surname><given-names>T.E.</given-names></name><name><surname>Boyd</surname><given-names>J.</given-names></name><name><surname>Christie</surname><given-names>J.D.</given-names></name><name><surname>Hall</surname><given-names>R.</given-names></name><name><surname>Poirier</surname><given-names>G.</given-names></name><name><surname>Ronco</surname><given-names>J.J.</given-names></name><name><surname>Tidswell</surname><given-names>M.</given-names></name><name><surname>Hardes</surname><given-names>K.</given-names></name><name><surname>Powley</surname><given-names>W.M.</given-names></name><name><surname>Wright</surname><given-names>T.J.</given-names></name><name><surname>Siederer</surname><given-names>S.K.</given-names></name><name><surname>Fairman</surname><given-names>D.A.</given-names></name><name><surname>Lipson</surname><given-names>D.A.</given-names></name><name><surname>Bayliffe</surname><given-names>A.I.</given-names></name><name><surname>Lazaar</surname><given-names>A.L.</given-names></name></person-group><article-title>A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome</article-title><source>Crit. Care</source><volume>21</volume><year>2017</year><fpage>234</fpage><pub-id pub-id-type="pmid">28877748</pub-id></element-citation></ref><ref id="b0520"><element-citation publication-type="journal" id="h0515"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Erdos</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Kenniston</surname><given-names>T.W.</given-names></name><name><surname>Balmert</surname><given-names>S.C.</given-names></name><name><surname>Carey</surname><given-names>C.D.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Epperly</surname><given-names>M.W.</given-names></name><name><surname>Klimstra</surname><given-names>W.B.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>Korkmaz</surname><given-names>E.</given-names></name><name><surname>Falo</surname><given-names>L.D.</given-names><suffix>Jr.</suffix></name><name><surname>Gambotto</surname><given-names>A.</given-names></name></person-group><article-title>Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development</article-title><source>EBioMedicine</source><volume>102743</volume><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102743</pub-id></element-citation></ref><ref id="b0525"><element-citation publication-type="journal" id="h0520"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>U.J.</given-names></name><name><surname>Won</surname><given-names>E.J.</given-names></name><name><surname>Kee</surname><given-names>S.J.</given-names></name><name><surname>Jung</surname><given-names>S.I.</given-names></name><name><surname>Jang</surname><given-names>H.C.</given-names></name></person-group><article-title>Combination therapy with lopinavir/ritonavir, ribavirin and interferon-&#x003b1; for middle east respiratory syndrome</article-title><source>Antivir. Ther.</source><volume>21</volume><year>2016</year><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">26492219</pub-id></element-citation></ref><ref id="b0530"><element-citation publication-type="journal" id="h0525"><person-group person-group-type="author"><name><surname>Krasnodembskaya</surname><given-names>A.</given-names></name><name><surname>Samarani</surname><given-names>G.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Zhuo</surname><given-names>H.</given-names></name><name><surname>Su</surname><given-names>X.</given-names></name><name><surname>Lee</surname><given-names>J.W.</given-names></name><name><surname>Gupta</surname><given-names>N.</given-names></name><name><surname>Petrini</surname><given-names>M.</given-names></name><name><surname>Matthay</surname><given-names>M.A.</given-names></name></person-group><article-title>Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes</article-title><source>Am. J. Physiol. Lung Cell Mol. Physiol.</source><volume>302</volume><year>2012</year><fpage>L1003</fpage><lpage>L1013</lpage><pub-id pub-id-type="pmid">22427530</pub-id></element-citation></ref><ref id="b0535"><element-citation publication-type="journal" id="h0530"><person-group person-group-type="author"><name><surname>Kuba</surname><given-names>K.</given-names></name><name><surname>Imai</surname><given-names>Y.</given-names></name><name><surname>Rao</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Guan</surname><given-names>B.</given-names></name><name><surname>Huan</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Chappell</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>D.</given-names></name><name><surname>Leibbrandt</surname><given-names>A.</given-names></name><name><surname>Wada</surname><given-names>T.</given-names></name><name><surname>Slutsky</surname><given-names>A.S.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Penninger</surname><given-names>J.M.</given-names></name></person-group><article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury</article-title><source>Nat. Med.</source><volume>11</volume><year>2005</year><fpage>875</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">16007097</pub-id></element-citation></ref><ref id="b0540"><mixed-citation publication-type="other" id="h0535">Lane, J.C.E., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M.T.F., Alghoul, H., Alser, O., Alshammari, T.M., Biedermann, P., Burn, E., Casajust, P., Conover, M., Culhane, A.C., Davydov, A., DuVall, S.L., Dymshyts, D., Bertol&#x000ed;n, S.F., Fi&#x00161;ter, K., Hardin, J., Hester, L., Hripcsak, G., Kent, S., Khosla, S., Kolovos, S., Lambert, C.G., ver der Lei, J., Londhe, A.A., Lynch, K.E., Makadia, R., Margulis, A.V., Matheny, M.E., Mehta, P., Morales, D.R., Morgan-Stewart, H., Mosseveld, M., Newby, D., Nyberg,F., Ostropolets, A., Park, R.W., Prats-Uribe, A., Rao, G.A., Reich, C., Reps, J., Rijnbeek, P., Sathappan, S.M.K., Schuemie, M., Seager, S., Sena, A., Shoaibi, A., Spotnitz, M., Suchard, M.A., Swerdel, J., Torre, C.O., Vizcaya, D., Wen, H., de Wilde, M., You, S.C., Zhang, L., Zhuk, O., Ryan, P., Prieto-Alhambra, D., 2020., Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv doi.org/10.1101/2020.04.08.20054551.</mixed-citation></ref><ref id="b0545"><element-citation publication-type="journal" id="h0540"><person-group person-group-type="author"><name><surname>Le Blanc</surname><given-names>K.</given-names></name><name><surname>Frassoni</surname><given-names>F.</given-names></name><name><surname>Ball</surname><given-names>L.</given-names></name><name><surname>Locatelli</surname><given-names>F.</given-names></name><name><surname>Roelofs</surname><given-names>H.</given-names></name><name><surname>Lewis</surname><given-names>I.</given-names></name><name><surname>Lanino</surname><given-names>E.</given-names></name><name><surname>Sundberg</surname><given-names>B.</given-names></name><name><surname>Bernardo</surname><given-names>M.E.</given-names></name><name><surname>Remberger</surname><given-names>M.</given-names></name><name><surname>Dini</surname><given-names>G.</given-names></name><name><surname>Egeler</surname><given-names>R.M.</given-names></name><name><surname>Bacigalupo</surname><given-names>A.</given-names></name><name><surname>Fibbe</surname><given-names>W.</given-names></name><name><surname>Ringd&#x000e9;n</surname><given-names>O.</given-names></name></person-group><article-title>Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study</article-title><source>Lancet</source><volume>371</volume><year>2008</year><fpage>1579</fpage><lpage>1586</lpage><pub-id pub-id-type="pmid">18468541</pub-id></element-citation></ref><ref id="b0550"><element-citation publication-type="journal" id="h0545"><person-group person-group-type="author"><name><surname>Lechien</surname><given-names>J.R.</given-names></name><name><surname>Chiesa-Estomba</surname><given-names>C.M.</given-names></name><name><surname>De Siati</surname><given-names>D.R.</given-names></name><name><surname>Horoi</surname><given-names>M.</given-names></name><name><surname>Le Bon</surname><given-names>S.D.</given-names></name><name><surname>Rodriguez</surname><given-names>A.</given-names></name><name><surname>Dequanter</surname><given-names>D.</given-names></name><name><surname>Blecic</surname><given-names>S.</given-names></name><name><surname>El Afia</surname><given-names>F.</given-names></name><name><surname>Distinguin</surname><given-names>L.</given-names></name><name><surname>Chekkoury-Idrissi</surname><given-names>Y.</given-names></name><name><surname>Hans</surname><given-names>S.</given-names></name><name><surname>Delgado</surname><given-names>I.L.</given-names></name><name><surname>Calvo-Henriquez</surname><given-names>C.</given-names></name><name><surname>Lavigne</surname><given-names>P.</given-names></name><name><surname>Falanga</surname><given-names>C.</given-names></name><name><surname>Barillari</surname><given-names>M.R.</given-names></name><name><surname>Cammaroto</surname><given-names>G.</given-names></name><name><surname>Khalife</surname><given-names>M.</given-names></name><name><surname>Leich</surname><given-names>P.</given-names></name><name><surname>Souchay</surname><given-names>C.</given-names></name><name><surname>Rossi</surname><given-names>C.</given-names></name><name><surname>Journe</surname><given-names>F.</given-names></name><name><surname>Hsieh</surname><given-names>J.</given-names></name><name><surname>Edjlali</surname><given-names>M.</given-names></name><name><surname>Carlier</surname><given-names>R.</given-names></name><name><surname>Ris</surname><given-names>L.</given-names></name><name><surname>Lovato</surname><given-names>A.</given-names></name><name><surname>De Filippis</surname><given-names>C.</given-names></name><name><surname>Coppee</surname><given-names>F.</given-names></name><name><surname>Fakhry</surname><given-names>N.</given-names></name><name><surname>Ayad</surname><given-names>T.</given-names></name><name><surname>Saussez</surname><given-names>S.</given-names></name></person-group><article-title>Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study</article-title><source>Eur. Arch. Otorhinolaryngol.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s00405-020-05965-1</pub-id></element-citation></ref><ref id="b0555"><element-citation publication-type="journal" id="h0550"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D.A.</given-names></name></person-group><article-title>Cellular therapy: Adoptive immunotherapy with expanded natural killer cells</article-title><source>Immunol. Rev.</source><volume>290</volume><year>2019</year><fpage>85</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">31355489</pub-id></element-citation></ref><ref id="b0560"><mixed-citation publication-type="other" id="h0555">Lei, C., Fu, W., Qian, K., Li, T., Zhang, S., Ding, M., Hu, S., 2020. Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig. bioRxiv, 2020.2002.2001.929976.</mixed-citation></ref><ref id="b0565"><element-citation publication-type="journal" id="h0560"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>R.</given-names></name><name><surname>Hou</surname><given-names>W.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>Q.</given-names></name><name><surname>Shan</surname><given-names>G.</given-names></name><name><surname>Meng</surname><given-names>F.</given-names></name><name><surname>Du</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Fan</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>K.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Jin</surname><given-names>R.</given-names></name><name><surname>Stambler</surname><given-names>I.</given-names></name><name><surname>Lim</surname><given-names>L.W.</given-names></name><name><surname>Su</surname><given-names>H.</given-names></name><name><surname>Moskalev</surname><given-names>A.</given-names></name><name><surname>Cano</surname><given-names>A.</given-names></name><name><surname>Chakrabarti</surname><given-names>S.</given-names></name><name><surname>Min</surname><given-names>K.J.</given-names></name><name><surname>Ellison-Hughes</surname><given-names>G.</given-names></name><name><surname>Caruso</surname><given-names>C.</given-names></name><name><surname>Jin</surname><given-names>K.</given-names></name><name><surname>Zhao</surname><given-names>R.C.</given-names></name></person-group><article-title>Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia</article-title><source>Aging Dis.</source><volume>11</volume><year>2020</year><fpage>216</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">32257537</pub-id></element-citation></ref><ref id="b0570"><element-citation publication-type="journal" id="h0565"><person-group person-group-type="author"><name><surname>Lew</surname><given-names>T.W.K.</given-names></name><name><surname>Kwek</surname><given-names>T.-K.</given-names></name><name><surname>Tai</surname><given-names>D.</given-names></name><name><surname>Earnest</surname><given-names>A.</given-names></name><name><surname>Loo</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Kwan</surname><given-names>K.M.</given-names></name><name><surname>Chan</surname><given-names>Y.</given-names></name><name><surname>Yim</surname><given-names>C.F.</given-names></name><name><surname>Bek</surname><given-names>S.L.</given-names></name><name><surname>Kor</surname><given-names>A.C.</given-names></name><name><surname>Yap</surname><given-names>W.S.</given-names></name><name><surname>Chelliah</surname><given-names>Y.R.</given-names></name><name><surname>Lai</surname><given-names>Y.C.</given-names></name><name><surname>Goh</surname><given-names>S.-K.</given-names></name></person-group><article-title>Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome</article-title><source>JAMA</source><volume>290</volume><year>2003</year><fpage>374</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">12865379</pub-id></element-citation></ref><ref id="b0575"><element-citation publication-type="journal" id="h0570"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>S.G.</given-names></name><name><surname>Gu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>X.X.</given-names></name><name><surname>Liang</surname><given-names>Z.A.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Jia</surname><given-names>H.Y.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>K.J.</given-names></name><name><surname>Xue</surname><given-names>C.X.</given-names></name><name><surname>Hu</surname><given-names>K.</given-names></name><name><surname>Zou</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>L.J.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia</article-title><source>Influenza Other Respir. Viruses</source><volume>11</volume><year>2017</year><fpage>345</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">28464462</pub-id></element-citation></ref><ref id="b0580"><element-citation publication-type="journal" id="h0575"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Tang</surname><given-names>S.</given-names></name><name><surname>Wei</surname><given-names>F.</given-names></name></person-group><article-title>Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats</article-title><source>J. Inflamm. (Lond)</source><volume>9</volume><year>2012</year><fpage>33</fpage><pub-id pub-id-type="pmid">22974286</pub-id></element-citation></ref><ref id="b0585"><element-citation publication-type="journal" id="h0580"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Moore</surname><given-names>M.J.</given-names></name><name><surname>Vasilieva</surname><given-names>N.</given-names></name><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Wong</surname><given-names>S.K.</given-names></name><name><surname>Berne</surname><given-names>M.A.</given-names></name><name><surname>Somasundaran</surname><given-names>M.</given-names></name><name><surname>Sullivan</surname><given-names>J.L.</given-names></name><name><surname>Luzuriaga</surname><given-names>K.</given-names></name><name><surname>Greenough</surname><given-names>T.C.</given-names></name><name><surname>Choe</surname><given-names>H.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><volume>426</volume><year>2003</year><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">14647384</pub-id></element-citation></ref><ref id="b0590"><element-citation publication-type="journal" id="h0585"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Liao</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Duan</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Hu</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Lei</surname><given-names>C.</given-names></name><name><surname>Dong</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Jia</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name></person-group><article-title>Caution on kidney dysfunctions of COVID-19 patients</article-title><source>medRxiv</source><year>2020</year><comment>2020.2002.2008.20021212</comment></element-citation></ref><ref id="b0595"><element-citation publication-type="journal" id="h0590"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Ge</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Qiao</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>R.</given-names></name><name><surname>Bi</surname><given-names>J.</given-names></name><name><surname>Zhan</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name><name><surname>Jia</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name></person-group><article-title>Vicarious traumatization in the general public, members, and non-members of medical teams aiding in COVID-19 control</article-title><source>Brain Behav. Immun.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.bbi.2020.03.007</pub-id></element-citation></ref><ref id="b0600"><element-citation publication-type="journal" id="h0595"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>H.S.</given-names></name><name><surname>Im</surname><given-names>J.S.</given-names></name><name><surname>Cho</surname><given-names>J.Y.</given-names></name><name><surname>Bae</surname><given-names>K.S.</given-names></name><name><surname>Klein</surname><given-names>T.A.</given-names></name><name><surname>Yeom</surname><given-names>J.S.</given-names></name><name><surname>Kim</surname><given-names>T.S.</given-names></name><name><surname>Choi</surname><given-names>J.S.</given-names></name><name><surname>Jang</surname><given-names>I.J.</given-names></name><name><surname>Park</surname><given-names>J.W.</given-names></name></person-group><article-title>Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax</article-title><source>Antimicrob. Agents Chemother.</source><volume>53</volume><year>2009</year><fpage>1468</fpage><lpage>1475</lpage><pub-id pub-id-type="pmid">19188392</pub-id></element-citation></ref><ref id="b0605"><element-citation publication-type="journal" id="h0600"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Gu</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Mai</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Lai</surname><given-names>R.</given-names></name><name><surname>Yan</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Shan</surname><given-names>H.</given-names></name></person-group><article-title>Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection</article-title><source>Gut</source><year>2020</year><pub-id pub-id-type="doi">10.1136/gutjnl-2020-321013</pub-id></element-citation></ref><ref id="b0610"><element-citation publication-type="journal" id="h0605"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection <italic>in vitro</italic></article-title><source>Cell Discov.</source><volume>6</volume><year>2020</year><fpage>16</fpage><pub-id pub-id-type="pmid">32194981</pub-id></element-citation></ref><ref id="b0615"><mixed-citation publication-type="other" id="h0610">Liu, J., Liu, Y., Xiang, P., Pu, L., Xiong, H., Li, C., Zhang, M., Tan, J., Xu, Y., Song, R., Song, M., Wang, L., Zhang, W., Han, B., Yang, L., Wang, X., Zhou, G., Zhang, T., Li, B., Wang, Y., Chen, Z., Wang, X., 2020b. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. medRxiv, 2020.2002.2010.20021584.</mixed-citation></ref><ref id="b0620"><element-citation publication-type="journal" id="h0615"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Fang</surname><given-names>Y.Y.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>M.F.</given-names></name><name><surname>Ma</surname><given-names>J.P.</given-names></name><name><surname>Xiao</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Y.N.</given-names></name><name><surname>Zhong</surname><given-names>M.H.</given-names></name><name><surname>Li</surname><given-names>C.H.</given-names></name><name><surname>Li</surname><given-names>G.C.</given-names></name><name><surname>Liu</surname><given-names>H.G.</given-names></name></person-group><article-title>Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province</article-title><source>Chin. Med. J. (Engl).</source><year>2020</year><pub-id pub-id-type="doi">10.1097/CM9.0000000000000744</pub-id></element-citation></ref><ref id="b0625"><element-citation publication-type="journal" id="h0620"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Peng</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Qin</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>D.</given-names></name><name><surname>Tan</surname><given-names>S.</given-names></name><name><surname>Yin</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name></person-group><article-title>Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury</article-title><source>Sci. China Life Sci.</source><volume>63</volume><year>2020</year><fpage>364</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">32048163</pub-id></element-citation></ref><ref id="b0630"><element-citation publication-type="journal" id="h0625"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.J.</given-names></name></person-group><article-title>IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors</article-title><source>Annu. Rev. Immunol.</source><volume>23</volume><year>2005</year><fpage>275</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">15771572</pub-id></element-citation></ref><ref id="b0635"><element-citation publication-type="journal" id="h0630"><person-group person-group-type="author"><name><surname>Loutfy</surname><given-names>M.R.</given-names></name><name><surname>Blatt</surname><given-names>L.M.</given-names></name><name><surname>Siminovitch</surname><given-names>K.A.</given-names></name><name><surname>Ward</surname><given-names>S.</given-names></name><name><surname>Wolff</surname><given-names>B.</given-names></name><name><surname>Lho</surname><given-names>H.</given-names></name><name><surname>Pham</surname><given-names>D.H.</given-names></name><name><surname>Deif</surname><given-names>H.</given-names></name><name><surname>LaMere</surname><given-names>E.A.</given-names></name><name><surname>Chang</surname><given-names>M.</given-names></name><name><surname>Kain</surname><given-names>K.C.</given-names></name><name><surname>Farcas</surname><given-names>G.A.</given-names></name><name><surname>Ferguson</surname><given-names>P.</given-names></name><name><surname>Latchford</surname><given-names>M.</given-names></name><name><surname>Levy</surname><given-names>G.</given-names></name><name><surname>Dennis</surname><given-names>J.W.</given-names></name><name><surname>Lai</surname><given-names>E.K.</given-names></name><name><surname>Fish</surname><given-names>E.N.</given-names></name></person-group><article-title>Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study</article-title><source>JAMA</source><volume>290</volume><year>2003</year><fpage>3222</fpage><lpage>3228</lpage><pub-id pub-id-type="pmid">14693875</pub-id></element-citation></ref><ref id="b0640"><element-citation publication-type="journal" id="h0635"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Bi</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Zhan</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>T.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Meng</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>Z.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>W.J.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Holmes</surname><given-names>E.C.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="b0645"><element-citation publication-type="journal" id="h0640"><person-group person-group-type="author"><name><surname>Luke</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Coleman</surname><given-names>C.M.</given-names></name><name><surname>Jiao</surname><given-names>J.A.</given-names></name><name><surname>Matsushita</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Postnikova</surname><given-names>E.N.</given-names></name><name><surname>Ork</surname><given-names>B.L.</given-names></name><name><surname>Glenn</surname><given-names>G.</given-names></name><name><surname>Flyer</surname><given-names>D.</given-names></name><name><surname>Defang</surname><given-names>G.</given-names></name><name><surname>Raviprakash</surname><given-names>K.</given-names></name><name><surname>Kochel</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Nie</surname><given-names>W.</given-names></name><name><surname>Smith</surname><given-names>G.</given-names></name><name><surname>Hensley</surname><given-names>L.E.</given-names></name><name><surname>Olinger</surname><given-names>G.G.</given-names></name><name><surname>Kuhn</surname><given-names>J.H.</given-names></name><name><surname>Holbrook</surname><given-names>M.R.</given-names></name><name><surname>Johnson</surname><given-names>R.F.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Sullivan</surname><given-names>E.</given-names></name><name><surname>Frieman</surname><given-names>M.B.</given-names></name></person-group><article-title>Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV <italic>in vivo</italic></article-title><source>Sci. Transl. Med.</source><volume>8</volume><year>2016</year><fpage>326ra321</fpage></element-citation></ref><ref id="b0650"><element-citation publication-type="journal" id="h0645"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>H.U.</given-names></name><name><surname>Stammler</surname><given-names>P.</given-names></name><name><surname>Jelezarova</surname><given-names>E.</given-names></name><name><surname>Nater</surname><given-names>M.</given-names></name><name><surname>Sp&#x000e4;th</surname><given-names>P.J.</given-names></name></person-group><article-title>High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes</article-title><source>Blood</source><volume>88</volume><year>1996</year><fpage>184</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">8704173</pub-id></element-citation></ref><ref id="b0655"><element-citation publication-type="journal" id="h0650"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>F.-J.</given-names></name><name><surname>Tuan</surname><given-names>R.S.</given-names></name><name><surname>Cheung</surname><given-names>K.M.C.</given-names></name><name><surname>Leung</surname><given-names>V.Y.L.</given-names></name></person-group><article-title>Concise review: the surface markers and identity of human mesenchymal stem cells</article-title><source>Stem Cells</source><volume>32</volume><year>2014</year><fpage>1408</fpage><lpage>1419</lpage><pub-id pub-id-type="pmid">24578244</pub-id></element-citation></ref><ref id="b0660"><element-citation publication-type="journal" id="h0655"><person-group person-group-type="author"><name><surname>Mair-Jenkins</surname><given-names>J.</given-names></name><name><surname>Saavedra-Campos</surname><given-names>M.</given-names></name><name><surname>Baillie</surname><given-names>J.K.</given-names></name><name><surname>Cleary</surname><given-names>P.</given-names></name><name><surname>Khaw</surname><given-names>F.M.</given-names></name><name><surname>Lim</surname><given-names>W.S.</given-names></name><name><surname>Makki</surname><given-names>S.</given-names></name><name><surname>Rooney</surname><given-names>K.D.</given-names></name><name><surname>Nguyen-Van-Tam</surname><given-names>J.S.</given-names></name><name><surname>Beck</surname><given-names>C.R.</given-names></name></person-group><article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis</article-title><source>J. Infect. Dis.</source><volume>211</volume><year>2015</year><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">25030060</pub-id></element-citation></ref><ref id="b0665"><mixed-citation publication-type="other" id="h0660">Mak, E. March 18, 2020. China approves first homegrown COVID-19 vaccine to enter clinical trials. https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials.</mixed-citation></ref><ref id="b0670"><mixed-citation publication-type="other" id="h0665">Mao, L., Wang, M., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., Li, Y., Jin, H., Hu, B., 2020. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv, 2020.2002.2022.20026500.</mixed-citation></ref><ref id="b0675"><element-citation publication-type="journal" id="h0670"><person-group person-group-type="author"><name><surname>Marchalonis</surname><given-names>J.J.</given-names></name><name><surname>Kaymaz</surname><given-names>H.</given-names></name><name><surname>Dedeoglu</surname><given-names>F.</given-names></name><name><surname>Schluter</surname><given-names>S.F.</given-names></name><name><surname>Yocum</surname><given-names>D.E.</given-names></name><name><surname>Edmundson</surname><given-names>A.B.</given-names></name></person-group><article-title>Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>89</volume><year>1992</year><fpage>3325</fpage><lpage>3329</lpage><pub-id pub-id-type="pmid">1565623</pub-id></element-citation></ref><ref id="b0680"><element-citation publication-type="journal" id="h0675"><person-group person-group-type="author"><name><surname>May</surname><given-names>J.M.</given-names></name><name><surname>Harrison</surname><given-names>F.E.</given-names></name></person-group><article-title>Role of vitamin C in the function of the vascular endothelium</article-title><source>Antioxid. Redox. Signal.</source><volume>19</volume><year>2013</year><fpage>2068</fpage><lpage>2083</lpage><pub-id pub-id-type="pmid">23581713</pub-id></element-citation></ref><ref id="b0685"><element-citation publication-type="journal" id="h0680"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P.</given-names></name><name><surname>McAuley</surname><given-names>D.F.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Sanchez</surname><given-names>E.</given-names></name><name><surname>Tattersall</surname><given-names>R.S.</given-names></name><name><surname>Manson</surname><given-names>J.J.</given-names></name></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="b0690"><element-citation publication-type="journal" id="h0685"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>S.H.J.</given-names></name><name><surname>Haitsma</surname><given-names>J.J.</given-names></name><name><surname>Dos Santos</surname><given-names>C.C.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Lai</surname><given-names>P.F.H.</given-names></name><name><surname>Slutsky</surname><given-names>A.S.</given-names></name><name><surname>Liles</surname><given-names>W.C.</given-names></name><name><surname>Stewart</surname><given-names>D.J.</given-names></name></person-group><article-title>Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis</article-title><source>Am. J. Respir. Crit. Care Med.</source><volume>182</volume><year>2010</year><fpage>1047</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">20558630</pub-id></element-citation></ref><ref id="b0695"><mixed-citation publication-type="other" id="h0690">Microft-West, C., Su, D., Elli, S., Guimond, S., Miller, G., Turnbull, J., Yates, E., Guerrini, M., Fernig, D., Lima, M., Skidmore, M., 2020. The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 receptor domain undergoes conformational change upon heparin binding. bioRxiv doi:10.1101/2020.02.29.971093.</mixed-citation></ref><ref id="b0700"><element-citation publication-type="journal" id="h0695"><person-group person-group-type="author"><name><surname>Minagawa</surname><given-names>H.</given-names></name><name><surname>Takenaka</surname><given-names>A.</given-names></name><name><surname>Mohri</surname><given-names>S.</given-names></name><name><surname>Mori</surname><given-names>R.</given-names></name></person-group><article-title>Protective effect of recombinant murine interferon beta against mouse hepatitis virus infection</article-title><source>Antiviral Res.</source><volume>8</volume><year>1987</year><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">2830846</pub-id></element-citation></ref><ref id="b0705"><mixed-citation publication-type="other" id="h0700">Moderna. Press release at March 16, 2020a. Moderna announces first participant dosed in NIH-led phase 1 study of mRNA vaccine (mRNA-1273) against novel coronavirus. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participant-dosed-nih-led-phase-1-study.</mixed-citation></ref><ref id="b0710"><mixed-citation publication-type="other" id="h0705">Moderna. Press release at April 16, 2020b. Moderna announces award from U.S. government agency BARDA for up to $483 million to accelerate development of mRNA vaccine (mRNA-1273) against novel coronavirus. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-award-us-government-agency-barda-483-million.</mixed-citation></ref><ref id="b0715"><element-citation publication-type="journal" id="h0710"><person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>B.M.</given-names></name><name><surname>Fisher</surname><given-names>B.J.</given-names></name><name><surname>Kraskauskas</surname><given-names>D.</given-names></name><name><surname>Farkas</surname><given-names>D.</given-names></name><name><surname>Brophy</surname><given-names>D.F.</given-names></name><name><surname>Fowler</surname><given-names>A.A.</given-names><suffix>3rd</suffix></name><name><surname>Natarajan</surname><given-names>R.</given-names></name></person-group><article-title>Vitamin C: a novel regulator of neutrophil extracellular trap formation</article-title><source>Nutrients</source><volume>5</volume><year>2013</year><fpage>3131</fpage><lpage>3151</lpage><pub-id pub-id-type="pmid">23939536</pub-id></element-citation></ref><ref id="b0720"><element-citation publication-type="journal" id="h0715"><person-group person-group-type="author"><name><surname>Munster</surname><given-names>V.J.</given-names></name><name><surname>Koopmans</surname><given-names>M.</given-names></name><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>van Riel</surname><given-names>D.</given-names></name><name><surname>de Wit</surname><given-names>E.</given-names></name></person-group><article-title>A novel coronavirus emerging in China - key questions for impact assessment</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>692</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">31978293</pub-id></element-citation></ref><ref id="b0725"><element-citation publication-type="journal" id="h0720"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>S.</given-names></name></person-group><article-title>Stress-induced change in tissue levels of ascorbic acid and histamine in rats</article-title><source>J. Nutr.</source><volume>114</volume><year>1984</year><fpage>1602</fpage><lpage>1608</lpage><pub-id pub-id-type="pmid">6206215</pub-id></element-citation></ref><ref id="b0730"><mixed-citation publication-type="other" id="h0725">National Health and Family Planning Commission of China (NHPFC). March 04, 2020. Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment (7th edition). http://kjfy.meetingchina.org/msite/news/show/cn/3337.html.</mixed-citation></ref><ref id="b0735"><mixed-citation publication-type="other" id="h0730">National Institutes of Health (NIH). March 16, 2020. NIH clinical trial of investigational vaccine for COVID-19 begins. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins. http://tribuneonlineng.com/china-approves-use-of-roche-drug-in-battle-against-coronavirus-complications/.</mixed-citation></ref><ref id="b0745"><element-citation publication-type="journal" id="h0735"><person-group person-group-type="author"><name><surname>Nishimoto</surname><given-names>N.</given-names></name><name><surname>Kishimoto</surname><given-names>T.</given-names></name><name><surname>Yoshizaki</surname><given-names>K.</given-names></name></person-group><article-title>Anti-interleukin 6 receptor antibody treatment in rheumatic disease</article-title><source>Ann. Rhum. Dis.</source><volume>59</volume><issue>Suppl 1</issue><year>2000</year><fpage>i21</fpage><lpage>i27</lpage></element-citation></ref><ref id="b0750"><mixed-citation publication-type="other" id="h0740">Novavax, Press Release April 08, 2020. Novavax identifies coronavirus vaccine candidate: accelerates initiation of first-in-human trial to mid-May. https://ir.novavax.com/news-releases/news-release-details/novavax-identifies-coronavirus-vaccine-candidate-accelerates.</mixed-citation></ref><ref id="b0755"><element-citation publication-type="journal" id="h0745"><person-group person-group-type="author"><name><surname>O'Shea</surname><given-names>J.J.</given-names></name><name><surname>Plenge</surname><given-names>R.</given-names></name></person-group><article-title>JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</article-title><source>Immunity</source><volume>36</volume><year>2012</year><fpage>542</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">22520847</pub-id></element-citation></ref><ref id="b0760"><element-citation publication-type="journal" id="h0750"><person-group person-group-type="author"><name><surname>Oestereich</surname><given-names>L.</given-names></name><name><surname>L&#x000fc;dtke</surname><given-names>A.</given-names></name><name><surname>Wurr</surname><given-names>S.</given-names></name><name><surname>Rieger</surname><given-names>T.</given-names></name><name><surname>Mu&#x000f1;oz-Fontela</surname><given-names>C.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name></person-group><article-title>Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model</article-title><source>Antiviral Res.</source><volume>105</volume><year>2014</year><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">24583123</pub-id></element-citation></ref><ref id="b0765"><element-citation publication-type="journal" id="h0755"><person-group person-group-type="author"><name><surname>Oudemans-van Straaten</surname><given-names>H.M.</given-names></name><name><surname>Spoelstra-de Man</surname><given-names>A.M.</given-names></name><name><surname>de Waard</surname><given-names>M.C.</given-names></name></person-group><article-title>Vitamin C revisited</article-title><source>Crit. Care</source><volume>18</volume><year>2014</year><fpage>460</fpage><pub-id pub-id-type="pmid">25185110</pub-id></element-citation></ref><ref id="b0770"><element-citation publication-type="journal" id="h0760"><person-group person-group-type="author"><name><surname>Painter</surname><given-names>G.R.</given-names></name><name><surname>Bowen</surname><given-names>R.A.</given-names></name><name><surname>Bluemling</surname><given-names>G.R.</given-names></name><name><surname>DeBergh</surname><given-names>J.</given-names></name><name><surname>Edpuganti</surname><given-names>V.</given-names></name><name><surname>Gruddanti</surname><given-names>P.R.</given-names></name><name><surname>Guthrie</surname><given-names>D.B.</given-names></name><name><surname>Hager</surname><given-names>M.</given-names></name><name><surname>Kuiper</surname><given-names>D.L.</given-names></name><name><surname>Lockwood</surname><given-names>M.A.</given-names></name><name><surname>Mitchell</surname><given-names>D.G.</given-names></name><name><surname>Natchus</surname><given-names>M.G.</given-names></name><name><surname>Sticher</surname><given-names>Z.M.</given-names></name><name><surname>Kolykhalov</surname><given-names>A.A.</given-names></name></person-group><article-title>The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection</article-title><source>Antiviral Res.</source><volume>171</volume><year>2019</year><object-id pub-id-type="publisher-id">104597</object-id></element-citation></ref><ref id="b0775"><element-citation publication-type="journal" id="h0765"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X.W.</given-names></name><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>L.H.</given-names></name><name><surname>Cui</surname><given-names>X.G.</given-names></name></person-group><article-title>Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis</article-title><source>Intensive Care Med</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s00134-020-06026-1</pub-id></element-citation></ref><ref id="b0780"><element-citation publication-type="journal" id="h0770"><person-group person-group-type="author"><name><surname>Papayannopoulos</surname><given-names>V.</given-names></name></person-group><article-title>Neutrophil extracellular traps in immunity and disease</article-title><source>Nat. Rev. Immunol.</source><volume>18</volume><year>2018</year><fpage>134</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">28990587</pub-id></element-citation></ref><ref id="b0785"><element-citation publication-type="journal" id="h0775"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>J.</given-names></name><name><surname>Cohen</surname><given-names>B.</given-names></name></person-group><article-title>An overview of the immune system</article-title><source>Lancet</source><volume>357</volume><year>2001</year><fpage>1777</fpage><lpage>1789</lpage><pub-id pub-id-type="pmid">11403834</pub-id></element-citation></ref><ref id="b0790"><element-citation publication-type="journal" id="h0780"><person-group person-group-type="author"><name><surname>Pepke-Zaba</surname><given-names>J.</given-names></name><name><surname>Higenbottam</surname><given-names>T.W.</given-names></name><name><surname>Dinh-Xuan</surname><given-names>A.T.</given-names></name><name><surname>Stone</surname><given-names>D.</given-names></name><name><surname>Wallwork</surname><given-names>J.</given-names></name></person-group><article-title>Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension</article-title><source>Lancet</source><volume>338</volume><year>1991</year><fpage>1173</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">1682593</pub-id></element-citation></ref><ref id="b0795"><element-citation publication-type="journal" id="h0785"><person-group person-group-type="author"><name><surname>Pfefferbaum</surname><given-names>B.</given-names></name><name><surname>North</surname><given-names>C.S.</given-names></name></person-group><article-title>Mental Health and the Covid-19 pandemic</article-title><source>N. Eng. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMp2008017</pub-id></element-citation></ref><ref id="b0800"><element-citation publication-type="journal" id="h0790"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>A.S.</given-names></name></person-group><article-title>Zinc in human health: effect of zinc on immune cells</article-title><source>Mol. Med.</source><volume>14</volume><year>2008</year><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">18385818</pub-id></element-citation></ref><ref id="b0805"><element-citation publication-type="journal" id="h0795"><person-group person-group-type="author"><name><surname>Prevosto</surname><given-names>C.</given-names></name><name><surname>Zancolli</surname><given-names>M.</given-names></name><name><surname>Canevali</surname><given-names>P.</given-names></name><name><surname>Zocchi</surname><given-names>M.R.</given-names></name><name><surname>Poggi</surname><given-names>A.</given-names></name></person-group><article-title>Generation of CD<sup>4+</sup> or CD<sup>8+</sup> regulatory T cells upon mesenchymal stem cell-lymphocyte interaction</article-title><source>Haematologica</source><volume>92</volume><year>2007</year><fpage>881</fpage><lpage>888</lpage><pub-id pub-id-type="pmid">17606437</pub-id></element-citation></ref><ref id="b0810"><element-citation publication-type="journal" id="h0800"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>K.</given-names></name><name><surname>Shang</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Tian</surname><given-names>D.S.</given-names></name></person-group><article-title>Dysregulation of immune response in patients with COVID-19 in Wuhan, China</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa248</pub-id></element-citation></ref><ref id="b0815"><element-citation publication-type="journal" id="h0805"><person-group person-group-type="author"><name><surname>Raimondo</surname><given-names>M.G.</given-names></name><name><surname>Biggioggero</surname><given-names>M.</given-names></name><name><surname>Crotti</surname><given-names>C.</given-names></name><name><surname>Becciolini</surname><given-names>A.</given-names></name><name><surname>Favalli</surname><given-names>E.G.</given-names></name></person-group><article-title>Profile of sarilumab and its potential in the treatment of rheumatoid arthritis</article-title><source>Drug Des. Devel. Ther.</source><volume>11</volume><year>2017</year><fpage>1593</fpage><lpage>1603</lpage></element-citation></ref><ref id="b0820"><mixed-citation publication-type="other" id="h0810">Regeneron. March 16, 2020. REGENERON AND SANOFI BEGIN GLOBAL KEVZARA&#x000ae; (SARILUMAB) CLINICAL TRIAL PROGRAM IN PATIENTS WITH SEVERE COVID-19. https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-begin-global-kevzarar-sarilumab-clinical/.</mixed-citation></ref><ref id="b0825"><element-citation publication-type="journal" id="h0815"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J.L.</given-names></name><name><surname>Zhang</surname><given-names>A.H.</given-names></name><name><surname>Wang</surname><given-names>X.J.</given-names></name></person-group><article-title>Traditional Chinese medicine for COVID-19 treatment</article-title><source>Pharmacol. Res.</source><volume>155</volume><year>2020</year><object-id pub-id-type="publisher-id">104743</object-id></element-citation></ref><ref id="b0830"><element-citation publication-type="journal" id="h0820"><person-group person-group-type="author"><name><surname>Reynard</surname><given-names>O.</given-names></name><name><surname>Nguyen</surname><given-names>X.N.</given-names></name><name><surname>Alazard-Dany</surname><given-names>N.</given-names></name><name><surname>Barateau</surname><given-names>V.</given-names></name><name><surname>Cimarelli</surname><given-names>A.</given-names></name><name><surname>Volchkov</surname><given-names>V.E.</given-names></name></person-group><article-title>Identification of a new ribonucleoside inhibitor of Ebola Virus replication</article-title><source>Viruses</source><volume>7</volume><year>2015</year><fpage>6233</fpage><lpage>6240</lpage><pub-id pub-id-type="pmid">26633464</pub-id></element-citation></ref><ref id="b0835"><element-citation publication-type="journal" id="h0825"><person-group person-group-type="author"><name><surname>Rhen</surname><given-names>T.</given-names></name><name><surname>Cidlowski</surname><given-names>J.A.</given-names></name></person-group><article-title>Antiinflammatory action of glucocorticoids&#x02013;new mechanisms for old drugs</article-title><source>N. Engl. J. Med.</source><volume>353</volume><year>2005</year><fpage>1711</fpage><lpage>1723</lpage><pub-id pub-id-type="pmid">16236742</pub-id></element-citation></ref><ref id="b0840"><element-citation publication-type="journal" id="h0830"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>P.</given-names></name><name><surname>Griffin</surname><given-names>I.</given-names></name><name><surname>Tucker</surname><given-names>C.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><name><surname>Oechsle</surname><given-names>O.</given-names></name><name><surname>Phelan</surname><given-names>A.</given-names></name><name><surname>Stebbing</surname><given-names>J.</given-names></name></person-group><article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>e30</fpage><lpage>e31</lpage><pub-id pub-id-type="pmid">32032529</pub-id></element-citation></ref><ref id="b0845"><element-citation publication-type="journal" id="h0835"><person-group person-group-type="author"><name><surname>Roback</surname><given-names>J.D.</given-names></name><name><surname>Guarner</surname><given-names>J.</given-names></name></person-group><article-title>Convalescent plasma to treat COVID-19: possibilities and challenges</article-title><source>JAMA</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.4940</pub-id></element-citation></ref><ref id="b0850"><mixed-citation publication-type="other" id="h0840">Routley, N. April 01, 2020. Every vaccine and treatment in development for COVID-19, so far. https://www.visualcapitalist.com/every-vaccine-treatment-covid-19-so-far/.</mixed-citation></ref><ref id="b0855"><mixed-citation publication-type="other" id="h0845">Ruan, Q., Yang, K., Wang, W., Jiang, L., Song, J., 2020. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. doi: 10.1007/s00134-020-05991-x.</mixed-citation></ref><ref id="b0860"><element-citation publication-type="journal" id="h0850"><person-group person-group-type="author"><name><surname>Runfeng</surname><given-names>L.</given-names></name><name><surname>Yunlong</surname><given-names>H.</given-names></name><name><surname>Jicheng</surname><given-names>H.</given-names></name><name><surname>Weiqi</surname><given-names>P.</given-names></name><name><surname>Qinhai</surname><given-names>M.</given-names></name><name><surname>Yongxia</surname><given-names>S.</given-names></name><name><surname>Chufang</surname><given-names>L.</given-names></name><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Zhenhua</surname><given-names>J.</given-names></name><name><surname>Haiming</surname><given-names>J.</given-names></name><name><surname>Kui</surname><given-names>Z.</given-names></name><name><surname>Shuxiang</surname><given-names>H.</given-names></name><name><surname>Jun</surname><given-names>D.</given-names></name><name><surname>Xiaobo</surname><given-names>L.</given-names></name><name><surname>Xiaotao</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>W.</given-names></name><name><surname>Nanshan</surname><given-names>Z.</given-names></name><name><surname>Zifeng</surname><given-names>Y.</given-names></name></person-group><article-title>Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)</article-title><source>Pharmacol. Res.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104761</pub-id><comment>104761</comment></element-citation></ref><ref id="b0865"><element-citation publication-type="journal" id="h0855"><person-group person-group-type="author"><name><surname>Sainz</surname><given-names>B.</given-names><suffix>Jr.</suffix></name><name><surname>Mossel</surname><given-names>E.C.</given-names></name><name><surname>Peters</surname><given-names>C.J.</given-names></name><name><surname>Garry</surname><given-names>R.F.</given-names></name></person-group><article-title>Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)</article-title><source>Virology</source><volume>329</volume><year>2004</year><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">15476870</pub-id></element-citation></ref><ref id="b0870"><element-citation publication-type="journal" id="h0860"><person-group person-group-type="author"><name><surname>Sakkas</surname><given-names>L.I.</given-names></name></person-group><article-title>Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis</article-title><source>Drug Des. Devel. Ther.</source><volume>10</volume><year>2016</year><fpage>2723</fpage><lpage>2728</lpage></element-citation></ref><ref id="b0875"><element-citation publication-type="journal" id="h0865"><person-group person-group-type="author"><name><surname>Saura</surname><given-names>M.</given-names></name><name><surname>Zaragoza</surname><given-names>C.</given-names></name><name><surname>McMillan</surname><given-names>A.</given-names></name><name><surname>Quick</surname><given-names>R.A.</given-names></name><name><surname>Hohenadl</surname><given-names>C.</given-names></name><name><surname>Lowenstein</surname><given-names>J.M.</given-names></name><name><surname>Lowenstein</surname><given-names>C.J.</given-names></name></person-group><article-title>An antiviral mechanism of nitric oxide: inhibition of a viral protease</article-title><source>Immunity</source><volume>10</volume><year>1999</year><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">10023767</pub-id></element-citation></ref><ref id="b0880"><element-citation publication-type="journal" id="h0870"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Boelaert</surname><given-names>J.R.</given-names></name><name><surname>Cassone</surname><given-names>A.</given-names></name><name><surname>Majori</surname><given-names>G.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name></person-group><article-title>Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect</article-title><source>Dis.</source><volume>3</volume><year>2003</year><fpage>722</fpage><lpage>727</lpage></element-citation></ref><ref id="b0885"><element-citation publication-type="journal" id="h0875"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Di Trani</surname><given-names>L.</given-names></name><name><surname>Donatelli</surname><given-names>I.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name><name><surname>Cassone</surname><given-names>A.</given-names></name></person-group><article-title>New insights into the antiviral effects of chloroquine</article-title><source>Lancet Infect. Dis.</source><volume>6</volume><year>2006</year><fpage>67</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">16439323</pub-id></element-citation></ref><ref id="b0890"><element-citation publication-type="journal" id="h0880"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>H.H.</given-names></name><name><surname>Walter</surname><given-names>U.</given-names></name></person-group><article-title>NO at work</article-title><source>Cell</source><volume>78</volume><year>1994</year><fpage>919</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">7923361</pub-id></element-citation></ref><ref id="b0895"><element-citation publication-type="journal" id="h0885"><person-group person-group-type="author"><name><surname>Schoeman</surname><given-names>D.</given-names></name><name><surname>Fielding</surname><given-names>B.C.</given-names></name></person-group><article-title>Coronavirus envelope protein: current knowledge</article-title><source>Virol J.</source><volume>16</volume><year>2019</year><fpage>69</fpage><pub-id pub-id-type="pmid">31133031</pub-id></element-citation></ref><ref id="b0900"><mixed-citation publication-type="other" id="h0890">ScienceDaily. April 02, 2020. COVID-19 vaccine candidate shows promise, research shows. https://www.sciencedaily.com/releases/2020/04/200402144508.htm.</mixed-citation></ref><ref id="b0905"><element-citation publication-type="journal" id="h0895"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>G.C.</given-names></name></person-group><article-title>Viruses and interferons</article-title><source>Annu Rev Microbiol</source><volume>55</volume><year>2001</year><fpage>255</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">11544356</pub-id></element-citation></ref><ref id="b0910"><element-citation publication-type="journal" id="h0900"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Menachery</surname><given-names>V.D.</given-names></name><name><surname>Gralinski</surname><given-names>L.E.</given-names></name><name><surname>Case</surname><given-names>J.B.</given-names></name><name><surname>Leist</surname><given-names>S.R.</given-names></name><name><surname>Pyrc</surname><given-names>K.</given-names></name><name><surname>Feng</surname><given-names>J.Y.</given-names></name><name><surname>Trantcheva</surname><given-names>I.</given-names></name><name><surname>Bannister</surname><given-names>R.</given-names></name><name><surname>Park</surname><given-names>Y.</given-names></name><name><surname>Babusis</surname><given-names>D.</given-names></name><name><surname>Clarke</surname><given-names>M.O.</given-names></name><name><surname>Mackman</surname><given-names>R.L.</given-names></name><name><surname>Spahn</surname><given-names>J.E.</given-names></name><name><surname>Palmiotti</surname><given-names>C.A.</given-names></name><name><surname>Siegel</surname><given-names>D.</given-names></name><name><surname>Ray</surname><given-names>A.S.</given-names></name><name><surname>Cihlar</surname><given-names>T.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Denison</surname><given-names>M.R.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</article-title><source>Sci. Transl. Med.</source><volume>9</volume><year>2017</year><fpage>eaal3653</fpage><pub-id pub-id-type="pmid">28659436</pub-id></element-citation></ref><ref id="b0915"><mixed-citation publication-type="other" id="h0905">Sheahan, T.P., Sims, A.C., Zhou, S., Graham, R.L., Pruijssers, A.J., Agostini, M.L., Leist, S.R., Sch&#x000e4;fer, A., Dinnon, K.H., Stevens, L.J., Chappell, J.D., Lu, X., Hughes, T.M., George, A.S., Hill, C.S., Montgomery, S.A., Brown, A.J., Bluemling, G.R., Natchus, M.G., Saindane, M., Kolykhalov, A.A., Painter, G., Harcourt, J., Tamin, A., Thornburg, N.J., Swanstrom, R., Denison, M.R., Baric, R.S., 2020. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 2020 Apr 6. doi: 10.1126/scitranslmed.abb5883.</mixed-citation></ref><ref id="b0920"><element-citation publication-type="journal" id="h0910"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Knowledge and attitudes of medical staff in Chinese psychiatric hospitals regarding COVID-19</article-title><source>Brain Behav. Immun. Health</source><volume>4</volume><year>2020</year><object-id pub-id-type="publisher-id">100064</object-id></element-citation></ref><ref id="b0925"><element-citation publication-type="journal" id="h0915"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Zou</surname><given-names>Q.M.</given-names></name></person-group><article-title>Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)</article-title><source>Zhonghua Yu Fang Yi Xue Za Zhi</source><volume>54</volume><year>2020</year><fpage>E029</fpage><pub-id pub-id-type="pmid">32234130</pub-id></element-citation></ref><ref id="b0930"><element-citation publication-type="journal" id="h0920"><person-group person-group-type="author"><name><surname>Shimabukuro-Vornhagen</surname><given-names>A.</given-names></name><name><surname>G&#x000f6;del</surname><given-names>P.</given-names></name><name><surname>Subklewe</surname><given-names>M.</given-names></name><name><surname>Stemmler</surname><given-names>H.J.</given-names></name><name><surname>Schl&#x000f6;&#x000df;er</surname><given-names>H.A.</given-names></name><name><surname>Schlaak</surname><given-names>M.</given-names></name><name><surname>Kochanek</surname><given-names>M.</given-names></name><name><surname>B&#x000f6;ll</surname><given-names>B.</given-names></name><name><surname>von Bergwelt-Baildon</surname><given-names>M.S.</given-names></name></person-group><article-title>Cytokine release syndrome. J. Immunother</article-title><source>Cancer</source><volume>6</volume><year>2018</year><fpage>56</fpage></element-citation></ref><ref id="b0935"><element-citation publication-type="journal" id="h0925"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>D.</given-names></name><name><surname>Hui</surname><given-names>H.C.</given-names></name><name><surname>Doerffler</surname><given-names>E.</given-names></name><name><surname>Clarke</surname><given-names>M.O.</given-names></name><name><surname>Chun</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Neville</surname><given-names>S.</given-names></name><name><surname>Carra</surname><given-names>E.</given-names></name><name><surname>Lew</surname><given-names>W.</given-names></name><name><surname>Ross</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Wolfe</surname><given-names>L.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Soloveva</surname><given-names>V.</given-names></name><name><surname>Knox</surname><given-names>J.</given-names></name><name><surname>Perry</surname><given-names>J.</given-names></name><name><surname>Perron</surname><given-names>M.</given-names></name><name><surname>Stray</surname><given-names>K.M.</given-names></name><name><surname>Barauskas</surname><given-names>O.</given-names></name><name><surname>Feng</surname><given-names>J.Y.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>G.</given-names></name><name><surname>Rheingold</surname><given-names>A.L.</given-names></name><name><surname>Ray</surname><given-names>A.S.</given-names></name><name><surname>Bannister</surname><given-names>R.</given-names></name><name><surname>Strickley</surname><given-names>R.</given-names></name><name><surname>Swaminathan</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>W.A.</given-names></name><name><surname>Bavari</surname><given-names>S.</given-names></name><name><surname>Cihlar</surname><given-names>T.</given-names></name><name><surname>Lo</surname><given-names>M.K.</given-names></name><name><surname>Warren</surname><given-names>T.K.</given-names></name><name><surname>Mackman</surname><given-names>R.L.</given-names></name></person-group><article-title>Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses</article-title><source>J. Med. Chem.</source><volume>60</volume><year>2017</year><fpage>1648</fpage><lpage>1661</lpage><pub-id pub-id-type="pmid">28124907</pub-id></element-citation></ref><ref id="b0940"><element-citation publication-type="journal" id="h0930"><person-group person-group-type="author"><name><surname>Siemieniuk</surname><given-names>R.A.C.</given-names></name><name><surname>Meade</surname><given-names>M.O.</given-names></name><name><surname>Alonso-Coello</surname><given-names>P.</given-names></name><name><surname>Briel</surname><given-names>M.</given-names></name><name><surname>Evaniew</surname><given-names>N.</given-names></name><name><surname>Prasad</surname><given-names>M.</given-names></name><name><surname>Alexander</surname><given-names>P.E.</given-names></name><name><surname>Fei</surname><given-names>Y.</given-names></name><name><surname>Vandvik</surname><given-names>P.O.</given-names></name><name><surname>Loeb</surname><given-names>M.</given-names></name><name><surname>Guyatt</surname><given-names>G.H.</given-names></name></person-group><article-title>Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis</article-title><source>Ann. Intern. Med.</source><volume>163</volume><year>2015</year><fpage>519</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">26258555</pub-id></element-citation></ref><ref id="b0945"><element-citation publication-type="journal" id="h0935"><person-group person-group-type="author"><name><surname>Sissoko</surname><given-names>D.</given-names></name><name><surname>Laouenan</surname><given-names>C.</given-names></name><name><surname>Folkesson</surname><given-names>E.</given-names></name><name><surname>M'Lebing</surname><given-names>A.B.</given-names></name><name><surname>Beavogui</surname><given-names>A.H.</given-names></name><name><surname>Baize</surname><given-names>S.</given-names></name><name><surname>Camara</surname><given-names>A.M.</given-names></name><name><surname>Maes</surname><given-names>P.</given-names></name><name><surname>Shepherd</surname><given-names>S.</given-names></name><name><surname>Danel</surname><given-names>C.</given-names></name><name><surname>Carazo</surname><given-names>S.</given-names></name><name><surname>Conde</surname><given-names>M.N.</given-names></name><name><surname>Gala</surname><given-names>J.L.</given-names></name><name><surname>Colin</surname><given-names>G.</given-names></name><name><surname>Savini</surname><given-names>H.</given-names></name><name><surname>Bore</surname><given-names>J.A.</given-names></name><name><surname>Le Marcis</surname><given-names>F.</given-names></name><name><surname>Koundouno</surname><given-names>F.R.</given-names></name><name><surname>Petitjean</surname><given-names>F.</given-names></name><name><surname>Lamah</surname><given-names>M.C.</given-names></name><name><surname>Diederich</surname><given-names>S.</given-names></name><name><surname>Tounkara</surname><given-names>A.</given-names></name><name><surname>Poelart</surname><given-names>G.</given-names></name><name><surname>Berbain</surname><given-names>E.</given-names></name><name><surname>Dindart</surname><given-names>J.M.</given-names></name><name><surname>Duraffour</surname><given-names>S.</given-names></name><name><surname>Lefevre</surname><given-names>A.</given-names></name><name><surname>Leno</surname><given-names>T.</given-names></name><name><surname>Peyrouset</surname><given-names>O.</given-names></name><name><surname>Irenge</surname><given-names>L.</given-names></name><name><surname>Bangoura</surname><given-names>N.</given-names></name><name><surname>Palich</surname><given-names>R.</given-names></name><name><surname>Hinzmann</surname><given-names>J.</given-names></name><name><surname>Kraus</surname><given-names>A.</given-names></name><name><surname>Barry</surname><given-names>T.S.</given-names></name><name><surname>Berette</surname><given-names>S.</given-names></name><name><surname>Bongono</surname><given-names>A.</given-names></name><name><surname>Camara</surname><given-names>M.S.</given-names></name><name><surname>Chanfreau Munoz</surname><given-names>V.</given-names></name><name><surname>Doumbouya</surname><given-names>L.</given-names></name><name><surname>Souley</surname><given-names>H.</given-names></name><name><surname>Kighoma</surname><given-names>P.M.</given-names></name><name><surname>Koundouno</surname><given-names>F.R.</given-names></name><name><surname>R&#x000e9;n&#x000e9;</surname><given-names>L.</given-names></name><name><surname>Loua</surname><given-names>C.M.</given-names></name><name><surname>Massala</surname><given-names>V.</given-names></name><name><surname>Moumouni</surname><given-names>K.</given-names></name><name><surname>Provost</surname><given-names>C.</given-names></name><name><surname>Samake</surname><given-names>N.</given-names></name><name><surname>Sekou</surname><given-names>C.</given-names></name><name><surname>Soumah</surname><given-names>A.</given-names></name><name><surname>Arnould</surname><given-names>I.</given-names></name><name><surname>Komano</surname><given-names>M.S.</given-names></name><name><surname>Gustin</surname><given-names>L.</given-names></name><name><surname>Berutto</surname><given-names>C.</given-names></name><name><surname>Camara</surname><given-names>D.</given-names></name><name><surname>Camara</surname><given-names>F.S.</given-names></name><name><surname>Colpaert</surname><given-names>J.</given-names></name><name><surname>Delamou</surname><given-names>L.</given-names></name><name><surname>Jansson</surname><given-names>L.</given-names></name><name><surname>Kourouma</surname><given-names>E.</given-names></name><name><surname>Loua</surname><given-names>M.</given-names></name><name><surname>Malme</surname><given-names>K.</given-names></name><name><surname>Manfrin</surname><given-names>E.</given-names></name><name><surname>Maomou</surname><given-names>A.</given-names></name><name><surname>Milinouno</surname><given-names>A.</given-names></name><name><surname>Ombelet</surname><given-names>S.</given-names></name><name><surname>Sidiboun</surname><given-names>A.Y.</given-names></name><name><surname>Verreckt</surname><given-names>I.</given-names></name><name><surname>Yombouno</surname><given-names>P.</given-names></name><name><surname>Bocquin</surname><given-names>A.</given-names></name><name><surname>Carbonnelle</surname><given-names>C.</given-names></name><name><surname>Carmoi</surname><given-names>T.</given-names></name><name><surname>Frange</surname><given-names>P.</given-names></name><name><surname>Mely</surname><given-names>S.</given-names></name><name><surname>Nguyen</surname><given-names>V.K.</given-names></name><name><surname>Pannetier</surname><given-names>D.</given-names></name><name><surname>Taburet</surname><given-names>A.M.</given-names></name><name><surname>Treluyer</surname><given-names>J.M.</given-names></name><name><surname>Kolie</surname><given-names>J.</given-names></name><name><surname>Moh</surname><given-names>R.</given-names></name><name><surname>Gonzalez</surname><given-names>M.C.</given-names></name><name><surname>Kuisma</surname><given-names>E.</given-names></name><name><surname>Liedigk</surname><given-names>B.</given-names></name><name><surname>Ngabo</surname><given-names>D.</given-names></name><name><surname>Rudolf</surname><given-names>M.</given-names></name><name><surname>Thom</surname><given-names>R.</given-names></name><name><surname>Kerber</surname><given-names>R.</given-names></name><name><surname>Gabriel</surname><given-names>M.</given-names></name><name><surname>Di Caro</surname><given-names>A.</given-names></name><name><surname>W&#x000f6;lfel</surname><given-names>R.</given-names></name><name><surname>Badir</surname><given-names>J.</given-names></name><name><surname>Bentahir</surname><given-names>M.</given-names></name><name><surname>Deccache</surname><given-names>Y.</given-names></name><name><surname>Dumont</surname><given-names>C.</given-names></name><name><surname>Durant</surname><given-names>J.F.</given-names></name><name><surname>El Bakkouri</surname><given-names>K.</given-names></name><name><surname>Gasasira Uwamahoro</surname><given-names>M.</given-names></name><name><surname>Smits</surname><given-names>B.</given-names></name><name><surname>Toufik</surname><given-names>N.</given-names></name><name><surname>Van Cauwenberghe</surname><given-names>S.</given-names></name><name><surname>Ezzedine</surname><given-names>K.</given-names></name><name><surname>D'Ortenzio</surname><given-names>E.</given-names></name><name><surname>Pizarro</surname><given-names>L.</given-names></name><name><surname>Etienne</surname><given-names>A.</given-names></name><name><surname>Guedj</surname><given-names>J.</given-names></name><name><surname>Fizet</surname><given-names>A.</given-names></name><name><surname>de Sainte</surname><given-names>Barte</given-names></name><name><surname>Fare</surname><given-names>E.</given-names></name><name><surname>Murgue</surname><given-names>B.</given-names></name><name><surname>Tran-Minh</surname><given-names>T.</given-names></name><name><surname>Rapp</surname><given-names>C.</given-names></name><name><surname>Piguet</surname><given-names>P.</given-names></name><name><surname>Poncin</surname><given-names>M.</given-names></name><name><surname>Draguez</surname><given-names>B.</given-names></name><name><surname>Allaford Duverger</surname><given-names>T.</given-names></name><name><surname>Barbe</surname><given-names>S.</given-names></name><name><surname>Baret</surname><given-names>G.</given-names></name><name><surname>Defourny</surname><given-names>I.</given-names></name><name><surname>Carroll</surname><given-names>M.</given-names></name><name><surname>Raoul</surname><given-names>H.</given-names></name><name><surname>Augier</surname><given-names>A.</given-names></name><name><surname>Eholie</surname><given-names>S.P.</given-names></name><name><surname>Yazdanpanah</surname><given-names>Y.</given-names></name><name><surname>Levy-Marchal</surname><given-names>C.</given-names></name><name><surname>Antierrens</surname><given-names>A.</given-names></name><name><surname>Van Herp</surname><given-names>M.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name><name><surname>de Lamballerie</surname><given-names>X.</given-names></name><name><surname>Ke&#x000ef;ta</surname><given-names>S.</given-names></name><name><surname>Mentre</surname><given-names>F.</given-names></name><name><surname>Anglaret</surname><given-names>X.</given-names></name><name><surname>Malvy</surname><given-names>D.</given-names></name></person-group><article-title>Experimental treatment with favipiravir for Ebola Virus disease (the JIKI Trial): A historically controlled, single-arm proof-of-concept trial in Guinea</article-title><source>PLoS Med.</source><volume>13</volume><year>2016</year><object-id pub-id-type="publisher-id">e1001967</object-id></element-citation></ref><ref id="b0950"><element-citation publication-type="journal" id="h0940"><person-group person-group-type="author"><name><surname>Smither</surname><given-names>S.J.</given-names></name><name><surname>Eastaugh</surname><given-names>L.S.</given-names></name><name><surname>Steward</surname><given-names>J.A.</given-names></name><name><surname>Nelson</surname><given-names>M.</given-names></name><name><surname>Lenk</surname><given-names>R.P.</given-names></name><name><surname>Lever</surname><given-names>M.S.</given-names></name></person-group><article-title>Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model</article-title><source>Antiviral Res.</source><volume>104</volume><year>2014</year><fpage>153</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">24462697</pub-id></element-citation></ref><ref id="b0955"><element-citation publication-type="journal" id="h0945"><person-group person-group-type="author"><name><surname>Sperber</surname><given-names>S.J.</given-names></name><name><surname>Hayden</surname><given-names>F.G.</given-names></name></person-group><article-title>Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta</article-title><source>J. Interferon Res.</source><volume>9</volume><year>1989</year><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">2545792</pub-id></element-citation></ref><ref id="b0960"><element-citation publication-type="journal" id="h0950"><person-group person-group-type="author"><name><surname>Stockman</surname><given-names>L.J.</given-names></name><name><surname>Bellamy</surname><given-names>R.</given-names></name><name><surname>Garner</surname><given-names>P.</given-names></name></person-group><article-title>SARS: systematic review of treatment effects</article-title><source>PLoS Med.</source><volume>3</volume><year>2006</year><object-id pub-id-type="publisher-id">e343</object-id></element-citation></ref><ref id="b0965"><mixed-citation publication-type="other" id="h0955">Strabelli, T.M.V., Uip, D.E., 2020. COVID-19 and the Heart. Arq. Bras. Cardiol. doi: 10.36660/abc.20200209.</mixed-citation></ref><ref id="b0970"><element-citation publication-type="journal" id="h0960"><person-group person-group-type="author"><name><surname>Str&#x000f6;her</surname><given-names>U.</given-names></name><name><surname>DiCaro</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Strong</surname><given-names>J.E.</given-names></name><name><surname>Aoki</surname><given-names>F.</given-names></name><name><surname>Plummer</surname><given-names>F.</given-names></name><name><surname>Jones</surname><given-names>S.M.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name></person-group><article-title>Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha</article-title><source>J. Infect. Dis.</source><volume>189</volume><year>2004</year><fpage>1164</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">15031783</pub-id></element-citation></ref><ref id="b0975"><element-citation publication-type="journal" id="h0965"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>A.C.K.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Bi</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title><source>Trends Microbiol.</source><volume>24</volume><year>2016</year><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">27012512</pub-id></element-citation></ref><ref id="b0980"><element-citation publication-type="journal" id="h0970"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Xue</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Cui</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Xuebijing protects against lipopolysaccharide-induced lung injury in rabbits</article-title><source>Exp. Lung Res.</source><volume>36</volume><year>2010</year><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">20426529</pub-id></element-citation></ref><ref id="b0985"><element-citation publication-type="journal" id="h0975"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>E.L.</given-names></name><name><surname>Ooi</surname><given-names>E.E.</given-names></name><name><surname>Lin</surname><given-names>C.Y.</given-names></name><name><surname>Tan</surname><given-names>H.C.</given-names></name><name><surname>Ling</surname><given-names>A.E.</given-names></name><name><surname>Lim</surname><given-names>B.</given-names></name><name><surname>Stanton</surname><given-names>L.W.</given-names></name></person-group><article-title>Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs</article-title><source>Emerg. Infect. Dis.</source><volume>10</volume><year>2004</year><fpage>581</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">15200845</pub-id></element-citation></ref><ref id="b0990"><element-citation publication-type="journal" id="h0980"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name></person-group><article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title><source>J Thromb. Haemost.</source><volume>18</volume><year>2020</year><fpage>844</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">32073213</pub-id></element-citation></ref><ref id="b0995"><element-citation publication-type="journal" id="h0985"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N.</given-names></name><name><surname>Bai</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name></person-group><article-title>Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy</article-title><source>J. Thromb. Haemost.</source><year>2020</year><pub-id pub-id-type="doi">10.1111/jth.14817</pub-id></element-citation></ref><ref id="b1000"><element-citation publication-type="journal" id="h0990"><person-group person-group-type="author"><name><surname>te Velthuis</surname><given-names>A.J.W.</given-names></name><name><surname>van den Worm</surname><given-names>S.E.V.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>van Hemert</surname><given-names>M.J.</given-names></name></person-group><article-title>Zn<sup>2+</sup> inhibits coronavirus and arterivirus RNA polymerase activity <italic>in vitro</italic> and zinc ionophores block the replication of these viruses in cell culture</article-title><source>PLoS Pathog.</source><volume>6</volume><year>2010</year><object-id pub-id-type="publisher-id">e1001176</object-id></element-citation></ref><ref id="b1005"><element-citation publication-type="journal" id="h0995"><person-group person-group-type="author"><name><surname>Thickett</surname><given-names>D.R.</given-names></name><name><surname>Armstrong</surname><given-names>L.</given-names></name><name><surname>Christie</surname><given-names>S.J.</given-names></name><name><surname>Millar</surname><given-names>A.B.</given-names></name></person-group><article-title>Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome</article-title><source>Am. J. Respir. Crit. Care Med.</source><volume>164</volume><year>2001</year><fpage>1601</fpage><lpage>1605</lpage><pub-id pub-id-type="pmid">11719296</pub-id></element-citation></ref><ref id="b1010"><mixed-citation publication-type="other" id="h1000">Third People's Hospital of Shenzhen. February 14, 2020. Familavir is more effective than Lopinavir/ritonavir in the treatment of COVID-19 (in Chinese). http://www.szdsyy.com/News/0a6c1e58-e3d0-4cd1-867a-d5524bc59cd6.html.</mixed-citation></ref><ref id="b1015"><element-citation publication-type="journal" id="h1005"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>B.T.</given-names></name></person-group><article-title>Glucocorticoids and acute lung injury</article-title><source>Crit. Care Med.</source><volume>31</volume><year>2003</year><fpage>S253</fpage><lpage>S257</lpage><pub-id pub-id-type="pmid">12682449</pub-id></element-citation></ref><ref id="b1020"><element-citation publication-type="journal" id="h1010"><person-group person-group-type="author"><name><surname>Toots</surname><given-names>M.</given-names></name><name><surname>Yoon</surname><given-names>J.-J.</given-names></name><name><surname>Cox</surname><given-names>R.M.</given-names></name><name><surname>Hart</surname><given-names>M.</given-names></name><name><surname>Sticher</surname><given-names>Z.M.</given-names></name><name><surname>Makhsous</surname><given-names>N.</given-names></name><name><surname>Plesker</surname><given-names>R.</given-names></name><name><surname>Barrena</surname><given-names>A.H.</given-names></name><name><surname>Reddy</surname><given-names>P.G.</given-names></name><name><surname>Mitchell</surname><given-names>D.G.</given-names></name><name><surname>Shean</surname><given-names>R.C.</given-names></name><name><surname>Bluemling</surname><given-names>G.R.</given-names></name><name><surname>Kolykhalov</surname><given-names>A.A.</given-names></name><name><surname>Greninger</surname><given-names>A.L.</given-names></name><name><surname>Natchus</surname><given-names>M.G.</given-names></name><name><surname>Painter</surname><given-names>G.R.</given-names></name><name><surname>Plemper</surname><given-names>R.K.</given-names></name></person-group><article-title>Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia</article-title><source>Sci. Transl. Med.</source><volume>11</volume><year>2019</year><fpage>eaax5866</fpage><pub-id pub-id-type="pmid">31645453</pub-id></element-citation></ref><ref id="b1025"><element-citation publication-type="journal" id="h1015"><person-group person-group-type="author"><name><surname>van den Borne</surname><given-names>B.E.</given-names></name><name><surname>Dijkmans</surname><given-names>B.A.</given-names></name><name><surname>de Rooij</surname><given-names>H.H.</given-names></name><name><surname>le Cessie</surname><given-names>S.</given-names></name><name><surname>Verweij</surname><given-names>C.L.</given-names></name></person-group><article-title>Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells</article-title><source>J. Rheumatol.</source><volume>24</volume><year>1997</year><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">9002011</pub-id></element-citation></ref><ref id="b1030"><element-citation publication-type="journal" id="h1020"><person-group person-group-type="author"><name><surname>Monteil</surname><given-names>V.</given-names></name><name><surname>Kwon</surname><given-names>H.</given-names></name><name><surname>Prado</surname><given-names>P.</given-names></name><name><surname>Hagelkr&#x000fc;ys</surname><given-names>A.</given-names></name><name><surname>Wimmer</surname><given-names>R.A.</given-names></name><name><surname>Stahl</surname><given-names>M.</given-names></name><name><surname>Leopoldi</surname><given-names>A.</given-names></name><name><surname>Garreta</surname><given-names>E.</given-names></name><name><surname>Del Pozo</surname><given-names>C.H.</given-names></name><name><surname>Prosper</surname><given-names>F.</given-names></name><name><surname>Romero</surname><given-names>J.P.</given-names></name><name><surname>Wirnsberger</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Slutsky</surname><given-names>A.S.</given-names></name><name><surname>Conder</surname><given-names>R.</given-names></name><name><surname>Montserrat</surname><given-names>N.</given-names></name><name><surname>Mirazimi</surname><given-names>A.</given-names></name><name><surname>Penninger</surname><given-names>J.M.</given-names></name></person-group><article-title>Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.004</pub-id></element-citation></ref><ref id="b1035"><element-citation publication-type="journal" id="h1025"><person-group person-group-type="author"><name><surname>Vivier</surname><given-names>E.</given-names></name><name><surname>Tomasello</surname><given-names>E.</given-names></name><name><surname>Baratin</surname><given-names>M.</given-names></name><name><surname>Walzer</surname><given-names>T.</given-names></name><name><surname>Ugolini</surname><given-names>S.</given-names></name></person-group><article-title>Functions of natural killer cells</article-title><source>Nat. Immunol.</source><volume>9</volume><year>2008</year><fpage>503</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">18425107</pub-id></element-citation></ref><ref id="b1040"><element-citation publication-type="journal" id="h1030"><person-group person-group-type="author"><name><surname>Wajanaponsan</surname><given-names>N.</given-names></name><name><surname>Cheng</surname><given-names>S.-F.</given-names></name></person-group><article-title>Acute renal failure resulting from intravenous immunoglobulin therapy</article-title><source>Hawaii Med. J.</source><volume>63</volume><year>2004</year><fpage>266</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">15540524</pub-id></element-citation></ref><ref id="b1045"><mixed-citation publication-type="other" id="h1035">Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., Peng, Z., 2020a. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel coronavirus-infected pneumonia in Wuhan, China. JAMA doi: 10.1001/jama.2020.1585.</mixed-citation></ref><ref id="b1050"><element-citation publication-type="journal" id="h1040"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Nie</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Mo</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia</article-title><source>J. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/infdis/jiaa150</pub-id></element-citation></ref><ref id="b1055"><element-citation publication-type="journal" id="h1045"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Xiao</surname><given-names>G.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) <italic>in vitro</italic></article-title><source>Cell Res.</source><volume>30</volume><year>2020</year><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="b1060"><element-citation publication-type="journal" id="h1050"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Zhai</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>C.</given-names></name><name><surname>Ren</surname><given-names>M.</given-names></name><name><surname>Bai</surname><given-names>C.</given-names></name><name><surname>Shang</surname><given-names>H.</given-names></name></person-group><article-title>Xuebijing injection in the treatment of severe pneumonia: study protocol for a randomized controlled trial</article-title><source>Trials</source><volume>17</volume><year>2016</year><fpage>142</fpage><pub-id pub-id-type="pmid">26983754</pub-id></element-citation></ref><ref id="b1065"><element-citation publication-type="journal" id="h1055"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>S.J.</given-names></name></person-group><article-title>Tissue destruction by neutrophils</article-title><source>N. Engl. J. Med.</source><volume>320</volume><year>1989</year><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">2536474</pub-id></element-citation></ref><ref id="b1070"><mixed-citation publication-type="other" id="h1060">World Health Organization(WHO). December 31, 2003. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. https://www.who.int/csr/sars/country/table2004_04_21/en/.</mixed-citation></ref><ref id="b1075"><mixed-citation publication-type="other" id="h1065">World Health Organization(WHO). March 12, 2020a. Coronavirus disease 2019 (COVID-19) situation report &#x02013; 52. https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_2.</mixed-citation></ref><ref id="b1080"><mixed-citation publication-type="other" id="h1070">World Health Organization(WHO). March 30, 2020b. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.</mixed-citation></ref><ref id="b1085"><element-citation publication-type="journal" id="h1075"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>J.X.</given-names></name></person-group><article-title>Evaluation of vitamin C for adjuvant sepsis therapy</article-title><source>Antioxid. Redox. Signal.</source><volume>19</volume><year>2013</year><fpage>2129</fpage><lpage>2140</lpage><pub-id pub-id-type="pmid">23682970</pub-id></element-citation></ref><ref id="b1090"><element-citation publication-type="journal" id="h1080"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name><name><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name><surname>Hsieh</surname><given-names>C.L.</given-names></name><name><surname>Abiona</surname><given-names>O.</given-names></name><name><surname>Graham</surname><given-names>B.S.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><year>2020</year><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="b1095"><mixed-citation publication-type="other" id="h1085">Wu, Y., Xu, X., Chen, Z., Duan, J., Hashimoto, K., Yang, L., Liu, C., Yang, C., 2020.Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav. Immun. doi: 10.1016/j.bbi.2020.03.031.</mixed-citation></ref><ref id="b1100"><element-citation publication-type="journal" id="h1090"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Lian</surname><given-names>N.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Xie</surname><given-names>Q.</given-names></name><name><surname>Zhuo</surname><given-names>H.</given-names></name></person-group><article-title>Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A Retrospective study</article-title><source>Liver Int</source><year>2020</year><pub-id pub-id-type="doi">10.1111/liv.14449</pub-id></element-citation></ref><ref id="b1105"><element-citation publication-type="journal" id="h1095"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D.M.</given-names></name><name><surname>Ma</surname><given-names>X.H.</given-names></name><name><surname>Ai</surname><given-names>Y.H.</given-names></name></person-group><article-title>Effect of Xuebijing injection pretreatment on expression of pulmonary surfactant-associated protein A in rat alveolar type II epithelial cells induced by lipopolysaccharide</article-title><source>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue</source><volume>21</volume><year>2009</year><fpage>690</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">19930893</pub-id></element-citation></ref><ref id="b1110"><element-citation publication-type="journal" id="h1100"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Woods</surname><given-names>C.R.</given-names></name><name><surname>Mora</surname><given-names>A.L.</given-names></name><name><surname>Joodi</surname><given-names>R.</given-names></name><name><surname>Brigham</surname><given-names>K.L.</given-names></name><name><surname>Iyer</surname><given-names>S.</given-names></name><name><surname>Rojas</surname><given-names>M.</given-names></name></person-group><article-title>Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice</article-title><source>Am. J. Physiol. Lung Cell Mol. Physiol.</source><volume>293</volume><year>2007</year><fpage>L131</fpage><lpage>L141</lpage><pub-id pub-id-type="pmid">17416739</pub-id></element-citation></ref><ref id="b1115"><element-citation publication-type="journal" id="h1105"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Tai</surname><given-names>Y.</given-names></name><name><surname>Bai</surname><given-names>C.</given-names></name><name><surname>Gao</surname><given-names>T.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Xia</surname><given-names>P.</given-names></name><name><surname>Dong</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>F.-S.</given-names></name></person-group><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>Lancet Respir. Med.</source><volume>8</volume><year>2020</year><fpage>420</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">32085846</pub-id></element-citation></ref><ref id="b1120"><element-citation publication-type="journal" id="h1110"><person-group person-group-type="author"><name><surname>Yagi</surname><given-names>T.</given-names></name><name><surname>Asakawa</surname><given-names>A.</given-names></name><name><surname>Ueda</surname><given-names>H.</given-names></name><name><surname>Ikeda</surname><given-names>S.</given-names></name><name><surname>Miyawaki</surname><given-names>S.</given-names></name><name><surname>Inui</surname><given-names>A.</given-names></name></person-group><article-title>The role of zinc in the treatment of taste disorders</article-title><source>Recent Pat. Food Nutr. Agric.</source><volume>5</volume><year>2013</year><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">23305423</pub-id></element-citation></ref><ref id="b1125"><element-citation publication-type="journal" id="h1115"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Zou</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>K.F.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>N.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name></person-group><article-title>Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model</article-title><source>Cell Res.</source><volume>23</volume><year>2013</year><fpage>300</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">23208422</pub-id></element-citation></ref><ref id="b1130"><mixed-citation publication-type="other" id="h1120">Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J.a., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., Wang, Y., Pan, S., Zou, X., Yuan, S., Shang, Y., 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. doi: 10.1016/S2213-2600(20)30079-5.</mixed-citation></ref><ref id="b1135"><element-citation publication-type="journal" id="h1125"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X.H.</given-names></name><name><surname>Li</surname><given-names>T.Y.</given-names></name><name><surname>He</surname><given-names>Z.C.</given-names></name><name><surname>Ping</surname><given-names>Y.F.</given-names></name><name><surname>Liu</surname><given-names>H.W.</given-names></name><name><surname>Yu</surname><given-names>S.C.</given-names></name><name><surname>Mou</surname><given-names>H.M.</given-names></name><name><surname>Wang</surname><given-names>L.H.</given-names></name><name><surname>Zhang</surname><given-names>H.R.</given-names></name><name><surname>Fu</surname><given-names>W.J.</given-names></name><name><surname>Luo</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Xiao</surname><given-names>H.L.</given-names></name><name><surname>Guo</surname><given-names>H.T.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Xiang</surname><given-names>D.F.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Q.R.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.Z.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Pan</surname><given-names>P.F.</given-names></name><name><surname>Huang</surname><given-names>X.Q.</given-names></name><name><surname>Ding</surname><given-names>Y.Q.</given-names></name><name><surname>Bian</surname><given-names>X.W.</given-names></name></person-group><article-title>A pathological report of three COVID-19 cases by minimally invasive autopsies</article-title><source>Zhonghua Bing Li Xue Za Zhi</source><volume>49</volume><year>2020</year><fpage>E009</fpage></element-citation></ref><ref id="b1140"><element-citation publication-type="journal" id="h1130"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Tang</surname><given-names>N.</given-names></name></person-group><article-title>Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2</article-title><source>J. Thromb. Thrombolysis</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s11239-020-02105-8</pub-id></element-citation></ref><ref id="b1150"><element-citation publication-type="journal" id="h1140"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.W.</given-names></name><name><surname>Sun</surname><given-names>C.D.</given-names></name><name><surname>Wen</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>C.H.</given-names></name></person-group><article-title>Effect of treatment with Xuebijing injection on serum inflammatory mediators and Th1/2 of spleen in rats with sepsis</article-title><source>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue</source><volume>18</volume><year>2006</year><fpage>673</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">17092419</pub-id></element-citation></ref><ref id="b1170"><mixed-citation publication-type="other" id="h1160">Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., Zuo, W., 2020. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv, 2020.2001.2026.919985.</mixed-citation></ref><ref id="b1160"><element-citation publication-type="journal" id="h1150"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Xiao</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name></person-group><article-title>Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China</article-title><source>Liver Int.</source><year>2020</year><pub-id pub-id-type="doi">10.1111/liv.14455</pub-id></element-citation></ref><ref id="b1165"><element-citation publication-type="journal" id="h1155"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group><article-title>Treatment concerns for psychiatric symptoms in COVID-19-infected patients with or without psychiatric disorders</article-title><source>Br. J. Psychiatry.</source><year>2020</year><pub-id pub-id-type="doi">10.1192/bjp.2020.84</pub-id></element-citation></ref><ref id="b1175"><element-citation publication-type="journal" id="h1165"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Tong</surname><given-names>H.</given-names></name><name><surname>Shu</surname><given-names>Q.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Ge</surname><given-names>M.</given-names></name><name><surname>Deng</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zou</surname><given-names>B.</given-names></name><name><surname>Cheng</surname><given-names>B.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name></person-group><article-title>Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study</article-title><source>Respir. Res.</source><volume>15</volume><year>2014</year><fpage>39</fpage><pub-id pub-id-type="pmid">24708472</pub-id></element-citation></ref><ref id="b1180"><mixed-citation publication-type="other" id="h1170">Zheng, M., Gao, Y., Wang, G., Song, G., Liu, S., Sun, D., Xu, Y., Tian, Z., 2020. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol. Immunol. doi: 10.1038/s4123-020-0402.</mixed-citation></ref><ref id="b1185"><element-citation publication-type="journal" id="h1175"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Xiang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>B.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><name><surname>Guan</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Tu</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="b1190"><element-citation publication-type="journal" id="h1180"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.L.</given-names></name><name><surname>Wang</surname><given-names>X.G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Si</surname><given-names>H.R.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>C.L.</given-names></name><name><surname>Chen</surname><given-names>H.D.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>R.D.</given-names></name><name><surname>Liu</surname><given-names>M.Q.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>X.R.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>X.S.</given-names></name><name><surname>Zhao</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Q.J.</given-names></name><name><surname>Deng</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>L.L.</given-names></name><name><surname>Yan</surname><given-names>B.</given-names></name><name><surname>Zhan</surname><given-names>F.X.</given-names></name><name><surname>Wang</surname><given-names>Y.Y.</given-names></name><name><surname>Xiao</surname><given-names>G.F.</given-names></name><name><surname>Shi</surname><given-names>Z.L.</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="b1195"><element-citation publication-type="journal" id="h1185"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Zhan</surname><given-names>F.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name><name><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref></ref-list><sec id="s0180" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0250">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary data 1</title></caption><media xlink:href="mmc1.xml"/></supplementary-material>
</p></sec><ack id="ak005"><title>Acknowledgements</title><p>This work was partly supported by the grants of <funding-source id="gp010"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source> (to K.H., 17H04243 and 19H05203) and <funding-source id="gp005"><institution-wrap><institution-id institution-id-type="doi">10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source>, AMED (to K.H., JP20dm0107119).</p></ack><fn-group><fn id="s0175" fn-type="supplementary-material"><label>Appendix A</label><p id="p0245">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbi.2020.04.046" id="ir005">https://doi.org/10.1016/j.bbi.2020.04.046</ext-link>.</p></fn></fn-group></back></article>